|
Principal company | Partner company | Value ($M) | Type/product area | Terms/details | Date |
23andme Inc. (South San Francisco) | Pfizer Inc. (New York) | ND | Expanded research agreement to provide Pfizer with access to 23andme's research platform, including services and analysis of the consumer genetics company's genotyped population of more than 800,000 customers | They will collaborate on certain genomewide association studies, surveys and clinical trial recruitment; one of the collaborations will be a longitudinal study to better understand the genetics of lupus | 1/13/15 |
3M Drug Delivery Systems (St. Paul, Minn.) | Astrazeneca plc (London) | ND | Research collaboration focused on developing next generation toll-like receptor agonists to activate innate immune cells and enhance the visibility of cancer tumors | Medimmune has in-licensed from 3M MEDI9197, a TLR 7/8 dual agonist | 9/28/15 |
3SBio Inc. (Shenyang, China) | Pharmabcine Inc. (Daejeon, South Korea) | ND | Exclusive licensing deal to develop, manufacture and market DIG-KT for cancer in Korea and Greater China | The deal includes up-front, milestone and royalty payments | 1/16/15 |
3SBio Inc. (Shenyang, China) | Alteogen Inc. (Daejeon, South Korea) | ND | Exclusive agreement to develop, manufacture and market an antibody drug conjugate that targets the HER2 pathway for cancer | The deal covers Mainland China, Hong Kong and Macau and includes an undisclosed up-front payment, as well as further milestone payments and royalties for the development of ALT-P7; terms include development, manufacturing and marketing rights of ALT-P7, which are to be done in China | 10/13/15 |
4D Molecular Therapeutics Inc. (San Francisco) | Roche AG (Basel, Switzerland) | ND | Collaboration and license agreement to discover and develop optimized next-generation AAV vectors for indications with high unmet medical need | The company will deploy its directed vector evolution platform to identify and optimize gene delivery vectors for use in gene therapy products | 4/28/15 |
4SC AG (Planegg, Germany) | Menarini Asia-Pacific Holdings Pte. Ltd. (Singapore) | $101.20 | Licensing and development partnership for 4SC's oral histone deacetylase inhibitor, resminostat, for the Asia-Pacific region | Menarini wil pay 4SC up-front and milestone payments of up to $101.2M in exchange for exclusive licensing rights to develop it in all APAC countries, excluding Japan, and in all oncological indications; 4SC will be eligible for double-digit royalties | 4/15/15 |
Abbvie Inc. (North Chicago) | C2N Diagnostics (St. Louis) | ND | Exclusive worldwide license agreement to develop and commercialize a portfolio of anti-tau antibodies for the treatment of Alzheimer's disease and other neurological disorders | Financial terms of the collaboration were not disclosed | 3/20/15 |
Abcheck s.r.o. (subsidiary Affimed N.V.; Heidelberg, Germany) | Pierre Fabre Pharmaceuticals SA (Saint-Julien-en-Genevois, France) | ND | Expanded their ongoing collaboration into a strategic research partnership in the field of human antibody discovery and optimization | Abcheck will deliver antibodies against two or more targets provided by Pierre Fabre per year over a period of three years, but could be extended to five years; Pierre Fabre has secured full rights to all antibodies selected in exchange for undisclosed discovery fees and milestone payments to Abcheck | 6/18/15 |
Ablynx NV (Ghent, Belgium) | Merck & Co. Inc. (Whitehouse Station, N.J.) | $7.10 | Ablynx extended its initial two-year research collaboration with Merck to develop and commercialize Nanobody candidates directed toward an undisclosed voltage gated ion channel | The collaboration, announced in October 2012, included a €6.5M (US$ 7.1M) up-front payment and €2M in initial research funding; Merck is now extending its funding of the research to the end of September 2016 | 3/27/15 |
Ablynx NV (Ghent, Belgium) | Sanofi SA (Paris) | ND | Exclusive research collaboration to investigate nanobodies against a target that plays an important role in multiple sclerosis and specifically aligns with Genzyme's early stage MS research programs | Genzyme will have the right to perform in vitro and in vivo research with Ablynx's nanobodies in MS-relevant models in return for an exclusivity fee | 5/19/15 |
Ablynx NV (Ghent, Belgium) | Taisho Pharmaceutical Co. Ltd. (Tokyo) | $3.00 | Exclusive license agreement to develop and commercialize in Japan Ablynx's ozoralizumab (ATN-103) for the treatment of rheumatoid arthritis | Ablynx will receive an up-front payment of $3M and is entitled to undisclosed development and commercial milestone payments plus royalties based on sales in Japan; Taisho will oversee development, registration and commercialization of therapeutics in Japan | 7/1/15 |
Ablynx NV (Ghent, Belgium) | Merck & Co. Inc. (Whitehouse Station, N.J.) | $6,300.00 | Agreement adding as much as 12 more immuno-oncology programs to the existing five in their deal focused on Ablynx's Nanobody single-domain fragment antibody platform | At up to €340M (US$372M) per program in research and milestone payments, the total potential deal size has ballooned from €1.7B to €5.78B (US$6.33B) plus sales royalties; Ablynx is getting €13M (US$14.24M) up front | 7/23/15 |
Ablynx NV (Ghent, Belgium) | Novo Nordisk A/S (Bagsvaerd, Denmark) | $201.80 | Global exclusive collaboration and licensing agreement to discover and develop multispecific Nanobody drug candidates for use in an undisclosed disease area, with an option to expand the agreement to include a second Nanobody program | Ablynx will receive an up-front license fee of E5M (US$5.3M) and up to E4M (US$4.2M) in research funding during the initial three-year term; if Novo decides to exercise the option to the second program, it will pay Ablynx an exercise fee of E4M (US$4.2M); Ablynx is eligible to receive potential development, regulatory and commercial milestone payments of up to E182M (US$192.3M) per program plus tiered royalties | 11/30/15 |
AC Immune SA (Lausanne, Switzerland) | Janssen Pharmaceuticals (arm of Johnson & Johnson; New Brunswick, N.J.) | $509.00 | Licensing deal for its first-in-class tau-targeting vaccine, ACI-35, which is in clinical development for Alzheimer's disease | AC Immune could receive up to $509M in up-front and milestone payments, plus tiered royalties on product sales; the deal extends to other tauopathies as well | 1/13/15 |
AC Immune SA (Lausanne, Switzerland) | Nestle Institute of Health Sciences SA | ND | Research collaboration agreement to develop a minimally invasive tau diagnostic assay for the early diagnosis of Alzheimer's disease | AC Immune will provide its expertise in the biology and pathology of tau as well as committing its laboratory capabilities to support the collaborative research program; the goal is to identify and validate a highly sensitive diagnostic assay for the detection of tau in human cerebrospinal fluid and blood plasma | 9/24/15 |
Accelis Pharma LLC (East Windsor, N.J.) | Fougera Pharmaceuticals Inc. (Melville, N.Y.; subsidiary of Sandoz Inc.) | ND | Agreement to promote Pandel (hydrocortisone probutate) cream 0.1% and Veregen (sinecatechins) ointment 15% to primary care practitioners | Pandel is approved for corticosteroid-responsive dermatoses, and Veregen is indicated for genital warts | 11/6/15 |
Achillion Pharmaceuticals Inc. (New Haven, Conn.) | Janssen Pharmaceuticals Inc. (Titusville, N.J.; unit of Johnson & Johnson) | $1,325.00 | Partnership to develop and commercialize one or more hepatitis C virus therapies, including ACH-3102, ACH-3422 and the protease inhibitor sovaprevir | Achillion is granting Janssen an exclusive, worldwide license to develop and commercialize the products, in exchange for development, regulatory and sales milestones, plus $225.4M in an up-front equity investment; total deal value is $1.325B, plus tiered royalties in the mid-teens to low-20s percentages | 5/20/15 |
Act Genomics Co. Ltd. (Taipei) | Aslan Pharmaceuticals Pte. Ltd. (Singapore) | ND | Collaboration to conduct stuides of the genomic background to extreme therapeutic responses | The company plans to study major responses from clinical trials of its lead development program, Aslan001, a small-molecule pan-HER inhibitor, in breast cancer and cholangiocarcinoma | 7/9/15 |
Actavis plc (Dublin) | Astrazeneca plc (London) | $700.00 | Agreement under which Astrazeneca will acquire the rights to Actavis' branded respiratory business in the U.S. and Canada for initial condieration of $600M and low single-digit royalties above a certain revenue threshold | Astrazeneca will gain rights to Tudorza Pressair (aclidinium bromide inhalation powder), a twice-daily long-acting muscarinic antagonist for chronic obstructive pulmonary disease (COPD), and Daliresp (roflumilast), a once-daily oral PDE4 inhibitor currently on the market for COPD; Astrazeneca will pay Actavis an additional $100 million, and Actavis has agreed to a number of contractual consents and approvals, including certain amendments to the ongoing collaboration agreements between Astrazeneca and Actavis. The transaction is set to complete this quarter. | 2/6/15 |
Actavis plc (Dublin) | Mayne Pharma Ltd. (Greenville, N.C.) | $50.00 | Agreement under which Actavis will divest U.S. rights to the Doryx brand acne treatment and related assets to Mayne for about $50M | Actavis will continue to package, distribute and actively promote the product for a transition period until May 2 following close of the deal | 2/11/15 |
Actavis plc (Dublin) | TPG (Fort Worth, Texas) | ND | Agreement for Actavis to divest Aptalis Pharmaceutical Technologies, or Pharmatech, to the investment firm | Financial details were not disclosed | 2/17/15 |
Adaptimmune Therapeutics plc (Abingdon, UK) | Universal Cells (Seattle) | $46.50 | Agreement for an exclusive global license to a gene editing technology that could lead to the creation of new allogeneic T-cell therapies | Terms include $5.5M up front and up to $41M in milestones | 12/2/15 |
Addex Therapeutics SA (Geneva) | Pierre Fabre Pharmaceuticals SA (Castres, France) | ND | Option to license its metabotropic glutamate receptor subtype 3 program to Pierre Fabre | Pierre Fabre will conduct chemistry, pharmacology and ADME, while Addex will support the project with its in vitro pharmacological assay platform | 9/9/15 |
Adimab LLC (Lebanon, N.H.) | Acceleron Pharma Inc., Surface Oncology Inc., Potenza Therapeutics Inc., and Oncothyreon Inc. (all of Cambridge, Mass.) | ND | Four discovery collaboration in which Adimab will discover and optimize therapeutic monoclonal or bispecific antibodies against multiple targets for each partner | Financial terms were not disclosed | 1/12/15 |
Adimab LLC (Lebanon, N.H.) | Glaxosmithkline plc (London) | ND | Expanded collaboration in which Adimab will build a custom library for GSK for use in generating bispecific antibody leads | Adimab will use that library as well as existing Adimab technology in collaboration with GSK to discover antibodies against multiple targets and generate bispecific antibodies against combinations of those targets; Adimab will also transfer the library to GSK for its internal use in the discovery of bispecifics. GSK will have the right to develop and commercialize therapeutic bispecifics generated from the library | 1/13/15 |
Adimab LLC (Lebanon, N.H.) | Sanofi SA (Paris) | ND | Multitarget discovery and optimization collaboration to pursue bispecific molecules against multiple targets | Sanofi obtained the right to develop and commercialize therapeutic antibodies and bispecifics resulting from the collaboration; Adimab is set to receive an undisclosed up-front payment, research fees and technical milestones, plus license fees, clinical milestones and sales royalties on any candidates that emerge from the relationship | 2/9/15 |
Adimab LLC (Lebanon, N.H.) | Celgene Corp. (Summit, N.J.) | ND | Collaboration to identify fully human antibodies against multiple targets and giving Celgene the right to develop and commercialize resulting antibodies | The deal allows Adimab to generate novel common light chain libraries with Celgene and use its platform to generate IgGs against multiple targets; Celgene retained the right to develop and commercialize therapeutic antibodies resulting; Adimab gets an up-front payment, license fees, clinical milestones and product royalties | 5/8/15 |
Adimab LLC (Lebanon, N.H.) | Kite Pharma Inc. (Santa Monica, Calif.) | ND | Collaboration in which Adimab will use its discovery and optimization platform to identify fully human antibodies against selected targets | Kite retains the right to research antibodies generated during the collaboration and has the option to license antibodies for development and commercialization as therapeutic CAR products; Adimab will receive an undisclosed up-front payment, research fees, technical milestones, license fees, and certain additional milestones and royalties on sales | 6/17/15 |
Aduro Biotech Inc. (Berkeley, Calif.) | Novartis AG (Basel, Switzerland) | $750.00 | Collaboration focused on immuno-oncology research using Aduro's stimulator of interferon genes targeted cyclic dinucleotide platform technology | Under terms of the agreement, Aduro will receive an initial up-front payment of $200M with Novartis making a 2.7% equity investment in the company valued at $25M, with a commitment for another $25M investment that will be made at a later date; Aduro is eligible to receive up to an additional aggregate amount of $500M in potential milestones; the companies will share profits in the U.S., Japan and major European countries, and Aduro will receive a mid-teens royalty for sales in the rest of the world | 3/31/15 |
Aduro Biotech Inc. (Berkeley, Calif.) | Incyte Corp. (Wilmington, Del.) | ND | Clinical trial agreement to evaluate the safety, tolerability and preliminary efficacy of Aduro's lead LADD immunotherapy, CRS-207, in combination with Incyte's oral indoleamine dioxygenase 1 inhibitor, epacadostat (INCB24360) in patients with ovarian cancer | The phase I/II trial will enroll up to 40 patients in phase I and up to 86 patients in phase II beginning in early 2016 | 9/10/15 |
Advanced Accelerator Applications SA (AAA; Saint-Genis-Pouilly, France) | Fujifilm RI Pharma Co. Ltd. (Tokyo) | ND | Distribution agreement for Lutathera (lutate; 177Lutetium DOTA0 Tyr3-Octreotate) in Japan | AAA will receive launch and development milestone payments and royalties on product sales; Lutathera will be manufactured by AAA in Europe and sold to Fujifilm by its subsidiary AAA International | 7/1/15 |
Advaxis Inc. (Princeton, N.J.) | Incyte Corp. (Wilmington, Del.) | ND | Clinical trial collaboration agreement to evaluate the combination of the Lm-LLO cancer immunotherapy, ADXS-HPV, with Incyte's epacadostat | The multicenter, open-label, preoperative phase II window-study will evaluate the safety and efficacy of ADXS-HPV as monotherapy and in combination with epacadostat in approximately 20 patients with Stage I-IIa human papillomavirus-associated cervical cancer; collaborating on a nonexclusive basis, the companies will jointly conduct and fund the study | 2/12/15 |
Advaxis Inc. (Princeton, N.J.) | Sorrento Therapeutics Inc. (San Diego) | ND | Research/clinical trial agreement to investigate combining Lm-LLO cancer immunotherapy technology platform with Sorrento's fully human antibodies targeting immune checkpoints | Advaxis will undertake the studies while both companies will equally share expenses | 5/20/15 |
Advaxis Inc. (Princeton, N.J.) | Knight Therapeutics Inc. (Westmount, Quebec) | $25.00 | Agreement to commercialize Advaxis' portfolio in Canada, including axalimogene filolisbac for human papilloma virus-associated cancers, ADXS-PSA for prostate cancer and ADXS-HER2 for HER2 expressing solid tumors | Knight will purchase 359,454 Advaxis shares at $13.91 each, about a 7% premium to the stock's closing price on Aug. 25; Canadian investment advisor, Sectoral Asset Management will purchase about 1.44M shares of Advaxis stock at the same price; combined gross proceeds are approximately $25M | 8/27/15 |
Aegerion Pharmaceuticals Inc. (Cambridge, Mass.) | Astrazeneca plc (London) | Aegerion completed the acquisition of Myalept (metreleptin) for injection to treat leptin deficiency in patients with generalized lipodystrophy | Aegerion paid $325M up front for the global rights to develop, manufacture and commercialize Myalept, subject to an existing distributor license with Shionogi & Co. Ltd., of Osaka, Japan, covering Japan, South Korea and Taiwan | 1/13/15 | |
Aequus Pharmaceuticals Inc. (Menlo Park, Calif.) | Corium International Inc. (Vancouver, British Columbia) | ND | Agreement to co-fund new transdermal products with an initial focus on neurological disorders | For each product selected, the parties will assign an allocation of responsibilities, costs, rights and product revenues; specific terms were not disclosed | 4/30/15 |
Aequus Pharmaceuticals Inc. (Vancouver, British Columbia) | Undisclosed partner | ND | Binding term sheet to promote and market tacrolimus IR and two additional transplant products in the Canadian market | Tacrolimus IR is the only generic version of the immunosuppressive therapy, used to treat and prevent acute rejection following organ transplantation, that is approved in Canada | 10/2/15 |
Aerie Pharmaceuticals Inc. (Research Triangle Park, N.C.) | Graybug Inc. (Baltimore) | ND | Research collaboration and license agreement to deliver certain of Aerie's preclinical product candidates to both the front and back of the eye using Graybug's technology | The partnership will focus on evaluating the ability of Graybug's polymer-based delivery technology to provide multi-month drug-release capability for an Aerie small molecule for wet age-related macular degeneration | 8/7/15 |
Aeterna Zentaris Inc. (Quebec City) | EMD Serono Inc. (Rockland, Mass.) | ND | Promotional services agreement that will allow Aeterna to promote Saizen in the U.S. | Saizen is used to treat growth hormone deficiency in children and adults | 5/8/15 |
Aeterna Zentaris Inc. (Quebec City) | Undisclosed German life sciences entrepreneurs | ND | Option agreement to license the company's live recombinant oral allogenic tumor vaccine technology, including AEZS-120 for prostate cancer, which is ready for phase I | The option is granted worldwide, for a period of 12 months, in exchange for an undisclosed up-front fee; it grants the right to obtain a worldwide exclusive license to develop, use and sell products relating to the technology and AEZS-120, in exchange for milestone payments and royalties on net sales of any product developed from the technology and an equity interest in the company formed to develop the technology | 7/29/15 |
Affimed NV (Heidelberg, Germany) | Pierre Fabre Pharmaceuticals (Castres, France) | ND | Expanded collaboration into a strategic research partnership in the field of human antibody discovery and optimization | Abcheck will use its human antibody discovery and optimization platform technologies, Absieve and Abaccel, to deliver antibodies against two or more targets provided by Pierre Fabre per year over a period of three years | 6/19/15 |
Affinivax Inc. (Cambridge, Mass.) | Nosocomial Vaccine Corp. (Rockville, Md.) | ND | Collaboration agreement to use Affinivax's vaccine platform, Multiple Antigen Presentation System, or MAPS, to develop vaccines to prevent bacterial nosocomial infections | The collaboration includes funding from NVC sufficient to support the development of product candidates to advance toward clinical testing | 10/27/15 |
Agalimmune Ltd. (London) | Kode Biotech Ltd. (Auckland, New Zealand) | $31.00 | Licensing agreement for Kode's function-spacer-lipid cell surface membrane modification technology to incorporate it into its cancer immunotherapy molecules | Kode may receive up to £21M (US$31M) in development and sales milestones, plus royalties on net sales; Agalimmune has exclusive rights to the use of the technology in the field of intratumoral injection for cancer treatment | 6/16/15 |
Agenus Inc. (Lexington, Mass.) | Incyte Corp. (Wilmington, Del.) | $410.00 | Agreement to investigate checkpoint modulators in onco-immunology using Agenus Retrocyte Display technology | Agenus gets $60M up front, in the form of a $25M technology and program access fee plus a $35M equity investment; across four lead programs, Agenus could earn up to $350M in development, regulatory and commercial milestone payments; for the GITR and OX40-targeting programs, the companies will split costs and profits evenly; for the TIM-3 and LAG-3 programs, Agenus is eligible for the milestone payments and royalties | 1/12/15 |
Agenus Inc. (Lexington, Mass.) | Celexion LLC (Cambridge, Mass.) | $4.00 | Agenus acquired Celexion's approaches to generate antibodies against membrane-bound protein targets such as GPCRs and ion channels | Agenus paid Celexion $1M in cash and $3M in Agenus stock at the closing | 4/9/15 |
Agenus Inc. (Lexington, Mass.) | Merck and Co. Inc. (Kenilworth, N.J.) | $100.00 | Extension until April 2016 the discovery phase of an existing collaboration and license between the companies | Agenus is responsible for discovering and developing therapeutic antibodies to Merck's immune checkpoint targets, using the Retrocyte display platform, and is eligible to receive $100M in milestone payments plus sales royalties | 6/4/15 |
Agenus Inc. (Lexington, Mass.) | Iontas Ltd. (Cambridge, UK) | ND | Exclusive license deal to a phage display library from Iontas | Terms were not disclosed | 11/9/15 |
Agenus Inc. (Lexington, Mass.) | Selexis SA (Geneva) | ND | Agreement for cell line development technology | Deal will offer Agenus advantages in the creation of high-expressing and stable master cell lines needed for antibody manufacturing | 11/9/15 |
Agenus Inc. (Lexington, Mass.) | Xoma Corp. (Berkeley, Calif.) | $6.00 | Agreement for Agenus to acquire Xoma's antibody pilot plant manufacturing facility and capabilities | The facility will enable Agenus to manufacture checkpoint modulator antibodies to meet its growing GMP antibody production requirments for development and future clinical trials; Agenus will pay $5M in cash on closing and up to $1M in common stock | 11/9/15 |
Agilvax Inc. (Albuquerque, N.M.) | Humabs Biomed SA (Bellinzona, Switzerland) | ND | Collaboration with monoclonal antibody for the rapid advancement of Agilvax's vaccine and immunotherapy pipeline | Agilvax will use antibodies from Humab in its development processes | 2/18/15 |
Agios Pharmaceuticals Inc. (Cambridge, Mass.) | Celgene Corp. (Summit, N.J.) | $120.00 | Exercised option to obtain an exclusive license outside the U.S. for AG-120, an inhibitor of the mutant IDH1 protein | Celgene will lead development and commercialization outside the U.S., and Agios will cover those costs in the U.S.; Celgene will be eligible to receive royalties on net U.S. sales, and Agios will be eligible for royalties for ex-U.S. sales, as well as up to $120M in milestone payments | 1/14/15 |
Akebia Therapeutics Inc. (Cambridge, Mass.) | Mitsubishi Tanabe Pharma Corp. (Osaka, Japan) | $350.00 | Japanese partnership for phase III-ready vadadustat, an oral therapy to treat anemia related to chronic kidney disease | The deal covers two dozen Asian territories, including Japan, Taiwan, South Korea, Indonesia and India - though excluding China - in exchange for $40M on signing and an additional $60M in committed funding, plus $250M in milestones and tiered royalties from the low teens up to 20% | 12/15/15 |
Akeso Biopharma Inc. (Zhongshan, China) | Merck & Co. Inc. (Kenilworth, N.J.) | $200.00 | Collaboration in the U.S. and Canada to research, develop and commercialize immuno-oncology therapeutics | Merck will retain exclusive worldwide rights to develop and commercialize AK-107; Akeso will receive an up-front payment from Merck and up to $200M in development and commercialization milestone payments | 12/8/15 |
Albany Molecular Research Inc. (Albany, N.Y.) | Genovi Pharmaceuticals Ltd. (Irvine, Calif.) | ND | Development and supply agreements to manufacture select generic parenteral drug products for registration and commercialization in the U.S., Europe and emerging markets | AMRI will initially provide cGMP manufacture and analytical support for five product candidates, and will be reimbursed for technology transfer activities, analytical development and manufacture of regulatory submission batches; AMRI is eligible to receive additional product delivery milestones; following FDA approval, AMRI will supply products to Genovi, receiving payments for certain ones based on sales | 1/13/15 |
Albany Molecular Research Inc. (Albany, N.Y.) | Perkinelmer Inc. (Waltham, Mass.) | ND | Strategic collaboration in connection with the opening of AMRI's drug discovery center as part of the new Buffalo Medical Innovation and Commercialization Hub, in Buffalo N.Y. | The partners expect the hub will accelerate drug discovery and innovation, and ultimately support the creation of more than 250 high-tech jobs | 6/18/15 |
Albany Molecular Research Inc. (Albany, N.Y.) | Saneca Pharmaceuticals AS (Hlohovec, Slovakia) | ND | Strategic collaboration focused on the development, manufacture and marketing of a portfolio of opium-derived active pharmaceutical ingredients | Saneca will supply intermediates and process transfer technology to enable AMRI to develop more than two dozen APIs | 9/1/15 |
Alcyone Lifesciences Inc. (Lowell, Mass.) | Dnatrix Inc. (Houston) | ND | Exclusive clinical collaboration in which Dnatrix will use Alcyone's MEMS Cannula targeted delivery platform with DNX-2401 for glioblastoma | Terms were not disclosed | 5/20/15 |
Alexion Pharmaceuticals Inc. (Cheshire, Conn.) | Bioxcel Corp. (Branford, Conn.) | ND | Data project to characterize and prioritize pertinent sets of rare diseases for relevant therapeutic modalities | Alexion will use Bioxcel's Big Data Innovation Lab, which applies recursive mapping and big data algorithms | 1/30/15 |
Alexza Pharmaceuticals Inc. (Mountain View, Calif.) | Grupo Ferrer Internacional SA (Barcelona) and Teva Pharmaceutical Industries Ltd. (Jerusalem) | ND | Amended Adasuve (staccato loxapine) commercial partnerships voering the European Union, Latin America and other countries | Alexza plans to complete Adasuve commercial production for Ferrer and Teva, pending orders in the third quarter, and then suspend commercial production of the drug; Alexza will transfer the EU marketing authorization for Adasuve to Ferrer, including the responsibilities for the ongoing post-approval clinical studies, a future phase III study in adolescents and ongoing pharmacovigilance responsibilities; milestone payments for first commercial sales in Russia, Brazil and Turkey were eliminated; Teva remains responsible for related regulatory and clinical activities as well as royalties and milestone payments on U.S. sales | 6/19/15 |
Alexza Pharmaceuticals Inc. (Mountain View, Calif.) | Teva Pharmaceuticals USA Inc. (subsidiary of Teva Pharmaceutical Industries Ltd.; Petah Tikva, Israel) | ND | Alexza plans to reacquire the U.S. rights for Adasuve (loxapine) inhalation powder with an estimated target completion date of Jan. 1, 2016 | Alexza and Teva also plan to restructure the obligations under the outstanding note from Teva and are working on a transition agreement to continue product availability to patients and health care providers after the return of the rights to Alexza | 11/3/15 |
Alimera Sciences Inc. (Atlanta) | Knight Therapeutics Inc. (Montreal) | ND | Exclusive agreement for Canadian distribution of Iluvien to treat diabetic macular edema | Knight will also handle all regulatory and commercial activities for Iluvien in Canada | 7/22/15 |
Alimera Sciences Inc. (Atlanta) | Societa Industria Farmaceutica Italiana SpA (Catania, Italy) | ND | Exclusive, five-year agreement to distribution of iluvien in Italy, San Marino and Vatican City | SIFI will handle all promotion, marketing and commercial activities for the sustained-release intravitreal injection to treat diabetic macular edema; royalty payments are included | 8/14/15 |
Alimera Sciences Inc. (Atlanta) | Meagate International FZLLC (United Arab Emirates) | ND | Agreement to distribute Iluvien throughout much of the Middle East, including Bahrain, Egypt, Iraq, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, UAE and Yemen | Financial terms were not disclosed | 12/16/15 |
Alk-Abello A/S (Copenhagen) | Biocsl Inc. (King of Prussia, Pa.) | ND | Partnership in Australia and New Zealand, granting Biocsl exclusive rights to promote and sell Alk's SLIT-tablets against house dust mite and grass pollen allergy, and ALK's Jext adrenaline auto-injector | Alk will receive an undisclosed up-front payment, followed by a milestone payment upon approval of the HDM SLIT-tablet in Australia; ALK will sell products to Biocsl at a pre-agreed price structure ensuring a certain split of the final in-market revenues generated by Biocsl | 2/10/15 |
Alkermes plc (Dublin) | Recro Pharma Inc. (Malvern, Pa.) | $170.00 | Agreement in which Alkermes is selling its Gainesville, Ga., manufacturing facility and the manufacturing and royalty revenue associated with product manufactured there and global rights to meloxicam | Alkermes will receive an initial cash payment of $50M, development and commercialization milestone payments of up to $120M related to meloxicam I.V./IM and low double-digit royalties on net sales of the product | 3/10/15 |
Allegro Ophthalmics LLC (San Juan Capistrano, Calif.) | Hanmi Pharmaceutical Co. Ltd. (Seoul, South Korea) | $20.00 | License agreement for Korea and China for Luminate (ALG-1001), an integrin peptide therapy in phase II to treat vitreo-retinal conditions | Hanmi will make a $20M strategic investment in Allegro that will advance and accelerate global developmen; Hanmi agreed to pay Allegro up-front license fees, sales milestone payments and running royalties | 1/14/15 |
Allergan plc (Dublin) | Merck & Co. Inc. (Kenilworth, N.J.) | $250.00 | Agreement under which Allergan will acquire the exclusive worldwide rights to Merck's small-molecule oral calcitonin gene-related peptide receptor antagonists for migraine | Allergan will make an up-front payment of $250M, $125M of which is payable upon Hart-Scott-Rodino clearance and $125M of which is payable in April 2016; Merck will additionally be entitled to receive potential development and commercial milestone payments and tiered double-digit royalties | 7/8/15 |
Alligator Bioscience AB (Lund, Sweden) | Janssen Biotech Inc. (Horsham, Pa.; unit of Johnson & Johnson) | ND | Exclusive worldwide license agreement for ADC-1013, an immuno-oncology agent in phase I studies | Janssen will attain rights to develop and commercialize ADC-1013, an agonistic fully human monoclonal antibody targeting CD40, in exchange for an undisclosed up-front payment to Alligator, as well as milestone payments | 8/13/15 |
Alliqua Biomedical Inc. (Langhorne, Pa.) | Celgene Cellular Therapeutics (subsidiary of Celgene Corp. (Summit, N.J.) | ND | Amended exclusive licensing agreement to develop and market CCT's connective tissue matrix product derived from human placental tissue | The company plans to launch CTM mid-2016 | 5/13/15 |
Almirall SA (Barcelona, Spain) | Allergan plc (Dublin) | ND | Allergan acquired rights to Constella (linaclotide) in the European Union, Switzerland, Turkey and the Commonwealth of Independent States from Almirall | Allergan also reacquired rights to linaclotide (Linzess) in Mexico from Almirall; Allergan gains an exclusive license to Constella, including the development and commercialization of the drug, for treating irritable bowel syndrome with constipation, chronic idiopathic constipation and other gastrointestinal condictions | 10/29/15 |
Almirall SA (Barcelona, Spain) | Stiefel (company of Glaxosmithkline plc; London) | ND | Acquisition of rights to two dermatology products, Veltin (clindamycin phosphate and tretinoin) and Altabax (retapamulin ointment) from Stiefel | The acquisition is in exchange for distribution rights to Toctino (alitretinoin) and an undisclosed cash payment | 11/24/15 |
Alnylam Pharmaceuticals Inc. (Cambridge, Mass.) | Genzyme (unit of Sanofi SA; Paris) | ND | Genzyme elected to opt in for the development and potential commercialization of Alnylam's ALN-AT3 hemophilia program in territories outside North America and Western Europe | Genzyme's decision was based on data from the phase I trial of ALN-AT3, including positive interim data; in January 2014, the companies formed a multi-product alliance to accelerate and expand the development and commercialization of RNAi therapeutics | 10/2/15 |
Altamira Bio (subsidiary of Fortress Biotech Inc.; New York) | New Zealand Pharmaceuticals Ltd. (Palmerston North, New Zealand) | ND | Altamira acquired from New Zealand Pharma a license from the NIH and Cooperative Research and Development Agreements for development of oral N-acetyl-D-mannosamine for hyposialylation disorders | Hyposialylation disorders are a group of pathologies associated with abnormal sialylation of tissues, characteristic of hereditary inclusion body myopathy, a rare genetic disorder which causes progressive muscle-wasting and weakness | 7/20/15 |
Alvogen Inc. (Pine Brook, N.J.) | Pfizer Inc. (New York) | ND | Agreement to pick up a portfolio of four products: three injectables and one inhaled solution | Two are on-market products, Clindamycin injection and Acetylcysteine inhalation solution; Alvogen will receive profit-sharing payments from marketer Fresenius AG, and will gain two pending abreviated new drug applications, Voriconazole injection and Melphalan injection | 8/27/15 |
Alvogen Pharma U.S. (Pinebrook, N.J., part of Alvogen) | Bayer Pharma AG (part of Bayer AG; Leverkusen, Germany) | ND | Acquisition of five products | Alvogen acquired Klimonorm (hormone replacement therapy), Progynova (hormone replacement therapy), Triquilar (female contraceptive), Microgynon (female contraceptive) and Climene (hormone replacement therapy) | 10/7/15 |
Amag Pharmaceuticals Inc. (Waltham, Mass.) | Velo Bio LLC (joint venture between Glenveigh Medical LLC, Chattanooga, Tenn., and Quatrobio LLC, Morrisville, N.C.) | $10.00 | Agreement granting it an exclusive option to acquire the rights to an orphan drug candidate at the conclusion of a phase IIb/IIIa trial | Digoxin immune fab (DIF) is a polyclonal antibody being developed for the treatment of severe preeclampsia in pregnant women; Amag will make an up-front payment of $10M from cash on hand to Velo Bio for the option to acquire global rights to the DIF program | 7/24/15 |
Amarantus Bioscience Holdings Inc. (San Francisco) | Chiltern International Inc. (Wilmington, N.C.) | ND | Agreement to manage the clinical research and monitoring program services for the phase IIb study of eltoprazine in Parkinson's disease levodopa-induced dyskinesia | Terms were not disclosed | 5/22/15 |
Amarin Corp. plc (Dublin) | Eddingpharm Co. Ltd. (Shanghai) | $169.00 | Exclusive agreement to develop and commercialize Vascepa in Mainland China, Hong Kong, Macao Special Administrative Regions and Taiwan | Amarin will provide development assistance and be responsible for supplying finished, and later bulk, product; terms include up-front and milestone payments to Amarin of up to $169M, including a nonrefundable $15M up-front payment and development, regulatory and sales-based milestone payments of up to an additional $154M; Eddingpharm will also pay Amarin tiered double-digit percentage royalties on net sales of Vascepa in the territory escalating to the high teens | 2/27/15 |
Amarin Corp. plc (Dublin) | Eddingpharm Co. Ltd. (Shanghai) | $184.00 | Deal to bring Vascepa to Greater China | Amarin will receive $15M up front, $169M in milestones and tiered sales royalties; the rights extend to Vascepa indications both commercialized and under development | 3/4/15 |
Amgen Inc. (Thousand Oaks, Calif.) | Kite Pharma Inc. (Santa Monica, Calif.) | $585.00 | Deal focused on chimeric antigen receptor T-cell therapies, and will involve applying Kite's technology against a set of cancer targets | Kite gets $60M up front, and Amgen also agreed to cover R&D funding costs, as Kite uses its autologous eACT platform; Kite will be entitled to up to $525M in milestones per Amgen program, while Amgen is eligible for up to $525M in milestones per Kite program; Kite also is eligible for tiered high single- to double-digit royalties; Amgen is eligible for tiered single-digit sales royalties from Kite programs | 1/6/15 |
Amgen Inc. (Thousand Oaks, Calif.) | Astrazeneca plc (London) | ND | Terminated development of brodalumab for plaque psoriasis, psoriatic arthritis and axial spondyloarthritis | Phase III data showed events of suicidal ideation and behavior, which would restrict the label; the co-development and commercialization deal is terminated | 5/27/15 |
Amgen Inc. (Thousand Oaks, Calif.) | Merck & Co. Inc. (Kenilworth, N.J.) | ND | Expanded their collaboration to evaluate the efficacy and safety of talimogene laherparepvec in combination with Keytruda (pembrolizumab) in a phase I trial in patients with recurrent or metastatic squamous cell carcinoma of the head and neck | The companies are also initiating a global, randomized phase III trial evaluating the combination in patients with regionally or distantly metastatic melanoma | 6/1/15 |
Amgen Inc. (Thousand Oaks, Calif.) | Roche AG (Basel, Switzerland) | ND | Deal for a phase Ib study of talimogene laherparepvec, Amgen's oncolytic immunotherapy, in combination with Roche's anti-PDL1 therapy, atezolizumab, in patients with triple-negative breast cancer and colorectal cancer with liver metastases | Terms were not disclosed | 6/3/15 |
Amgen Inc. (Thousand Oaks, Calif.) | Novartis AG (Basel, Switzerland) | ND | Agreement for Alzheimer's disease focused on Novartis' phase I/II oral beta-site APP-cleaving enzyme-1 inhibitor, CNP-520, while also enlisting Novartis as a co-developer and seller of Amgen's two migraine candidates in markets beyond North America and Japan | Amgen will make undisclosed up-front and milestone payments to Novartis and will carry most of the R&D costs for CNP-520 for a period of time, after which the partners will split the costs and profits; Novartis will fund most of the global R&D expenses for Amgen's phase III migraine candidate, AMG-334, and a phase I candidate, AMG-301, and will pay Amgen double-digit royalties on sales of the compounds | 9/3/15 |
Amgen Inc. (Thousand Oaks, Calif.) | Merck & Co. Inc. (Kenilworth, N.J.) | ND | Cancer immunotherapy collaboration to support a phase Ib/III study testing Blincyto (blintatumomab), Amgen's bispecific antibody, in combination with Merck's PD-1 inhibitor, Keytruda (pembrolizumab), in patients with diffuse large B-cell lymphoma | The companies also disclosed a second collaboration to support a phase I/II study of AMG 820, Amgen's anti-colony-stimulating factor 1 receptor antibody, in combination with Keytruda | 12/7/15 |
Amgen Inc. (Thousand Oaks, Calif.) | Glaxosmithkline plc (London) | ND | Amgen is reacquiring all of its remaining rights to Prolia, Xgeva and Vectibix from GSK in 48 countries in Asia, South America, Europe, Australia and other regions | The agreement involves key expansion markets for Amgen, including Brazil, China, Colombia, Hong Kong, Israel, Singapore, South Korea, Taiwan and Thailand; GSK has held select regional rights to Prolia and Xgeva since 2009 and to Vectibix since 2010 under licenses from Amgen | 12/16/15 |
Amoun Pharmaceutical Co. S.A.E. (Cairo, Egypt) | Valeant Pharmaceuticals International Inc. (Laval, Quebec) | $800.00 | Valeant plans to takeover Amoun for $800M | Valeant is acquiring Mercury (Cayman) Holdings to get Amoun, gaining branded generic drugs that lead the markets in such therapeutic spaces as hypertension and diarrhea, with broad-spectrum antibiotics also | 7/20/15 |
Amp Biosimilars AG (Hamburg, Germany) | Midsized Chinese pharma company | ND | Out-licensing agreement for a biosimilar, ABY-018, a humanized monoclonal antibody | The undisclosed partner will assume all financing for development and market approval processes starting from phase I through to production and marketing in China; it will pay royalties to Amp | 5/29/15 |
Amp Biosimilars AG (Hamburg, Germany) | Undisclosed medium-sized Chinese pharma firm | ND | Licensing agreement for the biosimilar ABY-021, a humanized monoclonal antibody for treating immunological symptoms | The Chinese pharma firm has rights to market the drug in China; outside of China, Amp retains rights; the pharma will pay Amp royalties starting from the marketing launch of the biosimilar | 6/11/15 |
Amunix Operating Inc. (Mountain View, Calif.) | Roche AG (Basel, Switzerland) | ND | Extended collaboration to evaluate Amunix's Xten technology, designed for protein half-life extension | The deal, focused on an undisclosed indication, began in 2013 and now extended into 2017 | 10/27/15 |
Anabios Corp. (San Diego) | Purdue Pharma LP (Stamford, Conn.) | ND | Joint venture aimed at accelerating the development of Purdue's Nav1.7 sodium ion channel compounds for the treatment of chronic pain | The joint R&D effort would leverage Purdue Pharma's intellectual property and lead compounds, combined with Anabios' Phase-X technology, which is designed to enable the study of ex-vivo human responses to drugs and the investigation of the molecular and functional basis of human physiology | 9/23/15 |
Anacor Pharmaceuticals Inc. (Palo Alto, Calif.) | Sandoz Inc. (Princeton, N.J.; part of Novartis AG) | $20.00 | Amended their distribution and commercialization agreement with regard to Pharmaderm, the dermatology division of Sandoz | The amended agreement calls for Sandoz to increase its investment in Kerydin (tavaborole) topical solution, 5%, in 2015, while Anacor will contribute $20M to Sandoz for commercialization; the minimum profit-sharing payments in 2016 going to Anacor will be $65M, up from $45M, and the 2017 minimum to Anacor will be $65M | 6/30/15 |
Angionetics Inc. (San Diego) | Shenzhen Qianhai Taxus Industry Capital Management Co. Ltd. (affiliate of Shanxi Taxus Pharmaceuticals Co. Ltd.; China) | $3.00 | Deal to help fund a recently launched subsidiary aimed at advancing Generx | Shenzhen purchased an equity stake in Angionetics, which will take over work on Generx, for $3M, payable in three tranches; it will have a right of first negotiation for exclusive licensing agreements for certain Asian markets for Generx, as well as dermal matrix wound healing product Excellagen | 4/14/15 |
ANI Pharmaceuticals Inc. (Baudette, Minn.) | Teva Pharmaceuticals Industries Ltd. (Jerusalem) | $5.00 | ANI acquired the approved new drug application for a testosterone gel 1% product previously licensed to Teva | ANI will pay Teva up to $5M at a rate of 5% of commercial sales of the product | 5/14/15 |
ANI Pharmaceuticals Inc. (Baudette, Minn.) | Teva Pharmaceuticals Industries Ltd. (Jerusalem) | $25.00 | Acquisition of 22 previously marketed generic drug products | ANI paid $25M in cash and a percentage of future gross profits from product sales | 7/14/15 |
Ani Pharmaceuticals Inc. (Baudette, Minn.) | Merck & Co. Inc. (Kenilworth, N.J.) | $75.00 | Agreement in which Ani is acquiring the new drug applications for purified corticotropin gel and corticotropin-zinc hydroxide | Ani is paying $75M in cash and a percentage of future net sales | 9/22/15 |
Anthera Pharmaceuticals Inc. (Hayward, Calif.) | Zenyaku Kogyo Co. Ltd. (Tokyo) | ND | Terminated December 2014 collaboration and licensed agreement for development and commercializaiton of blisibimod in Japan | The company said termination, which will go into effect Jan. 7, 2016, was "at will" and alleged no breach of the agreement; no patients had been enrolled in any blisibimod clinical studies in the Zenyaku territory and it had not purchased any blisibimod product from Anthera; blisibimod is a selective peptibody antagonist of the B-cell activating factor, or BAFF, cytokine that is initially being developed as a treatment for lupus and IgA nephropathy | 9/16/15 |
Antisense Therapeutics Ltd. (Melbourne, Australia) | Cortendo AB (Trevose, Pa., and Goteborg, Sweden) | $109.60 | In-licensing deal of ATL1103 | Cortendo paid Antisense A$3.7M (US$3M) in cash and making an A$2.5M (US$2M) investment in the company, plus up to A$131M (US$104.6M) in additional milestone payments and royalties | 5/18/15 |
Antitope Ltd. (subsidiary of Abzena Ltd.; Cambridge, UK) | Apitope International NV (Dipenbeek, Belgium) | ND | Agreement in which Antitope will investigate and measure the immunological status of hemophilia A patients after they receive treatment with ATX-F8-117 | ATX-F8-117 is designed to induce immune tolerance to blood coagulation factor VIII in those with hemophilia A | 5/20/15 |
AOP Orphan Pharmaceutical AG (Vienna) | Rigi Healthcare AG (Kussnacht, Switzerland) | ND | Agreement to focus on the development, in-licensing and commercialization of pharmaceutical specialties for rare diseases in North America | Hans Peter Hasler will be the chairman of Rigi Orphan, while Rudolf Widman will join its board | 4/9/15 |
Apexigen Inc. (San Carolos, Calif.) | 3SBio Inc. (Shenyang, China) | ND | Agreement in which 3SBio acquired the ex-China global rights to Apexigen's anti-TNF monoclonal antibody technology | The anti-TNF MAb, designated SSS07, has completed preclinical testing and demonstrated higher potency than the best-known available TNF inhibitors potentially improving treatment options for patients with rheumatoid arthritis and other inflammatory diseases | 6/23/15 |
Apexigen Inc. (San Carolos, Calif.) | 3SBio Inc. (Shenyang, China) | ND | Agreement in which 3SBio acquired the ex-China global rights to Apexigen's anti-TNF monoclonal antibody technology | The anti-TNF MAb, designated SSS07, has completed preclinical testing and demonstrated higher potency than the best-known available TNF inhibitors potentially improving treatment options for patients with rheumatoid arthritis and other inflammatory diseases | 6/23/15 |
Apogenix GmbH (Heidelberg, Germany) | Canbridge Life Sciences Inc. (Beijing) | ND | Exclusive licensing agreement for the development and commercialization of APG101 in China, Macao and Hong Kong | Apogenix will receive up-front and milestone payments, as well as royalty payments at tiered, double-digit royalty rates following commercial launch of APG101 in China | 7/16/15 |
Apogenix GmbH (Heidelberg, Germany) | R-Biopharm AG (Darmstadt, Germany) | ND | Agreement to develop companion diagnostic tests for Apogenix's APG101, a CD95 ligand inhibitor to treat solid tumors and malignant hematological diseases | Apogenix and R-Biopharm will develop patient-stratifying companion diagnostic tests to identify glioblastoma patients who are most likely to benefit from treatment with APG101 | 7/29/15 |
Applied Genetic Technologies Corp. (Gainesville, Fla.) | 4D Molecular Therapeutics LLC (San Francisco) | ND | Collaboration and license agreement to discover and develop optimized adeno-associated virus vectors to treat specific ophthalmic disease indications with high unmet medical need | 4DMT will deploy its AAV vector discovery platform, Directed vector Evolution, to identify and optimize vectors | 4/21/15 |
Applied Genetic Technologies Corp. (Gainesville, Fla.) | Biogen Inc. (Cambridge, Mass.) | $1,189.00 | Collaboration for a clinical candidate for X-linked retinoschisis and a preclinical prospect for the treatment of X-linked retinitis pigmentosa, plus exclusive license to a technology platform to make adeno-associated virus vectors for up to six genes | Deal is worth a potential $1.189B and brings $124M up front ($30M in an equity investment) for AGTC, with $472.5M in milestones, up to $592.5M in discovery program payments, and royalties in the high single-digit to mid-teen percentages for the two lead programs, and in the mid-single digits to low teen percentages for the discovery programs; AGTC will lead clinical development programs of XLRS through product approval and of XLRP through the finish of first-in-human trials; Biogen holds worldwide commercialization rights for the XLRS and XLRP programs, with AGTC gaining an option to share development costs and profits, and it has an option to co-promote | 7/6/15 |
Applied Genetic Technologies Corp. (Gainesville, Fla.) | Synpromics Ltd. (Edinburgh, Scotland) | $1.50 | Broad, multitarget collaboration, in which they will use Synpromics' technology to develop and optimize synthetic promoters for multiple cell types that will be used in the development of new gene therapy candidates | Potential payments to be made by AGTC to Synpromics include a $1.5M up-front payment, research funding, option exercise fees for each promoter and milestone payments, plus royalties | 12/10/15 |
Applied Molecular Transport LLC (South San Francisco) | Janssen Biotech Inc. (unit of Johnson & Johnson; New Brunswick, N.J.) | ND | Exclusive global license for an oral biologic candidate engineered for the treatment of inflammatory bowel diseases | Applied Molecular is eligible to receive undisclosed up-front license fees, support for research activities conducted in collaboration with Janssen immunology scientists, and undisclosed milestone payments plus tiered royalties on potential worldwide sales | 1/29/15 |
Applied Pharma Research SA (Balerna, Switzerland) | HBM Partners AG (Zug, Switzerland) | ND | HBM acquired a minority stake in Applied Pharma | The amount was not disclosed; in relation to the transaction, the fund's advisor, Alexander Asam, was named a member of APR's board, while Valentina Reiner, the company's co-founder, resigned from the board but remains head of regulatory affairs operations | 3/26/15 |
Apricus Biosciences Inc. (San Diego) | Allergan plc (Dublin) | $2.50 | Licensing agreement for U.S. development and commercialization rights for Vitaros | Terms call for Apricus to pay Allergan $1M up front and a future regulatory milestone payment of $1.5M; Allergan may elect to exercise its one-time opt-in right to assume all future marketing and selling activities in the U.S. in exchange for $25M in up-front and potential launch milestones plus a double-digit royalty on net sales | 9/11/15 |
Apricus Biosciences Inc. (San Diego) | Ferring Pharmaceuticals SA (Saint-Prex, Switzerland) | $18.25 | Exclusive distribution agreement to market Vitaros (alprostadil), its topical on-demand product to treat erectile dysfunction, in Latin America | Apricus is set to receive $2.25M up front and is eligible to receive up to $16M in regulatory and sales milestone payments, plus royalties | 10/2/15 |
Aptose Biosciences Inc. (Redwood City, Calif.) | Laxai Avanti Life Sciences Pvt Ltd. (Hyderabad, India) | ND | Discovery partnership under which LALS will be responsible for developing multiple clinical candidates, including optimizing candidates derived from Aptose's relationship with the Moffitt Cancer Center | Aptose will own global rights to all newly discovered candidates characterized and optimized under the collaboration, including all generated intellectual property | 11/11/15 |
Aqua Pharmaceuticals LLC (West Chester, Pa.) | Glaxosmithkline plc (London) | ND | Aqua acquired U.S. rights to two dermatology products, Veltin Gel, 1.2%/0.025% and Altabax Ointment, 1%, from GSK | Both drugs will be promoted through Aqua in the U.S. | 12/1/15 |
Arcturus Therapeutics Inc. (San Diego) | Precision Nanosystems Inc. (Vancouver, British Columbia) | ND | Partnership for the manufacture of RNA medicines | Precision's Nanoassemblr platform will be used to manufacture GMP batches to support clinical studies and commercial development for RNA medicines developed using Arcturus' Lunar RNA therapeutics platform | 1/12/15 |
Arcturus Therapeutics Inc. (San Diego) | Ultragenyx Pharmaceutical Inc. (Novato, Calif.) | $1,560.00 | Research collaboration and license deal to discover and develop messenger RNA (mRNA) therapeutics | Arcturus will design and optimize mRNA therapeutics for two undisclosed rare disease targets, and Ultragenyx has the option to add up to eight more targets; Ultragenyx will oversee development and commercialization of products in return for preclinical, clinical, regulatory and sales milestone payments of up to $156M for each target, plus reimbursement of research expenses and mid-single to low double-digit royalties on product sales | 10/30/15 |
Ardelyx Inc. (Fremont, Calif.) | Astrazeneca plc (London) | $125.00 | Ardelyx is regaining rights to its NHE3 sodium transporter portfolio, including tenapanor | The 2012 license was originally worth $272M; Ardelyx is paying for the return of the rights, including $15M up front, as well as $10M for R&D costs ; Ardelyx also agreed to purchase phase III trial material from Astrazeneca for up to another $10M, and Ardelyx will pay 10% royalties in net sales, and 20% of what it might earn from a new partnership, up to a $90M cap | 6/4/15 |
Ardelyx Inc. (Fremont, Calif.) | Sanofi SA (Paris) | ND | Terminated option and license agreement for Ardelyx's portfolio of phosphate transport NaP2b inhibitors | There was no payment associated with the decision; Ardelyx received a $1.25M up-front payment when the deal was first executed | 9/3/15 |
Arena Pharmaceuticals GmbH (subsidiary of Arena Pharmaceuticals Inc.; San Diego) | Roivant Sciences Ltd. (Hamilton, Bermuda) | $105.50 | Development, marketing and supply agreement for nelotanserin, an inverse agonist of the 5-HT2A receptor | Roivant gains exclusive worldwide rights to develop and commercialize the product; Arena gets $4M up-front and a potential $41.5M in regulatory and development milestone payments, plus 15% of net sales in exchange for the manufacture and supply of finished commercial drug product, and up to $60M in one-time purchase price adjustment payments tied to certain commercial sales milestones | 5/13/15 |
Areva Med (Bethesda, Md.; part of Areva) | Radiomedix Inc. (Houston) | ND | Agreement to co-develop treatment for neuroendocrine tumors using targeted alpha therapy with lead-212 | The companies will study the efficacy of combining somatostatin analogs' neuroendocrine tumor targeting with Areva Med's lead-212 radionuclide | 5/19/15 |
Argen-x NV (Breda, the Netherlands) | Leo Pharma A/S | $116.00 | Alliance on the development of antibody drugs for inflammatory skin conditions | Deal is worth more than E104.5M (US$116M), and will focus on an existing preclinical program initially; it includes a E4.5M (US$5M) and upward of E100M (US$111M) in development, regulatory and sales-based milestones | 5/22/15 |
Argen-x NV (Ghent, Belgium) | Lonza Group (Basel, Switzerland) | ND | Multiproduct commercial license agreement for the production of Argen-x's therapeutic antibodies | The license secures long-term access for Argen-x and its partners to Lonza's GS Xceed System for creation and development of cell lines to be used in the manufacture of biopharmaceuticals | 2/19/15 |
Argos Therapeutics Inc. (Durham, N.C.) | Saint-Gobain's Performance Plastics (Aurora, Colo.) | ND | Collaboration to help Argos design, integrate and scale production of a range of disposables for use in the automated manufacturing of Argos' lead product candidate, AGS-003, currently being tested in a phase III trial to treat metastatic renal cell carcinoma | Terms were not disclosed | 1/7/15 |
Argos Therapeutics Inc. (Durham, N.C.) | Lummy (Hong Kong) Co. Ltd. | $40.00 | Deal to manufacture, develop and commercialize AGS-003, an immunotherapy to treat cancer in China, Hong Kong, Taiwan and Macau | An affiliate of Lummy HK and the China BioPharma Capital I Fund purchased an aggregate of 1M shares of Argos' stock at a 12.5% premium price, for a total purchase price of $10M; Argos also is entitled to a royalty at a rate in the teens and up to $20M, and a $10M milestone-related investment | 4/15/15 |
Ariad Pharmaceuticals Inc. (Cambridge, Mass.) | Gen Ilac A.C. (Ankara, Turkey) | ND | Deal in which Ariad granted Gen Ilac exclusive rights to distribute Iclusig (ponatinib) in Turkey for patients with Philadelphia-positive leukemias | Gen Ilac has the right to sell Iclusig as an investigational product in Turkey on a named-patient basis and will provide associated medical affairs and regulatory support; Ariad retains the option to file for marketing authorization at a later date; Gen Ilac would then have exclusive marketing and commercialization rights | 5/7/15 |
Ariad Pharmaceuticals Inc. (Cambridge, Mass.) | Paladin Labs Inc. (Montreal) | ND | Exclusive rights agreement to distribute Iclusig in Canada for its newly approved indications | Health Canada recently approved Iclusig for the treatment of adult patients with all phases of chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia for whom other tyrosine kinase inhibitor (TKI) therapy is not appropriate, including cases that are T315I mutation-positive, or where there is prior TKI resistance or intolerance | 6/11/15 |
Armetheon Inc. (Milpitas, Calif.) | China Cardiovascular Focus Ltd. (subsidiary of Lee's Pharmaceuticals Holdings Ltd.; Hong Kong) | ND | Agreement to initiate advanced-stage clinical testing, manufacturing and commercialization of Armetheon's investigational oral anticoagulant, tecarfarin, in the greater China market | Lee's Pharma gains exclusive rights to the compound, which is poised to begin a final registration study in the U.S. under a special protocol assessment; Armetheon will receive an up-front cash payment in the form of a licensing fee along with an equity investment and development and sales milestone payments, plus royalties on future net sales, while Lee's Pharma will handle development, approval and commercialization of tecarfarin in the greater China market and Thailand | 9/23/15 |
Armune Bioscience Inc. (Kalamazoo, Mich.) | Aeterna Zentaris Inc. (Quebec City) | ND | Co-marketing agreement to promote the cancer-specific, nonprostate-specific antigen blood test, Apifiny, to certain medical professionals in its U.S. territories | Aeterna Zentaris will receive a commission for each test that results from its targeted promotion | 12/2/15 |
Arno Biosciences Inc. (Redwood City, Calif.) | Open Monoclonal Technology Inc. (Palo Alto, Calif.) | ND | Licensing agreement for exclusive rights to programmed cell death protein 1 asets, along with unlimited access to OMT's Omnirat, Monimouse and omniflic human antibody generation platforms | Financial terms were not disclosed | 10/19/15 |
Arqule Inc. (Woburn, Mass.) | Beryllium Discovery Corp. (Boston and Seattle) | ND | Research and development agreement to study small-molecule compounds by combining Arqule's chemistry and drug development expertise with Beryllium's discovery platforms | The companies plan to target PD-1 and PD-L1, two proteins that may play major roles in suppressing or limiting the response of the immune system | 5/6/15 |
Array Biopharma Inc. (Boulder, Colo.) | Novartis Pharma AG (unit of Novartis AG; Basel, Switzerland) | ND | Agreement for Array to acquire worldwide rights to encorafenib (LGX818), a BRAF inhibitor in phase III development | The agreement is conditional on the closing of transactions between Novartis and Glaxosmithkline plc | 1/26/15 |
Array Biopharma Inc. (Boulder, Colo.) | Novartis AG (Basel, Switzerland) | $85.00 | Definitive agreements for both binimetinib and encorafenib | Along with global ownership of both assets, the company will receive an up-front payment of $85M from the pharma company; there are no milestone payments or royalties; for all trials transferred to Array, Novartis will reimburse Array for out-of-pocket costs and 50% of FTE costs in connection with completing the trials | 3/3/15 |
Array Biopharma Inc. (Boulder, Colo.) | Pierre Fabre Pharmaceuticals SA (Castres, France) | $455.00 | Agreement for European, Asian and Latin American rights to its phase III Mek inhibitor binimetinib and its phase III BRAF inhibitor encorafenib | The deal includes $30M up front plus up to $425M in milestones; Array would also receive tiered double-digit royalties on eventual product sales; Array retains rights in the U.S. and Canada, as well as Japan, Korea and Israel | 11/17/15 |
Arrowhead Research Corp. (Pasadena, Calif.) | Novartis AG (Basel, Switzerland) | $35.00 | Agreement under which Arrowhead gains the entire RNAi portfolio of Novartis, picking up rights to a host of intellectual property and assets, including an existing license agreement with Alnylam Pharmaceuticals Inc., a pipeline of three preclinical candidates and a patent estate | Under the agreement terms, Arrowhead made a previous $7M cash payment to Novartis and will provide an additional $3M in cash and $25M in Arrowhead common stock within 30 days; Novartis is eligible for undisclosed milestones and single-digit royalties; Arrowhead gets patent families relating to RNAi trigger design rules and modifications | 3/6/15 |
Arsia Therapeutics Inc. (Cambridge, Mass.) | Biogen Inc. (Cambridge, Mass.) | $100.00 | Collaboration focused on improving the administration of hemophilia treatments by enabling subcutaneous delivery of therapies currently administered via intravenous infusion | Biogen will apply Arsia's formulation technology; Arsia is set to receive an undisclosed up-front payment and could be eligible to receive development, regulatory, launch and sales milestones of up to $100M if multiple products are commercialized, plus royalties on certain product sales | 12/17/15 |
Arvinas Inc. (subsidiary of Arvinas LLC; New Haven, Conn.) | Genentech (unit of Roche AG; Basel, Switzerland) | ND | Agreement to develop therapeutics using its proteolysis-targeting chimeras, or PROTAC, technology | Arvinas will receive an undisclosed up-front payment and $300M in potential development and commercial milestone payments, plus tiered royalties | 10/2/15 |
Arvinas LLC (Yale University spinout) | Merck & Co. Inc. (Whitehouse Station, N.J.) | $434.00 | Multiyear strategic partnership to create new therapies for multiple diseases, most likely including cancer | Deal includes an undisclosed up-front payment, funding to support Merck-related research and up to $434M in milestone payments related to research and development, regulatory and commercial goals for targets selected by Merck; Merck also would pay tiered royalties | 4/8/15 |
Ascendis Pharma A/S (Hellerup, Denmark) | Sanofi SA (Paris) | ND | Sanofi decided to terminate development of Transcon Insulin for reasons unrelated to the assessment of the Transcon technology | Sanofi intends to continue development of the Transcon peptide under its ongoing diabetes collaboration with Ascendis | 4/20/15 |
Aslan Pharmaceuticals Pte Ltd. (Singapore) | Hyundai Pharmaceutical Co. Ltd. (Seoul, South Korea) | ND | Collaboration and license agreement to develop and commercialize ASLAN001 (varlitinib) for treatment of cholangiocarcinoma (CCA) in South Korea | The companies intend to submit an investigational new drug application to the Korean Ministry of Food and Drug Safety to initiate clinical trials in Korea for CCA before the end of this year; Hyundai will pay to Aslan up-front and development milestones and royalties on sales upon successful commercialization of ASLAN001 | 11/10/15 |
Aspireo Pharmaceuticals Ltd. (Tel Aviv, Israel) | Cortendo AB (Trevose, Pa., and Goteborg, Sweden) | $30.00 | Acquisition of somatroprim (DG3173), the only asset at Aspireo | Cortendo will provide Aspireo with $30M in equity in return for full rights | 5/18/15 |
Astellas Pharma Inc. (Tokyo) | Ventana Medical Systems Inc. (Tucson, Ariz.; unit of the Roche Group) | ND | Master collaboration agreement to develop automated tissue diagnostics in support of therapeutic compounds in development | Initial projects will support early clinical trials for Astellas' ASP5878; Ventana will develop an immunohistochemistry test identifying FGF19 in certain solid tumors | 4/15/15 |
Astrazeneca plc (London) | Fujifilm Kyowa Kirin Biologics Co. Ltd. (joint venture of Fujifilm Corp. and Kyowa Hakko Kirin Co. Ltd.) | $45.00 | Joint biosimilar venture in which both parties will contribute equal shares to the JV targeting blockbuster cancer drugs | FKP will receive a $45M lump sum payment for transferring the rights to its FKB238 biosimilar to the venture | 8/4/15 |
Astrazeneca plc (London) | Perrigo Co. plc (Dublin) | $380.00 | Agreement for the divestment of U.S. rights to Entocort (budesonide) | Perrigo will pay Astrazeneca $380M upon completion of the transaction to acquire the rights to sell Entocort capsules and the authorized generic Entocort capsules marketed by Par Pharmaceuticals Cos. Inc., of Woodcliff Lake, N.J. | 11/24/15 |
Asuragen Inc. (Austin, Texas) | Illumina Inc. (San Diego) | ND | Collaboration to establish a framework for the development and commercialization of sequencing-based companion diagnostics in partnership with biotech and pharmaceutical companies | Terms were not disclosed | 9/10/15 |
Athersys Inc. (Cleveland) | Chugai Pharmaceutical Co. Ltd. (Tokyo) | $205.00 | Partnership and license agreement to exclusively develop and commercialize Multistem cell therapy for ischemic stroke in Japan | Chugai will be responsible for the development and commercialization of Multistem for ischemic stroke in Japan, and Athersys will have responsibility for product supply; Athersys will receive an up-front cash payment of $10M from Chugai and would receive additional payments as the program is further advanced; Athersys is eligible to receive milestone payments from Chugai of up to $45M upon the successful achievement of certain development and regulatory milestones, and sales milestones of up to approximately $150M | 3/3/15 |
Athersys Inc. (Cleveland) | Chugai Pharmaceutical Co. Ltd. (Tokyo) | ND | License agreement to develop and commercialize Multistem cell therapy for ischemic stroke in Japan | The decision to end the deal followed phase II trial data and lack of consensus on how to proceeds; all rights revert to Athersys, which will retain the $10M license fee from Chugai | 10/22/15 |
Aveo Oncology Inc. (Cambridge, Mass.) | Pharmstandard Group (Russia) | $12.00 | License agreement to develop, manufacture and commercialize Aveo's small-molecule vascular endothelial growth factor tyrosine kinase inhibitor, tivozanib, in Russia, Ukraine and the Commonwealth of Independent States for all indications excluding ocular conditions | Pharmstandard will pay Aveo an up-front amount of $1.5M, and Aveo will be eligible to receive up to $7.5M upon the first marketing authorization of tivozanib in Russia, $3M for each additional approved indication and a high single-digit royalty on net sales in those same territories | 8/6/15 |
Aveo Oncology Inc. (Cambridge, Mass.) | Novartis AG (Basel, Switzerland) | $326.00 | Development and commercialization deal for preclinical-stage growth differentiation factor 15-targeting antibody AV-380 | Deal is worth $15M up front, $53M in clinical milestone payments, $105M in regulatory payments, $150M in sales milestones, and up to $3.45M in reimbursements for Aveo's inventory of clinical-quality drug substance; Novartis gets worldwide rights to AV-380, a humanized inhibitor antibody targeting GDF15 for treating cachexia, as well as related antibodies; the deal also includes royalties | 8/18/15 |
Aveo Oncology Inc. (Cambridge, Mass.) | Eusa Pharma Ltd. | $396.50 | European partnership for the VEGF tyrosine kinase inhibitor, tivozanib | Deal includes $2.5M up front and up to $394M in potential milestones ($335M in sales milestones), plus tiered royalties ranging from the low double digits up to mid-20% range; Aveo will owe sublicensing fees to Asia partner Kyowa Hakko Kirin Co. Ltd., of Tokyo | 12/22/15 |
Avexis Inc. (Dallas) | Asklepios Biopharmaceutical Inc. (Chapel Hill. N.C.) | ND | Licensing agreement for Asklepios' Duplex vectors technology for use in the company's phase I adeno-associated virus gene transfer trial in spinal muscular atrophy patients | Avexis will have non-exclusive access to the use of Askbio's Duplex vectors to support SMA-based therapeutic development and commercialization efforts; Askbio is receiving an up-front payment, and is eligible for future development and commercial milestone payments and potential royalties | 6/18/15 |
Axovant Sciences Ltd. (Hamilton, Bermuda) | Roivant Sciences Ltd. (Hamilton, Bermuda) | $106.30 | Exercised option to acquire nelotanserin from parent company Roivant, which previously had acquired global rights from Arena Pharmaceuticals GmbH, a subsidiary of Mountain View, Calif.-based Arena Pharmaceuticals Inc. | Axovant paid RSL about $4.8M, including reimbursements for amounts paid to date; Arena also is eligible to receive future payments of up to an aggregate of $101.5M based on the achievement of specified developmental, regulatory and commercial milestone events; Arena will be the sole and exclusive manufacturer of nelotanserin for both clinical and commercial supply and will provide finished drug product to Axovant from Arena's manufacturing facility in Switzerland for a price equal to 15% of Axovant's net sales of nelotanserin | 11/4/15 |
Aytu Bioscience Inc. (Englewood, Colo.) | Jazz Pharmaceuticals plc (Dublin) | ND | Agreement to acquire the rights to Prostascint, an imaging agent used to detect the extent and spread of prostate cancer | Aytu said its established brand and revenue will enable the firm to expand its footprint in urology and advance a pipeline of therapeutics and diagnostics | 6/10/15 |
Basilea Pharmaceutica Ltd. (Basel, Switzerland) | Hikma Pharmaceuticals LLC (London) | ND | Exclusive distribution and supply deal for Basilea's broad-spectrum antibiotic, Zevtera (ceftobiprole medocaril), for the Middle East and North Africa region | Hikma will have the exclusive right to register, distribute and market Zevtera across the MENA region, with Basilea's European regulaotry dossier serving as the basis for filings in those countries | 10/16/15 |
Bavarian Nordic A/S (Kvistgaard, Denmark) | Johnson & Johnson (New Brunswick, N.J.) | $171.00 | Partnership to develop a therapeutic vaccine for human papillomavirus infection | Bavarian Nordic and J&J have not yet disclosed the antigens they are employing; a first clinical trial is expected in 2017, in patients with lower-grade (CIN1) neoplasias, identified through pap smears | 12/21/15 |
Bavarian Nordic A/S (Kvistgård, Denmark) | Bristol-Myers Squibb Co. (New York) | $975.00 | Option and licensing deal involving prostate cancer vaccine Prostvac | BMS is paying $60M up front and could pay up to $935M more in milestones linked to the progress of the immunotherapy, which is currently undergoing a phase III trial in 1,200 patients with metastatic castration-resistant prostate cancer (mCRPC) | 3/5/15 |
Baxter International Inc. (Deerfield, Ill.) | Sigma-Tau Finanziaria SpA (Rome) | $900.00 | Agreement for Baxter to acquire Oncaspar (pegaspargase) product portfolio | Baxter will pay the $900M through a combination of foreign cash and debt; Oncaspar is used to treat acute lymphoblastic leukemia and has about $100M in annual sales; the deal includes a new chemical entity, calaspargase pegol, and Oncaspar will be tested for potential new indications; the assets will fall under Baxter's new business unit, Baxalta Inc. | 5/13/15 |
Bellerophon Therapeutics Inc. (Hampton, N.J.) | Flextronics International Ltd. (Singapore) | ND | Agreement to manufacture, repair and service Inopulse Mark2, Bellerophon's pulsatile nitric oxide delivery device | Flextronics will manufacture the next-generation device in its Dallas facility; Inopulse is a drug-device portable unit designed to reduce pulmonary hypertension | 3/26/15 |
Bellerophon Therapeutics Inc. (Hampton, N.J.) | Mallinckrodt plc (Dublin) division Ino Therapeutics LLC | ND | Expanded license agreement allowing Bellerophon to develop Inopulse, a drug-device combination system designed to reduce pulmonary hypertension to treat three additional cardiopulmonary diseases, including chronic thromboembolic PH, PH associated with sarcoidosis and PH associated with pulmonary edema from high altitude sickness | Terms of the expanded license agreement include a 5% royalty on net sales for the three additional indications | 7/30/15 |
Bellicum Pharmaceuticals Inc. (Houston) | Astellas Pharma Inc. (Tokyo) | ND | Global license agreement granting Bellicum rights to develop and commercialize adoptive cell therapies, including CAR T cells, for tumors expressing prostate stem cell antigen | Terms were not disclosed | 12/14/15 |
Benitec Biopharma Ltd. (Sydney) | Asklepios Biopharmaceutical Inc. (Chapel Hill, N.C.) | ND | License deal granting Benitec rights to Asklepios' adeno-associated virus gene therapy technologies | Benitec will maintain access to the use of Asklepios' advanced recombinant AAV gene therapy technologies; Asklepios will receive an up-front payment and is eligible for milestone payments and a related product royalty | 4/17/15 |
Benitec Biopharma Ltd. (Sydney) | Omnia Biologics (Rockville, Md.) | ND | Agreement to manufacture clinical material for the first-in-human trial of TT-034, a ddRNAi-based therapeutic designed to treat and potentially cure hepatitis C with a single administration | Financial terms were not disclosed | 5/27/15 |
Benitec Biopharma Ltd. (Sydney) | Biomics Biotechnologies Co. Ltd. (Nantong, China) | A$6 | Benitec acquired full rights to the preclinical ddRNAi-based hepatitis B virus therapeutic program | The companies previously conducted the program as a joint venture; Benitec will pay Biomics A$2.5M (US$1.86M) up front with an additional A$3.5 million upon commercialization of the program; Biomics also will receive a single-digit royalty on net sales | 7/10/15 |
Bind Therapeutics Inc. (Cambridge, Mass.) | Pfizer Inc. (New York) | ND | Extended terms of the global collaboration to create nanomedicines that optimize the therapeutic potential of two molecularly targeted cancer drugs in Pfizer's pipeline | The collaboration was established in April 2013; the companies agreed to an extension of the timeline for the second program through March 2016; the deal includes about $200M in payments, plus low single- to high single-digit royalties | 4/6/15 |
Bind Therapeutics Inc. (Cambridge, Mass.) | Macrophage Therapeutics (subsidiary of Navidea Biopharmaceuticals Inc.; Dublin, Ohio) | ND | Research collaboration to engineer Accurins with the Manocept targeting platform that enables selective, efficient binding to CD206-positive disease-associated macrophages | Upon achievement of proof of concept, the companies anticipate expanding the collaboration to develop Manocept-linked Accurins as an approach to impact the tumor microenvironment which, in many forms of cancer, is a barrier to immune effector cells | 6/12/15 |
Bind Therapeutics Inc. (Cambridge, Mass.) | Pfizer Inc. (New York) | $203.50 | Exercised option to obtain an exclusive license to develop and commercialize an Accurin drug candidate to treat solid tumors under the firms' 2013 collaboration deal | Bind will get a $2.5M option fee; terms of the original deal involved an option for two Accurins using Pfizer targets, in exchange for a $4M up-front payment; Bind previously received a $1M preclinical milestone payment and has the potential to receive up to $86M more in development milestones and up to $110M in commercial milestones related to the selected compound | 9/25/15 |
Bioatla LLC (San Diego) | Pfizer Inc. (New York) | $1,000.00 | License and option deal worth as much as $1B for the CAB (Conditionally Active Biologics) platform, which enables the development of drug prospects that are activated only in specific micoenvironments, such as those created by tumors | Each party will have a license to the other's repsective technology to develop and commercialize several CAB-antibody drug conjugate antibodies, with Pfizer holding an exclusive option for those that target cytotoxic T-lymphocyte-associated antigen 4; each is eligible to get milestone payments and royalties; Bioatla could collect $1B in up-front and milestone money, plus tiered marginal royalties that extend to double digits | 12/9/15 |
Bioceros Holding BV (Ultrecht, the Netherlands) | Pangenetics BV (Ultrecht, Netherlands) | ND | Exclusive rights agreement to develop anti-human CD40 agonist monoclonal antibodies for treatment of cancer | The immune checkpoint regulator CD40 is expressed on antigen-presenting cells and its ligand is expressed on T cells; Pangenetics is eligible for undisclosed up-front and milestone payments | 1/30/15 |
Biodelivery Sciences International Inc. (Raleigh, N.C.) | Meda AB (Stockholm) | ND | Revenue-sharing agreement under which Meda will transfer the marketing authorizations for Onsolis for breakthrough cancer pain in the U.S. and the right to seek marketing authorizations for the product in Canada and Mexico back to BDSI, which originally licensed rights to Meda in 2007 | Financial terms have been established that enable Meda to share in the proceeds of any new North American partnership for Onsolis that may be executed by BDSI, and the execution of such a transaction by BDSI will require execution of a definitive termination agreement embodying those royalty-sharing terms and certain other provisions | 1/28/15 |
Biogazelle NV (Ghent, Belgium) | Isis Pharmaceuticals Inc. (Carlsbad, Calif.) | ND | Research collaboration in which they will identify and validate novel targets to treat colon, liver and lung cancers | Isis will provide access to its antisense platform for large-scale validation of therapeutic long noncoding RNA targets from Biogazelle's target identification pipeline | 10/19/15 |
Biogen Inc. (Cambridge, Mass.) | Mitsubishi Tanabe Pharma Corp. (Osaka, Japan) | $544.00 | Deal for Mitsubishi's oral sphingosine 1-phosphate antagonist MT-1303 | Biogen will pay $60M up front and up to $484M in additional milestones for an exclusive license to the phase II program outside Asia; Biogen will study it for multiple sclerosis, ulcerative colitis, Crohn's disease and other disorders, as well as inflammatory bowel diseases | 9/10/15 |
Biogen Inc. (Cambridge, Mass.) | Genomics plc (Oxford, UK) | ND | Deal in which Biogen will leverage a database and analysis tools produced by Genomics plc to guide drug R&D, refining target selection through the analysis of human genetic data | Terms were not disclosed | 10/2/15 |
Biohaven Pharmaceutical Holding Co. Ltd. (part of Portage Biotech Inc.; Toronto) | Catalent Pharma Solutions | ND | Exclusive worldwide agreement to provide its Zydis orally disintegrating tablet technology for Biohaven's lead drug candidate, BHV-0223, for treatment-resistant mood and anxiety disorders | Biohaven plans to begin a pharmacokinetic and biomarker study by later this year to confirm optimized drug exposure levels of its formulation | 3/25/15 |
Biohaven Pharmaceutical Holding Co. Ltd. (subsidiary of Portage Biotech Inc.; Toronto) | ALS Biopharma LLC (Doylestown, Pa.) | ND | Agreement in which Portage acquired worldwide intellectual property rights to a portfolio of more than 300 glutamate-modulating prodrugs for an undisclosed amount | Potential target indications that involve glutamate neurotransmission include amyotrophic lateral sclerosis, Alzheimer's disease, Rett syndrome, dementia, dystonia, tinnitus, anxiety disorders, affective disorders and a variety of cancers | 8/19/15 |
Bioinvent International AB (Lund, Sweden) | Undisclosed pharmaceutical company | ND | To provide manufacturing services for one of the products in its development portfolio | Terms were not disclosed | 12/18/15 |
Biomarin Pharmaceutical Inc. (San Rafael) | Dr. Reddy's Laboratories Inc. (Hyderabad, India) | ND | Agreement for a non-exclusive license to its patents related to Kuvan (sapropterin dihydrochloride) to allow Dr. Reddy to market 100 mg generic tablets in the U.S. | Dr. Reddy's intends to market the tablets for indications approved for Kuvan beginning at an undisclosed date, but more than five years from now | 9/22/15 |
Biomarin Pharmaceutical Inc. (San Rafael, Calif.) | Myriad Genetics Inc. (Salt Lake City) | ND | Expanded collaboration that began in September 2013 with Biomarin's use of Myriad's Bracaanalysis Cdx companion diagnostic in its pivotal phase III EMBRACA and phase II ABRAZO studies of talazoparib for advanced or metastatic breast cancer patients with BRCA mutations | Biomarin now plans to use Myriad's Mychoice HRD companion diagnostic to prospectively identify patients with metastatic breast, ovarian and potentially other tumor types that may be sensitive to talazoparib | 3/18/15 |
Biomarin Pharmaceutical Inc. (San Rafael, Calif.) | Merck Serono (division of Merck KGaA; Darmdstadt, Germany) | $380.50 | Biomarin regained global rights to the phenylketonuria drugs Kuvan and Peg-Pal from Merck Serono | Biomarin is paying Merck E340M (US$380.5M) up front and another E60M if combined sales hit levels that were undisclosed | 10/2/15 |
Biomay AG (Vienna) | VTU Technology (Grambach, Austria) | ND | Licensing agreement for the production of recombinant allergens | Biomay will use VTU's Pichia expression strains for commercial production, with VTU receiving royalties based on Biomay's worldwide sales of the recombinant allergens | 5/20/15 |
Biomedx GmbH (Heidelberg, Germany) | Boehringer Ingelheim GmbH (Ingelheim, Germany) | ND | Collaboration to establish a research group focusing on the identification of therapeutic concepts for treating patients with chronic obstructive pulmonary disease | Early career scientists from leading academic institutions worldwide will be invited to submit original project proposals in the field of epigenetics and COPD; Boehringer and Biomedx will jointly select the best ideas and talent to form a new research group within Biomedx's open innovation lab | 1/6/15 |
Biomotiv LLC | Biogen Inc. (Cambridge, Mass.) | $15.00 | Strategic partnership to leverage the strengths of both organizations to identify pioneering neuroscience discoveries and advance them into medicines | Biogen committed to invest $15M in Biomotiv over five years, providing Biogen with exclusive rights relating to neuroscience programs sourced and developed with the accelerator | 9/22/15 |
Bionaturis Group SA (Jerez, Spain) | Biological Mimetics Inc. (Frederick, Md.) | ND | Agreement to jointly develop vaccines for human and animal health applications | Bionaturis will use its Flylife platform to produce experimental batches of vaccines designed using BMI's Immune Refocusing Technology, or IRT; Bionaturis began manufacturing work on a BMI proof-of-concept candidate for a first-in-man vaccine against human rhinovirus | 6/19/15 |
Biondvax Pharmaceuticals Ltd. (Ness Ziona, Israel) | Cytovance Biologics Inc. (Oklahoma City) | ND | Development and manufacturing agreement for Cytovance to produce M-001, a universal flu vaccine, for a phase III trial | Cytovance will start the manufacturing process right away, with batches to be ready around fourth quarter 2016 | 11/4/15 |
Bionomics Ltd. (Adelaide, Australia) | Merck & Co. (Kenilworth, N.J.) | ND | Strategic collaboration for the discovery and development of drug candidates ot treat chronic and neuropathic pain | The agreement builds upon the deal signed in July 2013 focused on Bionomics' ionx and Multicore drug discovery platforms; Merck will purchase 21.66M ordinary shares of Bionomics at A$0.5938, a 29% premium | 10/9/15 |
Biontech AG (Mainz, Germany) | Eli Lilly and Co. (Indianapolis) | $360.00 | Research collaboration to discover cancer immunotherapies, aiming to identify and validate tumor targets and their corresponding T-cell receptors in one or more types of cancers | Biontech will get a $30M signing fee and could receive more than $300M in development, regulatory and commercial milestones, and would be eligible for tiered royalty payments up to double digits; Lilly also will make a $30M equity investment in Biontech's subsidiary, Cell & Gene Therapies GmbH | 5/12/15 |
Biontech AG (Mainz, Germany) | Genmab A/S (Copenhagen) | ND | Deal to research, develop and commercialize bispecific antibodies for cancer immunotherapy with Biontech's immunomodulatory antibodies and Genmab's Duobody technology platform | They will work for the generation of bispecific antibodies; Genmab will pay $10M up-front and near-term payments of $5M, if certain compounds are selected for development; costs will be shared equally | 5/20/15 |
Biontech AG (Mainz, Germany) | Siemens AG (Berlin) | ND | Strategic collaboration to construct a fully automated and digitalized production site for Biontech's personalized cancer vaccines | The project will allow Biontech to establish and integrate process and production steps to manufacture its Ivac individualized vaccines at a larger scale | 6/26/15 |
Biontech AG (Mainz, Germany) | Sanofi SA (Paris) | $1,560.00 | Research and collaboration agreement focused on applying synthetic messenger RNA encoding tumor antigens in cancer immunotherapy | Biontech is receiving $60M in up-front and near-term milestone payments, followed by potentially $300M for each of five products up to the point of commercialization and double-digit royalties on any sales | 11/4/15 |
Biontech Diagnostics GmbH (Mainz, Germany; subsidiary of Biontech AG) | Shuwen Biotech Co. Ltd. (Deqing, China) | ND | Strategic partnership to commercialize Biontech's molecular breast cancer stratification test Mammatyper in China | Shuwen will undertake clinical studies for regulatory approval of Mammatyper in China, and will become the exclusive distributor there | 12/4/15 |
Bioq Pharma Inc. (San Francisco) | Lunatus (Dubai) | ND | Strategic distribution, supply and development agreement for the registration and commercialization of Bioq's ropivacaine and propofol infusion products in Saudi Arabia, the United Arab Emirates, Qatar and Kuwait | Terms of the agreement were not disclosed | 12/3/15 |
Bioquiddity Inc. (San Francisco) | Lee's Pharmaceutical Ltd. (Honk Kong) | ND | Strategic license and supply agreement for the registration and commercialization of Bioquiddity's ropivacaine and propofol infusion pharmaceutical products in the People's Republic of China, Taiwan, Hong Kong and Macau | Terms were not disclosed | 8/25/15 |
Biospecifics Technologies Corp. (Lynbrook, N.Y.) | Endo International plc (Dublin) | $1.00 | Endo exercised an early opt-in for Xiaflex to include two new potential indications: lateral thigh fat and plantar fibromatosis | The company will receive a $500,000 opt-in fee for each indication | 11/9/15 |
Biotime Inc. (Alameda, Calif.) | Hepregen Corp. (Medford, Mass.) | ND | Companies formed Ascendance Biotechnology Inc., a company that combines Hepregen's application-directed, cellular micro-patterning drug and chemical screening technologies with Biotime's ESI BIO research products and stem cell technologies | Terms were not disclosed | 11/9/15 |
Biovista Inc. (Charlottesville, Va.) | Astellas Pharma Inc. (Tokyo) | ND | Drug repositioning collaboration | The collaboration is focused on identifying new indications for a number of undisclosed Astellas compounds using Biovista's Clinical Outcome Search Space technology | 12/4/15 |
Bioxcel Corp. (Branford, Conn.) | Takeda Development Center Americas (unit of Takeda Pharmaceutical Co. Ltd.; Osaka, Japan) | ND | Partnership for the repurposing of assets across the spectrum of rare diseases | The partnership will allow Takeda access to Bioxcel's Big Data Innovation Lab and PharmGPS orphan disease suite for drug discovery and repurposing | 4/10/15 |
Bioxcel Corp. (Branford, Conn.) | Pronutria Biosciences Inc. (Cambridge, Mass.) | ND | Strategic big data collaboration to identify diseases characterized by high unmet need for therapies and nutritional products that are amenable to Pronutria's technology platform, developing a new class of products to mediate amino acid biology | CRL will provide in vitro and in vivo pharmacology, drug metabolism and pharmacokinetics, and medicinal chemistry services to develop a drug to treat infections in cystic fibrosis patients | 10/21/15 |
Blinkbio Inc. (Jupiter, Fla.) | Janssen Pharmaceuticals Inc. (unit of Johnson & Johnson; New Brunswick, N.J.) | ND | Collaboration in the discovery research area, in order to accelerate the optimization of prototype leads discovered in the company's self-assembling dimer program targeting the inhibition of Protein-Protein Interactions | Terms were not disclosed | 10/9/15 |
Bluebird Bio Inc. (Cambridge, Mass.) | Five Prime Therapeutics Inc. (South San Francisco) | $131.50 | Exclusive rights agreement to Five Prime's human antibodies to an undisclosed cancer target for hematologic malignancies and solid tumors | Bluebird will leverage its lentiviral gene platform therapy and CAR-T capabilities; Five Prime gets $1.5M up front, plus more than $130M per licensed product if certain development, regulatory and commercial milestones are hit; deal also includes tiered royalties, and Bluebird will conduct and pay for clinical development, as well as regulatory and commercial activities | 5/28/15 |
Bluebird Bio Inc. (Cambridge, Mass.) | Celgene Corp. (Summit, N.J.) | $25.00 | Amended and restated deal to focus on developing product candidates targeting B-cell maturation antigen during a three-year commercial term | The original collaboration, initiated in 2013, was focused on applying gene therapy technology to genetically modify a patient's own T cells to target and destroy cancer cells; the firms will work on the initial lead anti-BCMA candidate, bb2121, with a phase I trial to start in 2016, and develop next-generation candidates; Bluebird gets $25M, plus milestones, and Celgene has an option to develop and commercialize each product candidate worldwide; Bluebird has the option to share equally in development, promotion and profits for each candidate | 6/5/15 |
Bluebird Bio Inc. (Cambridge, Mass.) | Viromed Co. Ltd. (Seoul, Korea) | $48.00 | Exclusive license agreement to research, develop and commercialize chimeric antigen receptor (CAR) T-cell therapies using Viromed's humanized antibody to an undisclosed cancer target for solid tumors | Bluebird will leverage its lentiviral gene therapy platform and CAR T capabilities to develop CAR T therapies against the target; financial terms include a $1M up-front payment and subsequent milestone payments to Viromed, which together could total more than $48M per licensed product; Viromed is eligible to receive tiered royalties; Bluebird will conduct and fund clinical development as well as regulatory and commercial activities | 12/4/15 |
Blueprint Medicines Corp. (Cambridge, Mass.) | Alexion Pharmaceuticals Inc. (Cheshire, Conn.) | $265.00 | Strategic collaboration centered on an undisclosed activated kinase target, which is the cause of a rare genetic disease | Blueprint gets $15M up-front, will be reimbursed for research expenses and will be eligible to receive more than $250M in milestone payments, plus royalties | 3/4/15 |
BMG Pharma Srl (Milan, Italy) | Sayre Therapeutics Ltd. (Bangalore, India) and Vestiq Pharmaceuticals Inc. | ND | Distribution agreements to distribute its cancer supportive products | Sayre will handle distribution in India and other Asian counties while Vestiq will handle U.S. distribution | 8/3/15 |
BMG Pharma Srl (Milan, Italy) | Sayre Therapeutics Ltd. (Bangalore, India) and Vestiq Pharmaceuticals Inc. | ND | Distribution agreements to distribute its cancer supportive products | Sayre will handle distribution in India and other Asian counties while Vestiq will handle U.S. distribution | 8/3/15 |
Boehringer Ingelheim Pharmaceuticals Inc. (Ridgefield, Conn.) | Hanmi Pharmaceutical Co. Ltd. (Seoul, South Korea) | ND | License and collaboration agreement for the development and global commercialization rights, except South Korea, China and Hong Kong, for HM61713 to treat lung cancer | Hanmi will receive an initial payment of $50M and is entitled to potential milestone payments of $680M plus tiered double-digit royalties on future net sales | 7/29/15 |
Boston Therapeutics Inc. (Manchester, N.H.) | Sugardown Co. Ltd. (Hong Kong) | ND | Expanded agreement for licensing and marketing of Boston's sugardown | SDCL can market sugardown in Japan; the agreement already includes China, Hong Kong, Macau, Korea, Taiwan, Singapore, Thailand, Malaysia, Vietnam, the Philippines, Myanmar, Indonesia, Laos, Brunei and Cambodia | 3/18/15 |
Braeburn Pharmaceuticals (Princeton, N.J.) | Endo International plc (Dublin) | ND | Agreement in which Braeburn acquired an implantable, six-month formulation of the antipsychotic risperidone from Endo | The deal included global rights to other potential applications of the implant platform technology known as the Medlaunch implant program; Braeburn plans to meet with the FDA and to begin by year-end a phase III study in schizophrenia | 5/4/15 |
Braeburn Pharmaceuticals (Princeton, N.J.) | Oncothyreon Inc. (Seattle) | ND | Licensing agreement for development and commercialization rights to ATI-9242 to treat schizophrenia | Braeburn plans to develop ATI-9242 as a long-acting formulation, with a phase II trial planned to begin this year | 5/4/15 |
Brickell Biotech Inc. (Miami) | Orca Pharmaceuticals Inc. (Oxford, U.K.) and New York University | ND | Exclusive worldwide licensing agreement to a series of retinoic acid-related orphan nuclear receptor gamma (RORy) inhibitors | Brickell will assume the responsibility for the continued research and development of those RORy inhibitors, initially targeting the topical treatment of psoriasis | 11/25/15 |
BRIM Biotechnology Inc. | Janssen Pharmaceutical NV (unit of Johnson & Johnson; New Brunswick, N.J.) | ND | Collaboration agreement for research, development and commercialization of compounds identified by Janssen for dengue fever indications | The deal involves milestone and royalty payment terms for BRIM, including if and when Janssen exercises their right of return on the drug | 6/22/15 |
Bristol-Myers Squibb Co. (New York) | Medical University of South Carolina (Charleston, S.C.) | ND | Translation research collaboration focused on fibrotic diseases, including scleroderma, renal fibrosis and idiopathic pulmonary fibrosis | The research will address mechanistic understanding of fibrosis, patient segmentation based on disease characteristics and biomarker approaches and predictors of disease progression | 7/16/15 |
Bristol-Myers Squibb Co. (New York) | Viiv Healthcare Ltd. (London) | $2,905.00 | BMS sold its HIV therapies, including its entire R&D pipeline, to Viiv | Viiv is paying $350M up front, plus milestones of up to $518M for the clinical assets and up to $587M for the discovery and preclinical programs; BMS also is entitled to tiered royalties on product sales, and Viiv agreed to pay sales-based milestone of up to $750M apiece for clinical assets and up to $700M for each of the discovery and preclinical programs | 12/21/15 |
Burning Rock (Guangzhou, China) | Illumina Inc. | ND | Partnership for next-generation sequencing (NGS) technology focused on oncology | Burning Rock will help Illumina develop advanced clinical applications for molecular diagnostics | 8/31/15 |
Calico Life Sciences LLC (South San Francisco) | QB3 (San Francisco) | ND | Partnership to pursue research on longevity and age-related diseases | Calico will fund the four-year partnership to support QB3 aging research projects; it has the option to exclusive rights to discoveries made during the life of the agreement | 3/25/15 |
Calithera Biosciences Inc. (San Francisco) | Transtech Pharma LLC and affiliate High Point Pharmaceuticals LLC (High Point, N.C.) | $108.10 | Exclusive global license agreement to a portfolio of hexokinase II inhibitors | Deal includes $600,000 up front; Calithera will owe development and regulatory milestone payments of up to $30.5M for the first licensed product, and Transtech is eligible for up to $77M in sales-based milestones, plus mid-single-digit royalty payments on tiered sales of the first commercialized product; Calithera also will fund up to $1.1M during the first 12 months to develop additional hexokinase inhibitors | 3/9/15 |
Camurus AB (Lund, Sweden) | Solasia Pharma K.K. (Tokyo) | ND | License and distribution agreement for episil oral liquid to treat oral mucositis pain | Solasia received exclusive commercialization rights to episil in Japan and China in return for a signing fee and development milestones; Camurus also will supply Solasia's requirements of commercial product for Japan and China | 3/31/15 |
Canbex Therapeutics Ltd. (London) | Ipsen SA (Paris) | $6.80 | Exclusive option for Ipsen to purchase the small University College London spin-off | Ipsen paid E6M (US$6.8M) up-front for the option; if exercised, it would pay E90M additional | 2/25/15 |
Canbridge Life Sciences Inc. (Beijing) | Apogenix GmbH (Heidelberg, Germany) | ND | Licensing deal for APG101, an onco-immunotherapy targeting the CD95 ligand for a highly lethal and difficult to treat type of brain cancer, glioblastoma multiforme | Canbridge has provided an up-front payment, with the promise of milestones and royalties, in exchange for the technology and rights to develop and commercialize APG101 in China, Hong Kong and Macau; Canbridge signed on for indications beyond glioblastoma as well | 7/20/15 |
Can-Fite Biopharma Ltd. (Petach Tikva, Israel) | Cipher Pharmaceuticals Inc. (Mississauga, Ontario) | $2.90 | Distribution agreement for CF101, an A3 adenosine receptor agonist to treat moderate to severe psoriasis and rheumatoid arthritis in the Canadian market | Cipher is making an up-front payment of C$1.65M (US$1.3M) and the agreement provides additional milestone payments of up to C$2M (US$1.6M) plus royalty payments of 16.5% of net sales of CF101 in Canada | 3/24/15 |
Cannabis Science Inc. (Washington) | Igxbio Inc. (Fairway, Kan.) | ND | Deal for Cannabis' Genepro DNA-based immunotherapy to develop joint protocols exploring potential synergistic effects of that candidate with Cannabis' cannabinoid drug CS-TATI-1 | Genepro is designed to promote an anti-HIV immune response that facilitates virus control in HIV-infected subjects | 11/3/15 |
Cannabis Sciences Inc. (Colorado Springs, Colo.) | Igxbio Inc. (Fairway, Kan.) | ND | Collaboration deal to develop a joint protocol to demonstrate potential synergistic effects of their drug candidates in HIV, as well as potential new drug candidates | Genepro is an immune-therapeutic intended to promote an anti-HIV immune response for virus control | 5/28/15 |
Capria Inc. (Redwood City, Calif.) | Clinvest (part of Banyan Group Inc.) | ND | Agreement to develop a therapeutic product to treat cluster headache using Capria's nasal, non-inhaled carbon dioxide technology | Clinvest will conduct an investigator-sponsored trial evaluating Capnia's nasal CO2 technology in up to 50 patients with episodic cluster headaches | 1/7/15 |
Cardio3 Biosciences SA (Mont-Saint-Guibert, Belgium) | Celdara Medical LLC (Lebanon, N.H.) | $60.00 | Deal to acquire Oncyte, the immuno-oncology arm of Celdara, in a CAR T-cell deal | Cardio3 is making an up-front payment of $10M, followed by $50M in development and regulatory milestones, plus up to $21M in milestones for each subsequent product; if net sales exceed $1B, Celdara gets $80M in sales milestones, plus royalties | 1/7/15 |
Cardiome Pharma Corp. (Vancouver, British Columbia) | AOP Orphan Pharmaceuticals AG (Vienna) | ND | Commercialization agreement for AOP Orphan to sell AOP's Esmocard and Esmocard Lyo in Italy, France, Spain and Belgium | Esmocard is a treatment for supraventricular tachycardia | 5/13/15 |
Cardiome Pharma Corp. (Vancouver, British Columbia) | Mitsubishi Tanabe Pharma Europe Ltd. (subsidiary of Mitsubishi Tanabe Pharma Corp.; Osaka, Japan) | ND | Agreement to co-promote Cardiome's Aggrastat (tirofiban HCL) and Mitsubishi Tanabe's Exembol (argatroban monohydrate) in the UK for an initial three-year term | Financial terms were not disclosed | 10/1/15 |
Catabasis Pharmaceuticals Inc. (Cambridge, Mass.) | Actigraph | ND | Collaboration to explore the potential utility of daily physiological activity monitoring in boys affected by Duchenne muscular dystrophy | The study is designed to monitor the activity of young boys who are affected by DMD and collect baseline and longitudinal data using Actigraph activity monitors, which use an accelerometer to continuously measure movement | 11/20/15 |
Celgene Corp. (Summit, N.J.) | Astrazeneca plc (London) | $450.00 | Out-licensing agreement to develop MEDI4736, an anti-PD-L1 antibody, I n hematological cancers | Celgene will pay $450M up-front and will lead the clinical program and be responsible for all R&D costs up to the end of 2016, when it will switch to paying 75% of those costs; Celgene will be responsible for commercialization and will receive royalties starting at 70%; Astrazeneca will do the manufacturing | 4/27/15 |
Celgene Corp. (Summit, N.J.) | Juno Therapeutics Inc. (Seattle) | $150.00 | Ten-year collaboration to leverage T-cell therapies and develop treatments targeting cancer and autoimmune diseases, with an initial focus on Chimeric Antigen Receptor Technology (CAR-T) and T Cell Receptor (TCR) technologies | Celgene has the option to be the commercialization partner for certain Juno candidates, including Juno's CD19 and CD22 directed CAR-T candidates; for Juno-originated programs, Juno will be responsible for research and development in North America and retains commercialization rights in those territories; Celgene will be responsible for development and commercialization in the rest of the world, will pay Juno a royalty on sales in those territories and has certain co-promotion options; Juno will receive an up-front payment of approximately $150M, and Celgene will purchase 9,137,672 shares of Juno's common stock at $93 per share | 6/30/15 |
Celgene Corp. (Summit, N.J.) | Bionor Pharma ASA (Oslo, Norway) | ND | Agreement to secure a continued supply of Istodax (romidepsin) for use in a phase II combination study of Vacc-4x | Financial terms of the agreement were not dislosed | 7/17/15 |
Celgene Corp. (Summit, N.J.) | Nurix Inc. (San Francisco) | $150.00 | Deal to discover and develop new therapies targeting the ubiquitin proteasome system for the treatment of cancer, inflammation and immune disorders | The deal includes a $150M up-front payment for Nurix, plus an undisclosed equity investment, validating earlier seed and series B investments by Third Rock Ventures and the Column Group that established the company | 9/17/15 |
Cell Medica Ltd. (London) | Cell Therapy Catapult (London) | ND | Collaboration to accelerate the UK's National Health Service's adoption of Cell Medica's Cytovir CMV, an individualized immune cell therapy that infuses immune cells from a bone marrow donor into an immunosuppressed patient | Cell Therapy Catapult said it would be one of the first cellular immunotherapies to be considered for use within the NHS | 3/12/15 |
Celladon Corp. (San Diego) | Novasep (Pompey, France) | ND | Development, manufacturing and supply agreement in which Novasep will manufacture Mydicar drug substance through 2018, with extension options through 2020 | Financial terms were not disclosed; Mydicar, a genetically targeted enzyme replacement therapy based on AAV1/SERCA2a, is in phase IIb testing for advanced heart failure | 3/26/15 |
Cellectar Biosciences Inc. (Madison, Wis.) | Pierre Fabre SA (Castres, France) | ND | Collaboration to study the combination of Cellectar's phospholipid drug conjugate delivery platform with some of Pierre Fabre's cytotoxics | Financial terms were not disclosed | 12/17/15 |
Cellectis SA (Paris) | Modiquest Research BV (Oss, the Netherlands) | ND | Collaboration to generate monoclonal antibodies against targets selected by Cellectis using Modiquest's electrofusion technology, Modifuse | Financial terms were not disclosed | 3/9/15 |
Cellectis SA (Paris) | Pfizer Inc. (New York) and Les Laboratoires Servier SAS (Neuilly-sur-Seine, France) | $338.00 | Agreements related to UCART19 allogeneic CAR T-cell therapy, which attained clinical proof of concept, in spectacular fashion, in acute lymphoblastic leukemia | Servier is paying $38M up front and could pay more than $300M more in milestone payments, plus research funding and sales royalties; Pfizer is getting U.S. rights to the program, by entering a co-development and co-commercialization deal with Servier, and the two firms will split development costs | 11/20/15 |
Celltrion Inc. (Incheon, South Korea) | Pfizer Inc. (New York) | ND | Pfizer returned rights to Celltrion to potential biosimilar candidates to Rituxan (rituximab, Biogen Inc. and Roche AG) and Herceptin (trastuzumab, Roche AG) | The big pharma said the move was intended to eliminate certain redundancies in its biosimilars pipeline following its $17B acquisition of Hospira Inc., of Lake Forest, Ill. | 10/28/15 |
Cellular Biomedicine Group Inc. (Shanghai) | Blackbird Bio Finance | $29.25 | Cellular is acquiring the immuno-oncology vaccine CD40LGVAX from Blackbird for $2.5M in cash and $1.75M in common stock | CBMG said it could pay more than $25 million in future milestones and royalty payments tied to the program, for which it is the exclusive global licensee | 6/10/15 |
Cel-Sci Corp. (Vienna, Va.) | Ergomed plc (London) | $12.00 | Expanded co-development agreement to include additional activities by Ergomed | Ergomed will contribute $12M (up from $10M) to a phase III trial of Multikine in those with advanced primary head and neck cancer; Ergomed will receive a single digit percentage of milestone and royalty payments | 10/6/15 |
Celyad SA (Mont-Saint-Guibert, Belgium) | Medisun International Ltd. (Hong Kong) | $22.46 | Collaboration and distribution agreement for C-Cure to treat ischemic heart failure | Celyad will pursue market approval in China, Hong Kong, Taiwan and Macau, with a minimum of $22.46M to come from Medisun; Celyad also will receive royalties and profit sharing, with royalties ranging from 10% to 30% and profit sharing from 20% to 25%; the deal is for an initial 15 years | 9/1/15 |
Cerecor Inc. (Baltimore) | Eli Lilly and Co. (Indianapolis) | ND | Exclusive, worldwide rights agreement to develop and commercialize LY2456302, a phase II-ready, selective kappa opioid receptor (KOR) antagonist | KORs are believed to play a key role in modulating stress, mood and addictive disorders; terms of the license includes undisclosed milestone payments and royalties | 2/23/15 |
Cerulean Pharma Inc. (Cambridge, Mass.) | Astrazeneca plc (London) and the National Cancer Institute | ND | Collaborative agreement focused on Lynparza (olaparib) and CRLX101 | They will explore the synergistic affects in a phase I/IIa trial conducted by the NCI | 11/18/15 |
Cerus Corp. (Concord, Calif.) | Untys (Buffalo, N.Y.) | ND | Three-year purchase agreement for the Intercept Blood System, which Untys will use to provide blood components to eight counties in Western New York | The deal involves supplying about 5,000 platelet and 11,000 plasma units per year | 7/22/15 |
Cesca Therapeutics Inc. (Rancho Cordova, Calif.) | Miltenyi Biotec GmbH (Bergisch Gladbach, Germany) | ND | Multiyear distribution agreement for clinical product sales throughout India | Totipotentrx's haploidentical transplant program will incorporate Miltenyi's Clinimacs cell separation system, used for selecting beneficial cells or depleting donor immune cells from grafts that may interfere with engraftment in preparation for bone marrow transplantation | 10/29/15 |
Cevec Pharmaceuticals GmbH (Cologne, Germany) | Biotest AG (Dreieich, Germany) | ND | Licensing agreement for its CAP Go technology for the development, production and commercialization of candidate molecules to treat symptoms of hemophilia patients | Cevec will receive service fees for ongoing development support, up-front and milestone payments as well as royalties on future product sales | 7/2/15 |
Cevec Pharmaceuticals GmbH (Cologne, Germany) | Genethon (Evry, France) | ND | Collaboration agreement for the development and exploitation of lentivirus packaging cell lines based on Cevec's CAPGT technology | Cevec will grant Genethon a license for the development of lentivirus packaging cell lines based on CAPGT to be used with its own portfolio of gene therapy products in the field of rare diseases | 9/18/15 |
Cevec Pharmaceuticals GmbH (Cologne, Germany) | Biolamina AB (Stockholm) | ND | Strategic collaboration for the commercial production of research-grade and clinical-grade laminins for ex vivo cell culture applications using Cevec's Capgo technology | Financial details were not disclosed | 10/29/15 |
Charles River Laboratories International Inc. (Wilmington, Mass.) | Antabio SAS (Labège, France) | ND | Drug discovery partnership | CRL will provide in vitro and in vivo pharmacology, drug metabolism and pharmacokinetics, and medicinal chemistry services to develop a drug to treat infections in cystic fibrosis patients | 10/8/15 |
Charles River Laboratories International Inc. (Wilmington, Mass.) | Pcovery A/S (Copenhagen, Denmark) | ND | Drug discovery partnership | CRL will provide in vitro and in vivo pharmacology, drug metabolism and pharmacokinetics, and medicinal chemistry services to develop antifungal treatments with the potential to destroy otherwise drug-resistant fungi | 10/8/15 |
Checkmate Pharmaceuticals Inc. (Cambridge, Mass.) | Cytos Biotechnology AG | $90.00 | Licensing agreement for all oncology applications of Cytos' immuno-stimulatory therapeutic vaccine CYT003 and its underlying phage Qbeta-based virus-like particle technology | The deal is worth up to $90M in milestones plus double-digit royalties | 8/13/15 |
Chemo-Sero Therapeutic Research Institute (Kaketsuken) (Kumumoto, Japan) | Valneva SE (Lyon, France) | ND | License agreement for the development of human vaccines on its EB66 cell line | Chemo-Sero receives a license to develop a human vaccine candidate using the EB66 cell line, following two marketing approvals in Japan for an EB66-based pandemic H5N1 influenza vaccine in March 2014 and for an EB66-based prototype vaccine against any strain of pandemic influenza in March 2015 | 8/28/15 |
Chemrar High Tech Center (Moscow) | Lancet Russian Distribution Co. | ND | Collaboration for research, development and commercialization of new medicines in Russia with the intention to stimulate the innovative development of the Russian pharmaceutical industry | Chemrar and Lancet plan to develop and manufacture new drugs in major therapeutic areas that are a high priority for the Russian Federation health care system | 4/17/15 |
Chromocell Corp. (North Brunswick, N.J.) | Astellas Pharma Inc. (Tokyo) | $500.00 | Development agreement for the oral Nav1.7 inhibitor CC8464 to treat neuropathic pain | The deal includes $15M up front, and is worth $500M total; Chromocell will conduct all development of CC8464 through the phase IIa proof-of-concept experiment and may launch studies in other indications, with Astellas holding the right to opt-in for development | 9/29/15 |
Cimaas BV (Maastricht, the Netherlands) | Pharmacell BV (Maastricht, the Netherlands) | ND | Collaboration for the clinical development of Cimaas' products | Pharmacell will provide consulting services in writing GMP-compliant documents in order to translate Cimaas cell therapy processes into GMP; options have been taken on a full technology transfer trajectory to be started and executed later, and there is a continuation option on a phase I and possibly a phase II trial | 7/14/15 |
Cipher Pharmaceuticals Inc. (Mississauga, Ontario) | Ferrer Internacional SA (Barcelona, Spain) | ND | Licensing agreement for Canadian rights to Ozenoxacin, a topical treatment for adult and pediatric patients with impetigo | In 2013, Ferrer successfully completed a first phase III trial of Ozenoxacin, which demonstrated the superiority of Ozenoxacin 1% cream vs. a placebo, applied topically twice daily for five days, on both the clinical and bacteriological endpoints by end of therapy visit | 1/8/15 |
Cipher Pharmaceuticals Inc. (Mississauga, Ontario) | Astion Pharma A/S (Copenhagen) | $31.97 | Agreement under which Cipher acquired worldwide rights to three products from Astion | The products include Dermadexin, a topical barrier-repair cream containing the pharmacologically active ingredient P3GCM, approved in the EU in 2014 for seborrheic dermatitis; Pruridexin, a topical cream for the treatment of chronic pruritis (itching); and ASF-1096. a product candidate in phase II for discoid lupus erythematosus; the transaction includes an up-front payment to Astion of C$6M (US$4.8M); a subsequent C$2.5M (US$2M) milestone will be paid upon regulatory approval and commercialization of Dermadexin or Pruridexin in the U.S, which is where Cipher will focus its commercialization efforts; the agreement includes approximately C$31.5M (US$25.17M) in additional payments contingent upon clinical milestones, regulatory approvals, commercialization and sales milestones in the both the U.S. and other regions | 2/27/15 |
Cipher Pharmaceuticals Inc. (Mississauga, Ontario) | Almirall SA (Barcelona, Spain) | ND | Agreement in which Cipher acquired the Canadian rights to Vaniqa and Actikerall from Almirall | Almirall will receive an up-front payment of C$450,000 (US$373,936) and is eligible for certain milestones from product sales in Canada | 5/7/15 |
Circassia Pharmaceuticals plc (Oxford, UK) | Nanopass Technologies Ltd. (Nes Ziona, Israel) | ND | Circassia gained an exclusive license to use Nanopass' Micronjet600 | Terms were not disclosed | 5/7/15 |
Clearside Biomedical Inc. (Alpharetta, Ga.) | Iscience Interventional Corp. (Menlo Park, Calif.) | ND | Acquisition of Iscience's patent portfolio covering drug delivery to the suprachoroidal space | Terms were not disclosed | 4/23/15 |
Clearside Biomedical Inc. (Alpharetta, Ga.) | Santen Inc. (subsidiary of Santen Pharmaceuticals Co. Ltd.; Osaka, Japan) | ND | Expanded research collaboration to include the field of glaucoma | The two companies have worked together since January 2013 to develop drugs to treat diseases afflicting the retina and chorioid that can eventually lead to blindness; they will now study the use of Clearside's microinjector to deliver sustained intraocular pressure-lowering medications | 5/5/15 |
Clinigen Group plc (Burton on Trent, UK) | Hospira Inc. (Lake Forest, Ill.) | ND | Extended and renegotiated an exclusive U.S. license and distribution agreement covering the antiviral Foscavir | The agreement extends the initial five-year term from May 2017 to December 2019; Foscavir was approved by the FDA in May 2012 to treat HIV/AIDS-related cytomegalovirus infections and herpes | 3/12/15 |
Cloud Pharmaceuticals Inc. (Research Triangle Park, N.C.) | Genomeon LLC (Floyd, Va.) | ND | Partnership designed to enable Cloud to offer ocmpanion biomarkers as part of its drug development process | Genomeon's technology is systematically farming the approximately 1M microsatellites in the genome to identify potentially informative patterns of variation between healthy and diseased individuals and to identify potential new drug targets | 8/6/15 |
Cloud Pharmaceuticals Inc. (Research Triangle Park, N.C.) | Therametrics Holding AG (Stans, Switzerland) | ND | Collaboration to design and develop therapeutics for orphan central nervous system diseases and other indications | The partnership will initially focus on Huntington's disease, amyotrophic lateral sclerosis, progressive supranuclear palsy and frontotemporal dementia; in parallel to those efforts, both companies will pursue sponsored development for additional respiratory indications | 9/30/15 |
CMC Biologics A/S (Copenhagen) | River Vision Development Corp. (New York) | ND | Agreement for the process transfer and cGMP production of RV001 (teprotumumab), River's recombinant monoclonal antibody targeting insulin-like growth factor 1, in development for treatment of Grave's orbitopathy and other indications | CMC will transfer teprotumumab manufacturing into its facility in Copenhagen for process optimization, validation and cGMP manufacture to support River's phase III trials and future commercial supply requirements for both the U.S. and Europe | 7/30/15 |
Codexis Inc. (Redwood City, Calif.) | Merck & Co. Inc. (Kenilworth, N.J.) | ND | Extension agreement to license and supply a proprietary enzyme used in the manufacturing process for sitagliptin, the active ingredient in Merck's Januvia and one of the active ingredients in Merck's Janumet | Under a research and development agreement, Codexis and Merck used the Codeevolver protein engineering platform technology to develop a customized enzyme to serve as a biocatalyst in the sitagliptin process | 12/18/15 |
Coherus Biosciences Inc. (Redwood City, Calif.) | Baxter International Inc. (Deerfield, Ill.) | $12.00 | Amended collaboration to develop and commercialize CHS-0214, a biosimilar of Enbrel (etanercept, Amgen Inc.), for Europe, Canada, Brazil and other markets | Milestones and funding obligations have been revised; expansion includes select pre-commercialization activities; revised milestones may exceed previous funding obligations by about $12M, and Baxter will buy Coherus stock in a private placement | 4/16/15 |
Coherus Biosciences Inc. (Redwood City, Calif.) | KBI Biopharma Inc. (Durham, N.C.) | ND | Manufacturing agreement for long-term manufacturing of CHS-1701, Coherus' Neulasta (pegfilgrastim, Amgen Inc.) biosimilar candidate | KBI will manufacture and deliver the necessary amounts of the product for a planned commercial launch and multiple years to supply CHS-1701 for sales; Coherus said it anticipates filing a biologics license application in the second quarter of 2016 | 12/22/15 |
Complix NV (Hasselt, Belgium) | Selexis SA (Geneva) | ND | Agreement to enable the production of CMX-02, a bispecific Alphabody-antibody fusion protein that simultaneously targets TNF-alpha and interleukin-23, as a potential treatment of cancer and severe autoimmune diseases | Complix will have access to Selexis’ Suretechnology Platform for the production of high-expressing and stable clonal cell lines for use in the development and commercial manufacturing of CMX-02 | 12/15/15 |
Concordia Healthcare Corp. (Toronto) | Covis Pharma Sarl (Zug, Switzerland) | $1,200.00 | Acquisition of 18 products, comprising 12 branded products, five authorized generic contracts and a product distributed by a third party in Australia | The $1.2B acquisition was pursuant to the terms of a distribution agreement | 4/22/15 |
Confluence Pharmaceuticals Inc. (Indianapolis) | Aop Orphan Pharmaceuticals AG (Vienna) | ND | Definitive agreement to co-develop and market Confluence's lead asset, a product for the treatment of Fragile X syndrome in Europe and the Middle East | Terms were not disclosed | 3/24/15 |
Congenica Ltd. (Cambridge, U.K.) | UCB SA (Brussels, Belgium) | ND | To use genome sequence analysis and interpretation in its core therapeutic areas of autoimmune and inflammatory disease, and diseases of the central nervous system | Terms were not disclosed | 12/18/15 |
Convoy Therapeutics Inc. (Tucson, Ariz.) | CTX Technology Inc. (Tucson, Ariz.) | ND | CTX acquired the intellectual property, formulations for both therapeutic and aesthetic applications and related data of Convoy | The peptide platform technology is capable of transporting small and large molecules, with a wide range of molecular weights, including biologics, into the skin and ensuring that they remain at the site of local placement | 8/5/15 |
Coronado Biosciences Inc. (New York) | Revogenex Ireland Ltd. (Dublin) | $2.00 | Exclusive license agreement to an intravenous formulation of tramadol for the U.S. market | Coronado formed a wholly owned subsidiary, Avenue Therapeutics Inc., to acquire, in-license, develop and commercialize products for use in the U.S. hospital market and will transfer the Revogenex license to Avenue; Revogenex received an up-front payment of $2M and will be eligible for additional milestone payments, plus royalties | 2/19/15 |
Correvio International Sarl (subsidiary of Cardiome Pharma Corp.; Vancouver, British Columbia) | Eddingpharm Co. Ltd. (Shanghai) | ND | Exclusive license and supply agreement to distribute and commercialize Aggrastat in China | Terms include milestone payments and minimum annual commercial commitments | 8/25/15 |
Corvus Pharmaceuticals Inc. (Burlingame, Calif.) | Genentech (unit of Roche Group; Basel, Switzerland) | ND | Clinical trial collaborative agreement for a phase I/Ib trial of CPI-444, Corvus' small-molecule immune checkpoint inhibitor | Financial details were not disclosed | 10/27/15 |
Crispr Therapeutics AG | Vertex Pharmaceuticals Inc. | $2,625.00 | Four-year collaboration to discover and develop treatments for genetic diseases, including cystic fibrosis and sickle cell disease | Crispr is set to receive $105M up front, including $75M in cash and a $30M equity investment; Vertex has the option to an exclusive license for up to six gene-based treatments that emerge from the collaboration; for each of the treatment in-licensed for development, Vertex will pay up to $420M in milestones - potentially broadening the deal to $2.625B, plus royalties on product sales | 10/27/15 |
Crispr Therapeutics AG (Basel, Switzerland) | Bayer AG (Leverkusen, Germany) | $335.00 | Long-term alliance to leverage the CRISPR-Cas9 gene-editing technology | A joint venture will be formed involving a newly established Bayer Lifescience Center; Crispr will be contributing its CRISPR-Cas9 gene-editing technology and intellectual property to the venture, with Bayer making available its protein engineering expertise and relevant disease know-how; Bayer is providing a minimum investment of $300M in research and development over the next five years, and a minority stake in Crispr for $35M in cash | 12/22/15 |
Cristal Therapeutics BV (Maastricht, the Netherlands) | PX Biosolutions Ltd. (Melbourne, Australia) | ND | Collaboration focused on the application of Cristal's vaccine technology Crivac | No terms were disclosed | 7/15/15 |
Crystalgenomics Inc. (Seoul, South Korea) | Daewoong Pharmaceutical Co. Ltd. (Seoul, South Korea) | ND | Sales and marketing agreement for the commercialization of Acelex (polmacoxib) for osteoarthritis in Korea | Crystalgenomics, which will receive an up-front payment and milestone payments from Daewoong and will share profit from sales of the drug, said it now plans to pursue international partnerships to expand the market base for Acelex | 2/10/15 |
Crystalgenomics Inc. (Seoul, South Korea) | Dong-A ST Co. Ltd. (Seoul, South Korea) | $0.85 | Sales and marketing deal for commercialization of Acelex (polmacoxib) in Korea | Dong-A ST will secure exclusive rights in Korea to sell and market Acelex, 2 mg capsule, an anti-inflammatory nonsteroidal drug developed for osteoarthritis; Crystalgenomics will receive up to $847,696 in up-front and milestone payments and will share profits from sales | 8/14/15 |
Cumberland Pharmaceuticals Inc. (Nashville, Tenn.) | Clinigen Group plc (Trent, UK) | ND | Agreement for a strategic alliance in which Cumberland will be responsible for the support of Clinigen's future products through marketing, promotion and distribution in the U.S. | Clinigen will be responsible for the marketing, promotion, distribution and sale of Cumberland's pharmaceutical products outside of the U.S., enabling Cumberland to use Clinigen's international reach to enter new markets outside of the U.S. | 9/18/15 |
Curadev Pharma Private Ltd. (New Delhi, India) | Roche Holding AG (Basel, Switzerland) | $555.00 | Research collaboration and licensing agreement to develop and commercialize IDO1 (indoleamine-2, 3-dioxygenase-1) and TDO (tryptophan-2, 3-dioxygenase) inhibitors | Curadev will receive an up-front payment of $25M and will also be eligible to receive up to $530M in milestone payments, plus royalties | 4/21/15 |
Curecell Co. Ltd. (Korea) | Masthercell SA (Gosselies, Belgium) | ND | Memorandum of understanding to form a joint venture primarily focused on development, manufacturing and commercialization of cell therapy products in Korea | The alliance is intended to provide a framework of collaborative research in cell therapy that aims to contribute to the regenerative medicine and industry growth in Korea | 5/26/15 |
Curis Inc. (Lexington, Mass.) | Aurigene Discovery Technologies Ltd. (Bangalore, India) | $345.50 | Two-year immuno-oncology deal will work on an oral small-molecule antagonist of programmed death ligand-1 as well as an oral small-molecule inhibitor of interleukin-1 receptor-associated kinase 4 | Aurigene was issued about 17.1M shares of common stock; for each of the first two programs, Curis is paying Aurigene up to $52.5M per program, including $42.5M per program for approval and commercial milestones; for the third and fourth programs Curis would pay up to $50M each, $42.5M in milestones, and as much as $140.5M for any programs thereafter, $87.5M in milestones; Curis also will pay royalties on net sales ranging from high single digits to 10% | 1/22/15 |
Curis Inc. (Lexington, Mass.) | Aurigene Discovery Technologies Ltd. (Bangalore, India) | $6.00 | Curis exercised its options under a collaboration agreement and is expanding its pipeline with CA-170, which targets PD-L1 and V-domain Ig suppressor of T cell activation, and a program focused on inhibitors of interleukin-1 receptor-associated kinase 4 | Curis made a one-time payment of $6M in exchange for an exclusive, royalty-bearing license to develop, manufacture and commercialize compounds from the programs, including CA-170, anywhere in the world with the exception of India and Russia, where Aurigene will hold an exclusive, royalty-free, fully paid commercial license; Curis also selected a second preclinical program with Aurigene focused on evaluating small molecule antagonists with dual PD-L1 and T-cell immunoglobulin and mucin domain containing protein-3-targeting properties | 10/20/15 |
Cyclenium Pharma Inc. (Sherbrooke, Quebec) | Fundacion Centro de Excelencia en Investigacion de Meciamentos Innovadores en Andalucia (Granada, Spain) | ND | Drug discovery and collaboration agreement to use Cyclenium's library of macrocyclic molecules in concert with Fundacion Medina's infective disease research expertise to discover new anti-infective drug candidates effectives against bacterial and fungal pathogens | Terms were not disclosed | 2/24/15 |
Cyclenium Pharma Inc. (Sherbrooke, Quebec) | Haplogen GmbH (Vienna) | ND | Research agreement aimed at the discovery of pharmaceutical candidates in multiple disease areas through a pairing of the companies' drug discovery platforms | The partners will initially focus on certain antiviral Haplogen targets, with targets in other therapeutic indications being phased in as the research progresses | 5/8/15 |
Cyclenium Pharma Inc. (Sherbrooke, Quebec) | Astellas Pharma Inc. (Tokyo) | ND | Two-year drug discovery collaboration using Cyclenium's Quest Library of next-generation synthetic small-molecule macrocycles | Cyclenium will receive an up-front payment and research funding from Astellas, which will be responsible for preclinical and clinical development of any drug candidates that result from the efforts | 5/13/15 |
Cynata Therapeutics Ltd. (Melbourne, Australia) | Regience K.K. (Tokyo) | ND | Signed a letter of intent regarding a future strategic alliance for Japan and certain other Asian countries | The companies identified a mutually beneficial business opportunity to enter a business partnership under which Regience would license, develop and commercialize Cynata's Cymerus therapeutic mesenchymal stem cell technology in certain territories, including Japan; the firms will evaluate and define a commercial relationship, and, if appropriate, enter a strategic alliance agreement | 12/4/15 |
Cypher Genomics Inc. (San Diego) | Celgene Corp. (Summit, N.J.) | ND | Collaboration to apply Cypher's Coral technology to discover genomic biomarkers that associate with patient response to medicines | Terms were not disclosed | 5/21/15 |
Cypralis Ltd. (Ongar, UK) | Janssen Pharmaceuticals Inc. (unit of Johnson & Johnson; New Brunswick, N.J.) | ND | Collaboration aimed at developing new cyclophilin inhibitors for neurodegenerative diseases | Terms were not disclosed | 12/8/15 |
Cytobioteck SAS (Bogota, Colombia) | Pharming Group (Leiden, the Netherlands) | ND | Exclusive distribution agreement for Ruconest (recombinant human C1 inhibitor) to treat acute attacks of hereditary angioedema in Colombia and Venezuela | Cytobioteck will drive all regulatory processes and will purchase its commercial supplies of Ruconest from Pharming at a fixed transfer price | 5/27/15 |
Cytori Therapeutics Inc. (San Diego) | Worthington Biochemical Corp. (Lakewood, N.J.) | ND | Nonexclusive, three-year agreement to distribute Cytori's Celase GMP enzyme for research markets in the U.S. and select international countries | Financial terms were not disclosed | 12/2/15 |
Cytos Biotechnology AG (Schlieren, Switzerland) | Oncore Biopharma Inc. (Doylestown, Pa.) | $522.00 | Licensing deal for Qbeta virus-like particle vaccine platform to develop therapeutic and prophylactic vaccines against hepatitis B virus in a multiproduct deal | The deal is worth up to $522M, $402M of which would come in development milestones with another $120M in sales milestones; Cytos also would receive double-digit sales royalties; there is no up-front payment, and the full value is based on six products reaching the market | 1/7/15 |
Dalcor Pharmaceuticals (Quebec) | Roche AG (Basel, Switzerland) | ND | Agreement to develop a companion diagnostic test for dalcetrapib | The test will target patients with a specific genotype who experienced a recent acute coronary syndrome event and will be used in a phase III trial that will seek to validate the clinical efficacy of dalcetrapib | 6/10/15 |
Dandrit Biotech A/S (Copenhagen, Denmark) | Riyadh Pharma Co. Ltd. (Riyadh, Saudi Arabia) | ND | Partnership in which Riyadh will be responsible for manufacturing Dandrit's dendritic cell cancer vaccine, MCV, in the Middle East | Financial terms were not disclosed | 4/24/15 |
Dara Biosciences Inc. (Raleigh, N.C.) | Onxeo SA (Paris) | ND | Commercialization agreement granting Dara exclusive U.S. rights to Oravig, an orally dissolving buccal tablet approved for oral thrush | Dara also has the right to pursue regulatory approval in Canada which, if granted, would give it exclusive rights to market and sell Oravig there; Onxeo will receive undisclosed milestone payments upon the achievement of defined sales thresholds | 3/11/15 |
Dauntless Pharmaceuticals Inc. (San Diego) | Aegis Therapeutics LLC (San Diego) | ND | Licensing agreement with Aegis granting access to its Intravail drug delivery technology for an undisclosed oncology application, with an option for three additional drugs | Terms were not disclosed | 7/22/15 |
Debiopharm Group (Lausanne, Switzerland) | Novartis AG (Basel, Switzerland) | ND | Debiopharm re-acquired full rights to Alisporivir (DEB025) from Novartis | The product is currently completing two phase II studies of interferon-free treatment in hepatitis C virus; the terminated deal was a strategic decision for Novartis; Biorestorative and Novartis entered the collaboration in January 2010 | 1/13/15 |
Debiopharm International SA (Lausanne, Switzerland; part of Debiopharm Group) | Spinomix SA (Lausanne, Switzerland) | ND | Debiopharm is acquiring Spinomix's Fibrotrap sample processing technology | Financial terms were not disclosed | 6/17/15 |
Dendreon Corp. (Seattle) | Valeant Pharmaceuticals International Inc. (Laval, Quebec) | $400.00 | Amended agreement in connection with the court-supervised sales process | Under the amended terms, subject to bankruptcy court approval, Valeant would acquire worldwide rights to prostate cancer vaccine Provenge (sipuleucel-T) and certain other Dendreon assets for $400M subject to higher and better bids; terms of the original agreement, disclosed earlier this month, called for Valeant to pay $296M for Provenge and certain other Dendreon assets, subject to higher and better bids | 2/6/15 |
Denovo Biopharma LLC (San Diego) | Eli Lilly and Co. (Indianapolis) | ND | Exclusive license agreement for pomaglumetad methionil, a late-stage mGlu2/3 receptor agonist | Denovo gained all rights to develop, manufacture and commercialize the drug globally, including transfer of all intellectual property and other rights, data and information; Lilly has an option to reacquire pomaglumetad upon a successful clinical trial, for predetermined undisclosed financial terms | 3/4/15 |
Depomed Inc. (Newark, Calif.) | Janssen Pharmaceuticals Inc. (unit of Johnson & Johnson; New Brunswick, N.J.) | $1,005.00 | Agreement for U.S. rights to Janssen's Nucynta pain drug franchise | Depomed is paying $1.05B for the two pain products, an immediate-release and an extended-release version of tapentadol; the deal is expected to be completed in the second quarter; Depomed also will assume related royalty obligations for Nucynta to German pharma Grünenthal Group | 1/20/15 |
Diatheva srl (Fano, Italy) | Agenus Inc. (Lexington, Mass.) | $44.00 | Agreement in which Agenus acquired rights to antibodies targeting carcinoembryonic antigen cell adhesion molecule 1, or CEACAM1, a glycoprotein expressed on T cell and NK cell lymphocytes | Agenus gets exclusive worldwide rights to the antibodies in exchange for certain up-front early development, clinical trial and regulatory milestone payments totaling as much as $44M; Diatheva is also eligible to receive additional sales milestones and royalties | 7/21/15 |
Diaxonhit SA (Paris) | Felicitex Therapeutics Inc. (Cambridge, Mass.) | ND | Exclusive worldwide license agreement for a series of lead-stage anti-cancer compounds for development of therapeutics against quiescent cancer cells | Felicitex paid an up-front fee and is responsible for annual licensing payments, as well as milestone payments and royalties | 5/20/15 |
Dimension Therapeutics Inc. (Cambridge, Mass.) | Regenxbio Inc. (Rockville, Md.) | ND | Added the OTC and GSD1a indications to the firms' existing license agreement, which will enable Dimension to develop and commercialize products to treat those diseases using Regenxbio's NAV technology | Financial terms were not disclosed | 4/24/15 |
Dnatrix Inc. (Houston) | Merck & Co. Inc. (Kenilworth, N.J.) | ND | Oncology collaboration to research the efficacy and safety of Dnatrix's DNX-2401, an oncolytic immunotherapy, combined with Merck's Keytruda (pembrolizumab), an anti-PD-1 therapy, in a phase II, multicenter trial in those with recurrent glioblastoma | The collaboration will be carried out through Dnatrix and a Merck subsidiary | 10/2/15 |
DNX Biopharmaceuticals Inc. (Irvine, Calif.) | XL-protein GmbH (XLp; Freising, Germany) | ND | Collaboration for the development and commercialization of long-acting biopharmaceutical products | XLp will contribute its Pasylation technology, and certain molecules that have completed preclinical studies; DNX will add its pipeline of candidate molecules to address a range of unmet needs in immunology, metabolism and ophthalmology | 7/1/15 |
Domain Therapeutics SA (Strasbourg, France) | Clevexel Pharma (Maisons-Alfort, France) | ND | Agreement to develop A2a/A1 preclinical candidate for Parkinson's disease | Clevexel and Kaldi inked a deal to share future revenues on the program; Kaldi is expected to grant a second license for the A2a in oncology to another partner | 3/5/15 |
Domainex Ltd. (Cambridge, UK) | Auspherix Ltd. (Stevenage, UK) | ND | Expanded their collaboration through to 2017 to develop new drugs to tackle antibiotic resistance | The extension will build upon their work started in 2014 on creating new compounds with activity against both gram-positive and gram-negative bacteria | 9/16/15 |
Dr. Reddy's Laboratories Ltd. (Hyderabad, India) | Amgen Inc. (Thousand Oaks, Calif.) | ND | Strategic collaboration to market and distribute three of Amgen's medicines in India | Dr. Reddy's will perform a full range of regulatory and commercial services to seek approval and launch Kyprolis (carfilzomib), Blincyto (blinatumomab) and Repatha (evolocumab) in India | 8/7/15 |
Dr. Reddy's Laboratories Ltd. (Hyderabad, India) | Hatchtech Pty. Ltd. (Melbourne, Australia) | ND | Commercialization deal for Xeglyze Lotion, a head lice product | Dr. Reddy's will have exclusive rights in the U.S., Canada, India, Russia and the CIS, Australia, New Zeland and Venezuela; Hatchtech will file an NDA for Xeglyze with the FDA immediately; Dr. Reddy's will pay $10M up front, up to $50M in commercial milestones and an undisclosed amount based on post-commercialization milestones | 9/15/15 |
Dynavax Technologies Corp. (Berkeley, Calif.) | Merck & Co. Inc. (Kenilworth, N.J.) | ND | Clinical trial collaborations to investigate the potential synergistic effect of combining immunotherapies from Merck's anti-PD-1 therapy, Keytruda, and its anti-interleukin-10 immunomodulator, MK-1966, with Dynavax's Toll-like receptor 9 agonist, SD-101 | Financial terms were not disclosed | 6/2/15 |
Eagle Pharmaceuticals Inc. (Woodcliff Lake, N.J.) | Teva Pharmaceutical Industries Ltd. (Jerusalem) | $120.00 | Exclusive license agreement for Eagle's EP-3102, its bendamustine hydrochloride rapid infusion product for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin lymphoma | Teva will conduct all U.S. commercial activities, while Eagle will spearhead obtaining regulatory approvals and any post-approval clinical studies that are needed; Eagle will receive an up-front cash payment of $30M and is eligible to receive up to $90M in additional milestone payments; Eagle also will receive double-digit royalties | 2/18/15 |
Eagle Pharmaceuticals Inc. (Woodcliff Lake, N.J.) | Teikoku Pharma USA Inc. (San Jose, Calif.) | ND | Exclusive license agreement to market, sell and distribute TPU's docetaxel injection, non-alochol formula in the U.S. | Terms call for Eagle to pay Taikoku near-term milestones, including an up-front cash payment, an additional payment based on timing of an FDA approval and double-digit royalties on gross profits | 10/16/15 |
Eagle Pharmaceuticals Inc. (Woodcliff Lake, N.J.) | Spectrum Pharmaceuticals Inc. (Henderson, Nev.) | $21.80 | Co-promotion agreement where the Spectrum 32-person corporate accounts sales team will dedicate 80% of its time to selling and marketing up to six of Eagle's products over a period of at least 18 months | Eagle will pay Spectrum a base fee of $12.8M over 18 months; Spectrum will also have the opportunity to earn an additional $9M in specific identified sales milestone payments if its sales team surpasses sales projections, for a potential total payment of up to $22M in base fee and specified milestones over 18 months; the agreement grants both companies the opportunity for six-month renewal periods upon mutual agreement | 11/6/15 |
Easton Pharmaceuticals Inc. (Toronto) | BMV Medica SA de CV (Mexico) | ND | Memorandum of understanding toward finalizing negotiations with BMV to jointly distribute and sell a line of the most common and used cancer drugs such as paclitaxel and docetaxel throughout Mexico and most of Latin America | Financial terms were not disclosed | 6/11/15 |
Eddingpharm Co. Ltd. (Shanghai) | Faes Farma SA (Madrid) | ND | In-licensing agreement to bring specialty products from Faes Farma to the Chinese market | In the joint venture with Faes, the plan is to start with four undisclosed products and consider more; Faes has been actively licensing out bilastine, an antihistabine indicated for rhinitis and urticaria | 6/3/15 |
Egalet Corp. (Wayne, Pa.) | Acura Pharmaceuticals Inc. (Palatine, Ill.) | $20.00 | Licensing agreement for worldwide rights to Oxaydo (oxycodone HCl, USP) tablets for oral use | Egalet paid Acura an up-front payment of $5M and will owe a $2.5M milestone payment upon first commercial sale, a payment of $12.5M when the product has achieved $150M in net sales in a calendar year and a tiered royalty of single-digit to double-digit percent based on sales thresholds | 1/9/15 |
Egalet Corp. (Wayne, Pa.) | Luitpold Pharmaceuticals Inc. (Shirley, N.Y.) | $7.00 | Acquisition agreement for Sprix (ketorolac tromethamine) nasal spray | Sprix is indicated for the management of moderate to moderately severe pain that requires analgesia at the opioid level; Egalet agreed to pay $7M and entered a six-month transition services agreement with Luitpold | 1/9/15 |
Egalet Corp. (Wayne, Pa.) | Shionogi & Co. Ltd. (Osaka, Japan) | ND | Ended the collaboration for its abuse-deterrent, extended-release hydrocodone product | Egalet gains worldwide rights to phase I candidate S-718632; the collaboration began in November 2013 and was ended due to Shionogi's internal prioritization process; Egalet received up-front and milestone payments totaling $20M, as well as an investment of $15M in Egalet stock | 12/7/15 |
Egalet Corp. (Wayne, Pa.) | Teva Pharmaceutical Industries Ltd. (Jerusalem) | ND | Exclusive marketing and commercialization rights to Sprix (ketorolac tromethamine) nasal spray in Israel, Gaza and the West Bank | Egalet will receive an undisclosed up-front payment, sales-based milestones and will share in the profits from net sales of Sprix in those territories | 12/15/15 |
Eiger Biopharmaceuticals Inc. (Palo Alto, Calif.) | Nippon Kayaku Co. Ltd. (Tokyo) | ND | License agreement to develop Bestatin (ubenimex) for pulmonary arterial hypertension as well as other inflammatory diseases involving leukotriene B4 | Bestatin is a well-characterized, oral, small molecule inhibitor of leukotriene A4 hydrolase (LTA4H), the enzyme responsible for converting LTA4 to LTB4, a naturally occurring inflammatory mediator | 11/10/15 |
Eisai Co. (Tokyo) | Nihon Medi-Physics (Tokyo) | ND | Agreement to work on the diagnosis and treatment of dementia with Lewy bodies | Terms were not disclosed | 5/1/15 |
Eisai Co. Ltd. | Merck & Co. Inc. | ND | Agreement to jointly develop combination cancer regimens | The companies have set up a joint development committee to oversee clinical trials to begin in the second half of 2015; the collaboration will focus on pembrolizumab, the anti-PD-1 therapy, when used in combination with Eisai products, lenvatinib mesylate and eribulin mesylate | 3/6/15 |
Eisai Inc. (Woodcliff Lake, N.J.) | Purdue Pharma LP (Stamford, Conn.) | ND | Collaborative agreement to develop and commercialilze Eisai's lemborexant (E2006) a dual orexin receptor antagonist beginning phase III studies in insomnia | The companies will share costs of the clinical trials, and they might pursue development in other indications; Eisai and Purdue plan to form a steering committee to oversee development and marketing activities worldwide; if approved, the companies plan to co-promote lemborexant and share costs and profits in the U.S. and other territories, to be determined, which may include the EU, China, Japan and Canada | 9/1/15 |
Eli Lilly and Co. (Indianapolis) | Hanmi Pharmaceutical Co. Ltd. (South Korea) | $690.00 | Exclusive license and collaboration agreement for the development and commercialization of Hanmi's oral Bruton's tyrosine kinase inhibitor, HM71224, to treat autoimmune and other diseases | The companies will investigate the molecule for the potential treatment of rheumatoid arthritis, lupus, lupus nephritis, Sjögren's syndrome and other related conditions; Lilly will receive worldwide rights to the molecule for all indications, excluding China, Hong Kong, Taiwan and Korea; Hanmi will receive an initial payment of $50M and will be eligible for up to $640M in potential development, regulatory and sales milestones; if the BTK inhibitor is successfully commercialized, Hanmi would also be eligible for tiered double-digit royalty payments | 3/20/15 |
Eli Lilly and Co. (Indianapolis) | Bristol-Myers Squibb Co. (New York) | ND | Agreement to transfer rights to Erbitux (cetuximab) in North America, including the U.S., Canada and Puerto Rico, from BMS to Lilly | The move comes after a 14-year collaboration, which includes Lilly's wholly owned subsidiary, Imclone LLC; BMS will receive tiered royalties based on net product sales in North America after the completion of the transition through September 2018 | 4/17/15 |
Eli Lilly and Co. (Indianapolis) | Astrazeneca plc (London) | ND | Clinical trial collaboration to test anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with Cyramza (ramucirumb) in patients with advanced solid tumors | The trial will be sponsored by Lilly; tumors to be studied and financial terms were not disclosed | 6/1/15 |
Eli Lilly and Co. (Indianapolis) | Sanofi SA (Paris) | ND | Settlement agreement to resolve patent disputes on Sanofi's insulin glargine product, Basaglar | Lilly and partner Boehringer Ingelheim GmbH may launch the drug in the U.S. on Dec. 15, 2016; Sanofi has granted Lilly a royalty-bearing license so Lilly can manufacture and sell Basaglar in the Kwikpen device globally | 9/29/15 |
Eli Lilly and Co. (Indianapolis) | Astrazeneca plc (Dublin) | ND | Extended an immuno-oncology collaboration exploring combination therapies for treatment of patients with solid tumors | Lilly and Astrazeneca will evaluate the safety and efficacy of a range of additional combinations; Lilly will lead the execution of the studies, while both companies will contribute resources; Astrazeneca’s anti-PD-L1 immune checkpoint inhibitor, durvalumab (MEDI4736), will be combined with Lilly molecules that target the immune system, including TGF-beta kinase inhibitor galunisertib, a CXCR4 peptide antagonist and a anti-CSF-1R monoclonal antibody that also will be assessed with Astrazeneca’s anti-CTLA-4 monoclonal antibody, tremelimumab | 10/23/15 |
Eli Lilly and Co. (Indianapolis) | Wuxi Pharmatech (Cayman) Inc. | ND | Strategic collaboration agreement with a local Chinese company to co-develop a novel candidate for the China market | Wuxi will be responsible for the development, regulatory filing and manufacturing of the Lilly-discovered candidate; commercialization in China will be Lilly's responsibility; both parties will invest in the development process | 11/16/15 |
Eli Lilly and Co. (Indianapolis) | Merck & Co. Inc. (Kenilworth, N.J.) | ND | Extended collaboration to include an evaluation of the safety and efficacy of Lilly's Alimta (pemetrexed for injection) in combination with Merck's Keytruda (pembrolizumab) in a pivotal phase III study in first-line nonsquamous non-small-cell lung cancer | The study, sponsored by Merck, will enroll patients with NSCLC in the first-line setting, regardless of PD-L1 status; earlier this year, the pharmas presented phase I data on the combination of pemetrexed, carboplatin and pembrolizumab in first-line nonsquamous NSCLC at the 16th World Congress on Lung Cancer in Denver | 11/20/15 |
Eli Lilly and Co. (Indianapolis) | Merck & Co. Inc. (Kenilworth, N.J.) | ND | Expanded immuno-oncology collaboration to evaluate Abemaciclib (LY2835219) and Keytruda (pembrolizumab) in a phase I study across multiple tumor types | Lilly is the sponsor of the phase I study, and of any subsequent phase II studies; financial details of the collaboration were not disclosed | 12/11/15 |
Elixirgen LLC (Baltimore) | Sumitomo Dainippon Pharma Co. Ltd. (Osaka, Japan) | ND | Exclusive license agreement for research on biologics targeting diseases associated with genome instability and chromosome abnormalities | Sumitomo gained exclusive rights to conduct additional research, development and commercialization of the biologics in Japan in return for an undisclosed up-front payment to Elixirgen in addition to development and commercial milestones and royalties on product sales in Japan; Elixirgen retained global rights outside Japan | 11/20/15 |
Elsalys Biotech (Lyon and Illkirch-Graffenstaden, France; a spinoff of Transgene SA) | Mablife SAS | ND | Agreement to acquire the development and marketing rights of the anti-CD160 antibody | As the anti-CD160 antibody has shown its efficacy in cancer and eye disease animal models, the company already has initiated the preclinical evaluation of different humanized versions of this antibody in age-related macular degeneration | 7/6/15 |
EMD Serono (unit of Merck KGaA; Darmstadt, Germany) | Illumina Inc. (San Diego) | ND | Collaboration to expand the development of a universal next-generation sequencing-based oncology diagnostic for clinical trials of targeted cancer therapies | The companies will work together to develop assays that detect and simultaneously measure multiple genetic variants in a single tumor sample in a clinical trial setting | 3/11/15 |
Emisphere Technologies Inc. (Roseland, N.J.) | Novo Nordisk A/S (Bagsvaerd, Denmark) | $87.50 | Development and license agreement to develop and commercialize oral formulations of four classes of Novo Nordisk molecules targeting metabolic disorders, including diabetes and obesity, using Emisphere's oral Eligen Technology | Emisphere licensed to Novo Nordisk the exclusive right to develop potential product candidates in three molecule classes, and the nonexclusive right to develop potential product candidates in a fourth molecule class, using Eligen; Emisphere gets $5M up front and has the opportunity to receive up to $62.5M in development and sales milestone payments for each of the three exclusively licensed molecule classes, and up to $20M in development milestone payments for the nonexclusively licensed molecule class; Emisphere also would receive royalties | 10/16/15 |
Emulate Inc. (Cambridge, Mass.) | Janssen Biotech Inc. (unit of Johnson & Johnson; New Brunswick, N.J.0 | ND | Partnership to test Janssen therapeutic candidates in Emulate's Organs-on-Chips technology | The deal will focus on three research and development programs: Lung-on-Chip and Thrombosis-on-Chip to evaluate pulmonary thrombosis; Liver-on-Chip to predict liver toxicity; and an undisclosed third area; rights to any discoveries go to Emulate, and Janssen can extend the collaboration beyond the initial three programs to include other organs, disease models or drugs | 6/22/15 |
Emulate Inc. (Cambridge, Mass.) | Merck & Co. (Kenilworth, N.J.) | ND | Expanded research collaboration to deploy Emulate's organ-chips across certain Merck discovery programs to improve models of human inflammatory diseases and to better predict the potential human response of therapeutic candidates | The research will focus on using Emulate’s Small Airway Lung-Chip and Intestine-Chip to enable predictive modeling of inflammatory processes in the human lung and the gastrointestinal system; Emulate will retain rights to any resulting discoveries related to the Organ-Chip technology; Merck has the option to extend the collaboration to include additional organs, disease models or drug programs | 12/22/15 |
Endo International plc (Dublin) | Aspen Holdings Inc. | $130.00 | Endo bought a broad portfolio of branded and generic injectable and established products focused on pain, anti-infectives, cardiovascular and other specialty therapeutics areas | The deal adds a product portfolio that generated about $28M of revenues last fiscal year, as well as a pipeline of products | 5/12/15 |
Engene Inc. (Montreal) | Janssen Biotech LLC (Johnson & Johnson unit; New Brunswick, N.J.) | $342.40 | Agreement to develop and commercialize new therapies for inflammatory bowel disease | In addition to an undisclosed up-front payment and equity investment, the company is eligible to receive various preclinical, clinical, regulatory and commercial milestone payments up to C$441M (US$342.4M), plus tiered royalties | 10/15/15 |
Enteris Biopharma Inc. (Boonton, N.J.) | Cara Therapeutics Inc. (Shelton, Conn.) | ND | Renewed and revised manufacturing and clinical supply agreement | Agreement for continued clinical testing involving Cara's CR845 for the treatment of acute and chronic pain, and includes technology access payments to Enteris | 7/15/15 |
Enyo Pharma SAS (Lyon, France) | Poxel SA (Lyon, France) | ND | License agreement to a key patent from Poxel, enabling Enyo to use agonists of the farnesoid X receptor as hepatitis B treatments | EYP001, the first product developed under this program is nearing the end of its regulatory toxicology trials | 12/1/15 |
Eolas Therapeutics Inc. (Carlsbad, Calif.) | Astrazeneca plc (London) | $145.00 | Global license and partnership agreement to develop the Eolas Orexin-1 receptor antagonist, or EORA, program for smoking cessation and other indications | Eolas said the deal potential exceeds $145M, including up-front, clinical and regulatory milestone payments; Eolas also is eligible for royalties on product sales | 7/1/15 |
Epirus Biopharmaceuticals Inc. (Boston) | Mabxience (subsidiary of Chemo Group) | ND | Development and future distribution deal for BOW015 for Latin American markets, including Argentina, Chile, Ecuador, Paraguay, Uruguay and Venezuela | Mabxience will be responsible for regulatory submissions, using BOW015's existing data package, and eventual commercialization in those select markets | 5/15/15 |
Epirus Biopharmaceuticals Inc. (Boston) | Polpharma Group (Gda?ski, Poland) | $30.00 | Profit-sharing collaboration to commercialize biosimilars BOW015 (infliximab), BOW050 (adalimumab) and BOW070 (tocilizumab) in the Middle East, Turkey, Russia, the Commonwealth of Independent States and much of the EU | Development costs and operating profit will be split 51% for Polpharma and 49% for Epirus; Epirus will lead product and clinical development, with Polpharma contributing approximately $30M; the partners will collaborate on regulatory filings; Epirus retains responsibility for process development, scale-up and manufacturing, and Polpharma will oversee commercialization and cover product launch costs; Epirus retains commercial rights in Switzerland, Norway, Austria, Belgium, Denmark, Finland, Luxembourg, the Netherlands, Sweden, North America and other markets | 7/15/15 |
Epizyme Inc. (Cambridge, Mass.) | Eisai Co. Ltd. (Tokyo) | $110.00 | Agreement to reacquire global rights to its EZH2 program, including EPZ-6438, from Eisai | Epizyme will now be solely responsible for global development, manufacturing and commercialization in all countries outside of Japan, where Eisai will retain rights; Epizyme will make a $40M up-front payment to Eisai, with a total of up to $20M in potential milestone payments and up to $50M in potential regulatory milestone payments, plus a royalty at a percentage in the midteens on sales of EPZ-6438 outside of Japan; Eisai will pay Epizyme a royalty at a percentage in the midteens on sales in Japan and will have a limited right of first negotiation for Asia rights if Epizyme decides to license Asia rights to a third party; the companies originally inked the potential $206M deal in 2011 | 3/13/15 |
Epizyme Inc. (Cambridge, Mass.) | Celgene Corp. (Summit, N.J.) | $620.00 | Extended research collaboration for at least three years, giving Celgene the option to license histone methyltransferase inhibitors being developed by Epizyme against three predefined targets | Revised terms call for Epizyme to receive a $10M extension fee in return for an option to individually license global rights for two of the targets and ex-U.S. rights for the third target, and Celgene may exercise those options at the time of investigational new drug application filing for an additional pre-specified license payment; Epizyme will fund development for each candidate through phase I trials and may earn total potential milestones of up to $610M on the three targets, including up to $75M in development milestones and license fees, $365M in regulatory milestones and $170M in sales milestones, plus royalties up to the low double digits on worldwide sales | 7/10/15 |
Ergomed plc (London) | Dilaforette AB (Stockholm) | ND | Co-development agreement for the phase II development of sevuparin in patients with sickle cell disease experiencing acute vaso-occlusive crisis | Ergomed will serve as the clinical development organization to conduct Dilaforette's phase II study, set to start in the second quarter, and will co-invest a proportion of its revenues from the clinical and regulatory activities of the trial in return for an equity stake in Dilaforette | 2/20/15 |
Espero Pharmaceuticals Inc. (Jacksonville, Fla.) | G. Pohl-Boskamp GmbH & Co. (Hohenlockstedt, Germany) | ND | Exclusive licensing and distribution agreement for Pohl-Boskamp's nitroglycerin sublingual powder formulation to treat an attack or for prophylaxis of angina pectoris for the U.S. market | Espero said it will assist Pohl-Boskamp with the submission of the new drug application for the product | 9/17/15 |
Evotec AG | Sanofi SA (Paris) | $331.00 | Diabetes alliance focused on beta cell regeneration in which Sanofi will produce an implantable, retrievable device that can encapsulate stem cells capable of generating insulin-producing, glucose-responsive human beta cells or beta-like cells | Deal includes E3M (US$3.3M) up front and more than E300M in milestone payments | 8/10/15 |
Evotec AG (Hamburg, Germany) | C4X Discovery Holdings plc (Manchester, UK) | ND | Agreement to optimize orexin-1 selective inhibitors discovered through C4XD's NMR technology | Evotec will apply its drug discovery platform with C4XD to further develop several series of orexin-1 selective inhibitors; activation of the orexin-1 receptor in the brain is associated with stress-related addictive disorders | 1/21/15 |
Evotec AG (Hamburg, Germany) | Second Genome Inc. (South San Francisco) | ND | Collaboration in small molecule-based discovery and development activities to treat microbiome-mediated diseases | The partners plan to identify and optimize novel compounds as well as those covered by license agreements for assets developed by Evotec; the agreement triggered an undisclosed up-front payment to Evotec, which also is eligible for preclinical, clinical and regulatory milestones and royalties related to commercialized products | 3/16/15 |
Evotec AG (Hamburg, Germany) | Sanofi SA (Paris) | $270.00 | Agreement for a major multicomponent strategic alliance over the next five years | Sanofi will make a minimum guaranteed commitment to Evotec of €250M (US$270M) including more than €40M (US$43.7M) in an up-front cash payment | 3/23/15 |
Evotec AG (Hamburg, Germany) | Asahi Kasei Corp. (subsidiary of Asahi Kasei Pharma Corp.; Tokyo) | ND | Multitarget screening collaboration on several ion channel targets | Evotec will identify inhibitors of multiple ion channel targets | 3/27/15 |
Evotec AG (Hamburg, Germany) | Facio Therapies BV (Leiden, the Netherlands) | ND | Agreement aimed at the identification of compounds showing activity as potential treatments to stop the progression of facioscapulohumeral dystrophy | The project entails the setup and execution of an automated high-throughput screen to identify small molecules having a positive effect on SMCHD1 and DUX4 activity in human FSHD-affected muscle cell lines | 4/30/15 |
Evotec AG (Hamburg, Germany) | Pfizer Inc. (New York) | ND | Four-year research collaboration in the field of tissue fibrosis | Pfizer will make an undisclosed up-front and potential development and sales milestone payments to Evotec | 9/10/15 |
Evotec AG (Hamburg, Germany) | Spero Therapeutics (Cambridge, Mass.) | ND | Extended collaboration to discover and develop therapeutics for gram-negative bacteria | Evotec will provide early stage research to support projects such as Spero's Potentiator program to increase the potency of existing drugs and multidrug-resistant bacteria; Spero will oversee Evotec's in vitro and in vivo infectious disease capabilities; Evotec receives substantial research funding and the agreement runs to the end of 2016 | 12/16/15 |
Evotec AG (Hamburg, Germany) and Apeiron Biologics AG (Vienna) | Sanofi SA (Paris) | $219.80 | Deal to develop small-molecule-based cancer immunotherapies | The collaboration includes research and development efforts to advance a first-in-class small-molecule approach to treat solid and hematopoietic cancers and it will also focus on the identification of small-molecule hits and their targets for next-generation therapies in immuno-oncology; the deal triggers two years of substantial research payments as well as milestones of more than €200M (US$219.8M) and royalties | 8/11/15 |
Eyegate Pharmaceuticals Inc. (Waltham, Mass.) | Valeant Pharmaceuticals International Inc. (Laval, Quebec) | ND | Exclusive global licensing agreement for commercial and manufacturing rights to EGP-437 | Valeant gains rights in anterior uveitis, with a right of last negotiation to license it in additional indications; Eyegate will receive an up-front cash payment, development and regulatory milestones in uveitis and is eligible for royalties on net sales and additional milestone payments; Eyegate retains responsibility and will foot the bill to complete the development of EGP-437 in the U.S. in anterior uveitis, but Valeant assumed the right to develop it in uveitis, and to bear the costs elsewhere | 7/13/15 |
Eyenovia Inc. (Tampa, Fla.) | Senju Pharmaceutical Co. Ltd. (Osaka, Japan) | ND | Exclusive license and development agreement whereby Senju acquired the exclusive rights to develop and commercialize microdosed ophthalmic therapeutics in Japan and the rest of Asia | Senju will also assume responsibility for all Asia research and development activities | 4/17/15 |
Faron Pharmaceuticals Oy (Turku, Finland) | Selexis SA (Geneva) | ND | Agreement giving Faron access to the Suretechnology platform and Sure CHO-M Cell Line from Selexis | The companies said the technology and cell line will enable Faron to produce high-expressing, stable clonal cell lines for Clevegen, Faron's cancer immunotherapy antibody; Selexis will receive an ongoing service fee and will be entitled to milestone payments if Clevegen achieves clinical development and commercial sales | 11/4/15 |
Fatro SpA (Ozzano Emilia, Italy) | Valneva SE (Lyon, France) | ND | License agreement for the development of veterinary vaccines on its EB66 cell line | Fatro gains a license for the development and commercialization of two veterinary vaccines on EB66 cells; Valneva received an undisclosed up-front payment and is eligible to receive milestone payments along with future royalties on net sales | 8/28/15 |
Ferring Pharmaceuticals SA (Saint Prex, Switzerland) | Ctcbio Inc. (Seoul, South Korea) | ND | Agreement to acquire rights to an unnamed oral drug delivery technology | Deal includes an up-front payment, milestones and royalties; the two companies will collaborate to develop prototype formulations for in-vitro and in-vivo testing and the subsequent up-scaling required to manufacture the technology to meet worldwide good manufacturing practice requirements | 2/24/15 |
Ferring Pharmaceuticals SA (Saint-Prex, Switzerland) | Teva Women's Health Inc. (North Wales, Pa.; part of Teva Pharmaceuticals Industries Ltd.) | ND | Agreement for global rights to Milprosa (progesterone vaginal ring) | Teva anticipates that the drug could be the first once-weekly progesterone treatment for luteal phase support in women undergoing assisted reproductive technology treatment approved in the U.S. | 9/29/15 |
Five Prime Therapeutics Inc. (South San Francisco) | Inhibrx LLC (La Jolla, Calif.) | $452.50 | Strategic research collaboration and license agreement for Inhibrx's novel glucocorticoid-induced tumor necrosis factor receptor (GITR) antibody program | Five Prime will pay Inhibrx a $10M license fee for exclusive, worldwide therapeutic and diagnostic rights to Inhibrx antibodies, as well as an option to license other antibodies; Inhibrx is eligible to receive up to $342.5M in development, regulatory and commercial milestone payments per therapeutic product, or up to $442.5M in development, regulatory and commercial milestone payments if the FDA grants a breakthrough therapy designation to a product; the deal includes milestones for development, regulatory and first commercial sale events, and Inhibrx is eligible for low double-digit tiered royalties | 7/17/15 |
Five Prime Therapeutics Inc. (South San Francisco) | Bristol-Myers Squibb Co. (New York) | $2,283.00 | Bristol-Myers exercised its option to exclusively license FPA008 and other candidates in the colony-stimulating factor 1 receptor program | This positions Five Prime to earn up to $1.74B for FPA008, which includes $350M up front and $1.05B in development and regulatory milestone payments per anti-CSF1R product for oncology indications, including combinations with Opdivo and any other agent, $542.5M in milestones for oncology-focused combination of a Five Prime CSF1R asset and a BMS asset that's not Opdivo, and $340M in development and regulatory milestone payments per anti-CSF1R product for non-oncology indications, as well as double-digit royalties | 10/16/15 |
Flexion Therapeutics Inc. (Burlington, Mass.) | Patheon (Durham, N.C.) | ND | Manufacturing and supply agreement for a redundant supply of FX006 | The intra-articular sustained-release steroid is in development to treat osteoarthritis | 8/6/15 |
Forge Therapeutics Inc. (San Diego) | Janssen Research & Development LLC (Raritan, N.J.) | ND | Pilot study to investigate the Forge chemistry platform in the discovery of metalloprotein inhibitors | Forge will receive undisclosed funding from Janssen | 7/22/15 |
Forma Therapeutics Inc. (Watertown, Mass.) | Cancer Research Technology Ltd. | ND | Agreement to form two new virtual asset discovery and development companies with chemical matter targeting undisclosed de-ubiquitinating enzymes | ADDCos are virtual companies seeking to achieve rapid innovation in a compelling scientific area through the collaboration of academic thought leaders, Forma drug discovery scientists and a world-class development network | 3/24/15 |
Foundation Medicine Inc. (Cambridge, Mass.) | Roche AG (Basel, Switzerland) | $1,050.00 | Agreement for Roche to acquire a majority ownership in Foundation Medicine | Roche will invest $250M for 5M newly issued shares of FMI at $50 apiece, and will acquire approximately 15.6M FMI shares at $50 apiece, giving the pharma an overall stage of at least 52.4%; the transaction closed in April | 1/13/15 |
Foundation Medicine Inc. (Cambridge, Mass.) | H3 Biomedicine Inc. (Cambridge, Mass.) | ND | Multiyear collaboration for the discovery and development of precision medicines in oncology | H3 Biomedicine will pay Foundation Medicine a technology access fee for identification of target concepts arising from Foundationcore and success milestones for selection, validation, clinical progression and commercialization of products developed from the program; Foundation Medicine is eligible to receive royalties on sales of any products resulting | 2/24/15 |
Galapagos NV (Mechelen, Belgium) | Janssen Pharmaceutica NV (Beerse, Belgium; a unit of Johnson & Johnson) | ND | Galapagos regained rights to GLPG1690, a selective autotaxin inhibitor, after it mutually agreed to terminate inflammation alliance and option agreements with Janssen | The alliance with Janssen, inked in October 2007, generated three clinical molecules, with GLPG1690 and GLPG1250 both at phase II; the partnership was initially said to be worth up to €1B (US$1.43B) in up-front payments, license fees and milestones to Galapagos and to involve as many as 15 to 19 targets | 3/18/15 |
Galapagos NV (Mechelen, Belgium) | Abbvie Inc. | ND | Abbvie declined to exercise its option to in-license the JAK1 inhibitor filgotinib, electing instead to advance its own same-class candidate, ABT-494 | The decision ends the 2012 deal and returns full filgotinib rights to Galapagos | 9/28/15 |
Galena Biopharma Inc. (San Ramon, Calif.) | Private company | $12.00 | Galena sold its Abstral (fentanyl) sublingual tablet product to a private company in a deal valued at up to $12M | The deal includes $8M in cash up front and up to $4M in additional cash upon achievement of certain sales milestones | 11/23/15 |
Galena Biopharma Inc. (San Ramon, Calif.) | Midatech Pharma plc (Oxford, UK) | $29.75 | Agreement for the sale of Zuplenz (ondansetron) oral, soluble film product in a deal valued at up to $29.75M, with $3.75M cash up front and up to $26M in additional cash upon achievement of milestones | In connection with the transaction, Galena will pay Monosol Rx LLC, of Warren, N.J., $900,000 of the up-front fee and 20% of any future milestone payments from sales of Zuplenz | 12/21/15 |
Galmed Pharmaceuticals Ltd. (Tel Aviv, Israel) | Perrigo API Ltd. (subsidiary of Perrigo Co. plc; Dublin) | ND | Manufacturing services agreement for large-scale production of the active pharmaceutical ingredient of Galmed's aramchol | The API produced pursuant to that deal is expected to provide sufficient quantities of aramchol for Galmed's potential future phase III trials of aramchol for the treatment of non-alcoholic steatohepatitis | 1/29/15 |
Galmed Pharmaceuticals Ltd. (Tel Aviv, Israel) | One Way Liver Genomics S.L. (Biscay, Spain) | ND | Agreement to develop a non-invasive, blood-based companion diagnostic tool | The companies will work to predict therapeutic responses to Aramchol, Galmed's once-daily, oral therapy for the treatment of non-alcoholic steato-hepatitis; OWL will develop the companion diagnostic to be co-funded by Galmed up to €437,000; upon commercialization, OWL may earn 10% royalties on annual net sales of the companion diagnostic product, and could earn two milestone payments during ARREST: €75,000 on successful completion of the study's interim results, which are anticipated in the first half of 2016; €100,00 will be paid on successful completion of ARREST | 7/9/15 |
Gencia LLC (Charlottesville, Va.) | Takeda Pharmaceutical Co. Ltd. (Osaka, Japan) | $500.00 | Deal to develop a class of small-molecule drugs called mitochondrial agonists of the glucocorticoid receptor | Takeda will make up-front and preclinical milestone payments to Gencia for the two compounds, with the option to license the candidates in return for clinical, commercialization and sales milestones totaling up to approximately $500M; Gencia also is eligible for royalties | 9/11/15 |
Genentech (South San Francisco; unit of Roche AG) | Almac Discovery Inc. (Craigavon, UK) | $14.50 | Discovery and development of small molecule inhibitors of ubiquitin-specific protease | Genentech is paying Almac $14.5M up front, plus milestone payments at undisclosed stages and escalating tiered royalties; Genentech will be responsible for all preclinical and clinical development and commercialization of any products arising from the deal | 6/16/15 |
Genentech Inc. (South San Francisco) | 23andme Inc. | ND | Deal to generate whole genome sequencing data for about 3,000 people in 23andme's Parkinson's disease community | The goal of the multiyear collaboration is to identify new therapeutic targets for treating Parkinson's disease | 1/7/15 |
Generex Biotechnology Corp. (Toronto) | NH Therapeutics Inc. (Toronto) | ND | Memorandum of understanding in which the two companies will co-develop a formulation of Leuprolide to be delivered using Generex's Rapidmist buccal drug delivery system | NHT holds intellectual property for the dosing regimen and route of administration of Leuprolide and other gonadotropin-releasing hormone agonists to treat hypogonadism and other endocrine disorders | 5/27/15 |
Generex Biotechnology Corp. (Toronto) | Nhtherapeutics Inc. (Toronto) | ND | Agreement to develop a formulation to deliver Leuprolide via buccal mucosa while using Generex's Rapidmist buccal drug delivery platform | Generex received the first tranche of funding in addition to the first shipment of Leuprolide | 9/9/15 |
Generex Biotechnology Corp. (Worcester, Mass.) | Smoofi Inc. (San Clemente, Calif.) | $10.00 | Entered a nonbinding letter of intent to license Generex's Rapidmist drug delivery technologies to Smoofi for the delivery of medicinal and recreational cannabis-derived products into the bloodstream through the buccal membrane | Generex will receive $10M worth of Smoofi stock, plus a warrant to acquire up to 15M shares | 4/24/15 |
Generex Biotechnology Corp. (Worcester, Mass.) | Cannscience Innovations Inc. (Toronto) | ND | Co-development agreement enabling Cannscience to use the Rapidmist drug delivery platform technologies developed by Generex for the buccal delivery of cannabinoids and cannabinoid-derived products | Generex also granted Cannscience an exclusive license to commercialize such products in Canada in exchange for royalty payments | 9/3/15 |
Genexine Inc. | Tasgen (subsidiary of Tasly Pharmaceutical Group Co. Ltd.) | $100.00 | Licensing and technology transfer agreement in which Genexine will grant the China rights for three compounds, GX-H9, GX-G6 and GX-G3, to Tasgen in exchange for $20M up front and up to $80M in milestones | Tasgen paid $100M for the rights, including $20M up front and up to $80M in milestones; lead asset GX-H9 is targeted for the treatment of adult and pediatric growth hormone deficiency | 10/21/15 |
Genmab A/S (Copenhagen) | Bionovion BV (Oss, the Netherlands) | ND | Co-development and commercialization agreement to evaluate a number of Duobody product candidates targeting immune checkpoints | Both firms will contribute panels of antibodies for the creation of bispecific antibody products using Genmab's Duobody platform; development costs will be shared equally, with each party retaining a 50% share of the product rights | 2/20/15 |
Genmab A/S (Copenhagen) | ADC Therapeutics Sarl (Epalinges, Switzerland) | ND | Genmab decided not to exercise the co-development right for Humax-TAC-ADC under its agreement with ADC, and will retain 25% of the rights to the product | Under the terms of the agreement, Genmab had a 50% ownership stake with an option to maintain equal ownership of Humax-TAC-ADC prior to the submission of an investigational new drug application and fund half of the development costs | 3/17/15 |
Genmab A/S (Copenhagen) | Bristol-Myers Squibb Co. (New York) | $4.00 | Agreement for an exclusive license to a panel of human antibodies targeting CD19, together with associated intellectual property | Genmab will make a one-time $4M licensing payment to BMS upon execution of the license | 6/3/15 |
Genmab A/S (Copenhagen) | Novo Nordisk A/S (Bagsvaerd, Denmark) | $502.00 | Agreement in which Novo Nordisk is in-licensing two Duobody bispecific antibody technology programs | The deal is worth up to $500M in development, regulatory and sales milestones, as well as $2M up front; Novo Nordisk receives an initial period of exclusivity on the two target combinations | 8/17/15 |
Genmab Holding B.V. (subsidiary of Genmab A/S; Copenhagen) | IDD Biotech SAS | $111.68 | Agreement to purchase antibodies and related patents and know-how from IDD Biotech | The preclinical stage antibodies are directed to DR5, also known as trail receptor 2 (TRAIL-R2), an emerging cancer target; under terms of the agreement, Genmab will pay IDD Biotech an up-front fee of €2.5M (US$2.68M); future payments range from a minimum of €3.5M (US$3.79M) to potentially €101.5M (US$109M) in development and sales milestones and single-digit royalties on commercialized products | 3/19/15 |
Genometry Inc. (Cambridge, Mass.) | Janssen Pharmaceutica NV (Beerse, Belgium; part of Johnson & Johnson) | ND | Service agreement under the terms of which Genometry will generate gene-expression profiles from 250,000 compounds from Janssen's small-molecule screening library using its L1000 Expression Profiling technology | The data will be used for primary screening and library characterization as well as to improve the selection of candidate drugs prior to clinical studies | 10/9/15 |
Gensight Biologics SA (Paris) | Pixium Vision SA and Fondation Voir et Entendre (Paris) | $21.90 | Five-year research and development project to restore vision to legally blind patients with retinitis pigmentosa at different stages | The €18.5M (US$21.9M) deal involves the development of two complementary therapeutic products to restore vision: an anoptogenetic gene therapy product and a "vision restoration system" with a retinal implant | 1/8/15 |
Genvec Inc. (Gaithersburg, Md.) | Therabiologics Inc. (Arcadia, Calif.) | ND | Collaboration to develop cancer therapeutics, which will lever its gene delivery platform with Therabiologics' neural stem cell technology | In exchange for an economic participation in the products being developed under the collaboration, Genvec will contribute technology, know-how, vector construction, and technical and regulatory support to the program; Therabiologics will be responsible for all other development costs | 3/24/15 |
Genzyme (division of Sanofi SA; Paris) | Astrazeneca plc (London) | $300.00 | Divestment of Caprelsa (vandetanib) to Genzyme | Genzyme made an up-front payment of $165M for global rights to sell and develop Caprelsa and will make further development and sales milestone payments of up to $135M | 10/8/15 |
Genzyme Corp. (Cambridge, Mass.; unit of Sanofi SA; Paris) | Astrazeneca plc (London) | $300.00 | Agreement to acquire Caprelsa (vandetanib), approved by the FDA in 2011 as the first drug to treat symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease | Genzyme agreed to pay Astrazeneca up to $300M, including an up-front payment of $165M to acquire the global rights to sell and further develop Caprelsa and development and sales milestone payments of up to $135M; the transaction does not include the transfer of Astrazeneca employees or facilities | 7/28/15 |
Gilead Sciences Inc. (Foster City, Calif.) | Phenex Pharmaceuticals AG (Ludwigshafen, Germany) | $470.00 | Deal to acquire Phenex's early stage farnesoid X receptor program | Gilead is paying up to $470M; the purchase gives Gilead a new avenue for approaching both nonalcoholic steatohepatitis and other liver diseases | 1/7/15 |
Gilead Sciences Inc. (Foster City, Calif.) | Mylan Laboratories Ltd. (Hyderabad, India; subsidiary of Mylan Inc.) | ND | Expanded hepatitis C licensing agreement to include the non-exclusive rights to manufacture and distribute the NS5A inhibitor GS-5816 and single-tablet regimen of sofosbuvir (Sovaldi)/GS-5816 | The single-tablet regimen is being evaluated in phase III studies for the treatment of all six genotypes of hepatitis C | 1/27/15 |
Gilead Sciences Inc. (Foster City, Calif.) | Mylan Inc. (Pittsburgh) | ND | Agreement for exclusive distribution in India of Sovaldi and Harvoni to treat chronic hepatitis C | Mylan expects to begin distribution of Sovaldi in India in Q2; this new agreement is in addition to the licensing and technology transfer agreement that Mylan entered into with Gilead, which grants the non-exclusive rights to manufacture and distribute generic sofosbuvir, ledipasvir/sofosbuvir and, upon approval, the investigational NS5A inhibitor GS-5816 and single tablet regimen of sofosbuvir/GS-5816 in 91 developing countries | 2/24/15 |
Gilead Sciences Inc. (Foster City, Calif.) | Wuxi Pharmatech Inc. (Shanghai) | ND | Strategic partnership to conduct analytical and stability studies of small-molecule new chemical entities to support global marketing applications and commercial products | Wuxi will equip and operate a dedicated, fully cGMP-compliant analytical testing facility in Shanghai to provide analytical method development, transfer and validation for investigational new drug and new drug applications, commercial API and drug product testing and other services | 11/2/15 |
Gilead Sciences Inc. (Foster City, Calif.) | Galapagos NV (Mechelen, Belgium) | $2,075.00 | Exclusive agreemtn for rights to Galapagos' filgotinib (GLPG0634) | Gilead is paying $725M, with up to $1.35B more in milestones for the drug; Gilead is paying $300M up front and is investing another $425M in Galapagos shares; Galapagos also stands to receive tiered royalties that start at 20%, as well as an option to co-promote the drug in Europe's biggest markets – Germany, France, the U.K., Italy and Spain and in its home Benelux territory, comprising Belgium, the Netherlands and Luxembourg; Galapagos will pick up 20% of the outstanding development costs for the drug | 12/18/15 |
Glaxosmithkline plc (London) | Novartis Pharma AG (part of Novartis AG; Basel, Switzerland) | ND | Agreement that allows Novartis Pharma to acquire GSK's oncology products including ofatumumab | The deal Genmab A/S, of Copenhagen, made with GSK and Novartis to transfer the ofatumumab collaboration from GSK to Novartis in November 2014 has become effective; Novartis will develop and commercialize the drug in cancer and GSK will continue to develop and commercialize the drug for autoimmune indications; Genmab is not required to pay existing funding liabilities or fund development costs for ofatumumab beyond Dec. 31, 2014 | 3/3/15 |
Glide Pharmaceutical Technologies Ltd. (Oxford, UK) | Cilian AG (Germany) | ND | Collaboration to develop a solid dose formulation of Cilian's experimental recombinant influenza vaccine, Ciflu, for delivery using Glide's solid dose injector device | Initial results from the collaboration demonstrate robust room-temperature stability for the solid dose Ciflu formulation and preclinical potency testing is planned to confirm the potential for an enhanced immune response to the vaccine, before the year end | 9/22/15 |
Globavir Biosciences Inc. (Los Altos, Calif.) | Sorrento Therapeutics Inc. | $80.00 | Exclusive license for BC001, a preclinical hypoxia-inducible factors-1 inhibitor to treat solid tumors | Globavir is entitled to $80M in regulatory and sales milestones, plus multitiered royalty payments on global net sales; Sorrento assumes development and commercialization costs | 7/10/15 |
Globeimmune Inc. (Louisville, Colo.) | Celgene Corp. (Summit, N.J.) | $1.90 | Exercised option under the 2009 deal to exclusively license GI-6207, a Tarmogen product candidate targeting cancers that express carcinoembryonic antigen | Globeimmune will receive an option exercise payment of $1.9M, and is eligible for regulatory and sales milestones, as well as royalties on product sales | 8/5/15 |
Glycotope GmbH (Berlin) | Octapharma AG | $431.00 | Licensing and equity investment deal covering a preclinical portfolio of blood coagulation factors | Glycotope is getting E80M (US$90M) up front and could receive up to E300M (US$340.99M) more in milestone payments, plus royalties | 10/9/15 |
Google's life sciences team | Sanofi SA (Paris) | ND | Partnership to work on ways to collect, analyze and understand multiple sources of information impacting diabetes | The parties will explore how to improve diabetes care by developing new tools | 9/1/15 |
Green Cross Corp. (Yongin, South Korea) | Nanolek LLC (Moscow) | ND | Strategic partnership for the commercializaiton of Green Cross' biologics in the Russian market | Nanolek will obtain marketing authorizations and set up the production of a number of Green Cross' biologics | 3/27/15 |
Grunenthal GmbH (Aachen, Germany) and Nordic Bioscience A/S (Herlev, Denmark) | Argenta Discovery 2009 Ltd. (Harlow, UK) | ND | Collaboration to focus on research and development in multi-organ fibrosis | The goal is to develop better preclinical and clinical assays to improve identification of new therapies | 10/22/15 |
H3 Biomedicine Inc. (Cambridge, Mass.) | Selvita SA (Krakow, Poland) | ND | Strategic collaboration to develop precision medicines for cancer | The partnership, begun in 2013, is validating the druggability of two kinase targets in an undisclosed genetic context | 9/24/15 |
Halozyme Therapeutics Inc. | Abbvie (North Chicago) | $1,193.00 | Global collaboration and license agreement to apply Enhanze delivery platform to up to nine compounds | Halozyme gets $23M up front, $130M in milestones for each target, up to $1.193B in total value; Halozyme also is entitled to tiered mid-single-digit royalties | 6/4/15 |
Halozyme Therapeutics Inc. (San Diego) | Ventana Medical Systems Inc. (member of the Roche Group; Basel, Switzerland) | ND | Global agreement to collaborate on the development of, and for Ventana to ultimately commercialize, a companion diagnostic assay for use with Halozyme's new drug, PEGPH20 | Financial terms were not disclosed | 5/28/15 |
Halozyme Therapeutics Inc. (San Diego) | Eli Lilly and Co. (Indianapolis) | $825.00 | Agreement to develop products incorporating its Enhanze delivery platform, a potential aid in the dispersion and absorption of its injectables | The deal includes $25M up front and up to $160M for each of up to five collaboration targets, as well as mid-single-digit royalties if products are commercialized | 12/22/15 |
Hanmi Pharmaceutical Co. Ltd. (Seoul, South Korea) | Sanofi SA (Paris) | $4,250.00 | Partnership to develop a portfolio of long-acting diabetes treatments | Hanmi is set to receive an up-front payment of E400M and is eligible for up to E3.5B in development, registration and sales milestones, plus double-digit royalties on net sales, for a total deal value of E3.9B (US$4.25B); Sanofi will obtain an exclusive global license to develop and commercialize a trio of assets, including efpeglenatide, plus two earlier-stage candidates, a weekly insulin therapy and a fixed-dose weekly GLP-1-RA/insulin drug combination; Hanmi retained an exclusive option to co-commercialize the diabetes products in Korea and China | 11/6/15 |
Hanmi Pharmaceutical Co. Ltd. (Seoul, South Korea) | Janssen Pharmaceuticals Inc. (unit of Johnson & Johnson; New Brunswick, N.J.) | $915.00 | Exclusive global rights agreement outside Korea and China to develop and commercialize Hanmi's oxyntomodulin-based therapies, including HM12525A, a GLP-1/glucagon receptor dual agonist | Hanmi will receive an up-front payment of $105M with the potential for up to $810M in development, regulatory and sales milestones, plus tiered double-digit royalty payments on product sales | 11/10/15 |
Harris Corp. (St. Paul, Minn.) | Nanthealth (subsidiary of Nantworks LLC; Culver City, Calif.) | ND | Nanthealth completed the acquisition of Harris Corp.'s commercial health care solutions business | Terms were not disclosed | 7/17/15 |
Heat Biologics Inc. | Oncosec Medical Inc. | ND | Agreement to evaluate the preclinical efficacy of combining Heat's tumor-specific cytotoxic T-cell immunotherapy with Oncosec's Immunopulse intratumoral DNA delivery platform to expand the impact for the benefit of cancer patients | Parallel studies will lay the groundwork for an approach with potentially broad applications for super-charging immunotherapies for numerous cancers | 2/19/15 |
Helsinn Group (Lugano, Switzerland) | Stendhal International (Mexico City) | ND | Exclusive rights deal for the distribution and marketing of netupitant-palonosetron (NEPA) to prevent chemotherapy-induced nausea and vomiting | Helsinn retains all international regulatory and clinical development activities and the supply of NEPA for commercial use; Stendhal will be responsible for all distribution and marketing activities in the designated territories | 2/3/15 |
Helsinn Group (Lugano, Switzerland) | Mundipharma International Corp. Ltd. (Singapore) | ND | Exclusive distribution and licensing agreement of NEPA, an oral fixed combination of netupitant and palonosetron developed to prevent chemotherapy-induced nausea and vomiting, in Brazil | Helsinn retains all international regulatory and clinical development activities and the supply of NEPA for commercial use; Mundipharma will have rights related to marketing, promotion and sales of NEPA in the designated territory | 2/10/15 |
Helsinn Group (Lugano, Switzerland) | Mundipharma International Corp. Ltd. (Singapore) | ND | Exclusive agreement for the distribution and licensing of NEPA, an oral fixed combination of netupitant an dpalonosetron to prevent chemotherapy-induced nausea and vomiting, in Brazil | NEPA is an oral fixed combination of a novel NK1 receptor antagonist (netupitant) and the best-in-class 5-HT3 receptor antagonist palonosetron, already approved as a combination in the U.S. with the trade name Akynzeo for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy | 2/12/15 |
Helsinn Group (Lugano, Switzerland) | Mundipharma International Corp. Ltd. (Singapore) | ND | Distribution and license agreement for the exclusive rights to ghrelin receptor agonist anamorelin for cancer anorexia-cachexia in non-small-cell lung cancer patients in Mainland China, Hong Kong and Macao | Helsinn retains all international development as well as regulatory and clinical development activities and the supply of anamorelin for commercial use; Mundipharma will obtain the rights to marketing, promotion, distribution and sales ofanamorelin in the designated territories | 3/27/15 |
Helsinn Group (Lugano, Switzerland) | Bial-Portela & Ca. SA (Porto, Portugal) | ND | Agreement in which Bial-Portela gained exclusive distribution and license rights to anamorelin in Spain, Portugal, Angola and Mozambique | Helsinn retained international regulatory and clinical development activities and the commercial supply of anamorelin to treat cancer anorexia | 9/9/15 |
Helsinn Holding SA (Lugano, Switzerland) | Mundipharma Medical Co. (Basel, Switzerland) | ND | Distribution, license and supply agreements granting Mundipharma exclusive rights to register, market, promote, distribute and sell the orally active ghrelin receptor agonist anamorelin in Switzerland and Liechtenstein | Helsinn retains all international development as well as regulatory and clinical development activities and the supply of anamorelin for commercial use in other areas not covered by pre-existing partnerships with Mundipharma | 9/4/15 |
Hemispherx Biopharma Inc. (Philadelphia) | Emerge Health Pty Ltd. (Australia) | ND | Agreement to file for approval of Alferon N Injection in Australia and New Zealand and begin distribution on a named-patient basis | Emerge will coordinate regulatory-compliant programs to inform physicians about Alferon; Hemispherx will support the programs | 8/12/15 |
Hemispherx Biopharma Inc. (Philadelphia) | Armada Health Care LLC | ND | Extended sales and marketing agreement for two years for Alferon N Injection in the U.S. | Hemispherx will manufacture and supply Alferon N Injection, and Armada has agreed to provide ongoing sales and marketing to support the product's re-launch | 8/18/15 |
Hemispherx Biopharma Inc. (Philadelphia) | Mytomorrows (Amsterdam, the Netherlands) | ND | Contract to collaborate for access to its natural alpha interferon for patients who have become intolerant to treatment with recombinant interferon or where such treatment fails in Brazil, Columbia and Chile | In January 2012, ANMAT approved the product for treatment of hepatitis C, multiple sclerosis and cancers in patients whose treatment with recombinant alpha interferon fails or who become intolerant to treatment with recombinant alpha interferon as a result of the appearance of neutralizing antibodies | 11/10/15 |
Hemoshear LLC (Charlottesville, Va.) | Pfizer Inc. (New York) | ND | Multiyear platform collaboration in which they will combine scientific and technical expertise | Hemoshear will leverage its discovery platform with the aim to develop a predictive model for preclinical drug-induced vascular injury | 1/13/15 |
Hemostemix Inc. (Toronto) | Hemostemix Asia Inc. (Taipei, Taiwan) | ND | Strategic alliance that covers a manufacturing and commercial license to Hemostemix's ACP-01 technology to treat critical limb ischemia patients in Taiwan, China and South Korea | Deal includes funding and up to 20 participants in Taiwan who will become part of the ongoing Hemostemix phase II trial for treating CLI; Hemostemix will be an equity partner with 35% ownership in HEMA | 7/24/15 |
Heptares Therapeutics (Welwyn Garden City, UK) | Pfizer Inc. (New York) | $1,890.00 | G-protein coupled receptor platform technology deal in which Heptares will be given 10 GPCR targets from which to produce high resolution crystal structures for use in Pfizer's in-house discovery efforts | Heptares will receive research, development and commercial milestones of up to $189M per target, plus royalties, valuing the deal at $1.89B; Pfizer's Japanese subsidiary, Pfizer Seiyaku KK is to invest $33M in new shares of Heptares' parent, Sosei Group Corp. | 12/1/15 |
Heptares Therapeutics (Welwyn Garden City, UK; subsidiary of Sosei Group Corp.; Tokyo) | Astrazeneca plc (London) | $510.00 | Out-licensing deal for A2A adenosine receptor antagonist HTL-1071 for development in immuno-oncology indications | Heptares is getting $10M up front and more than $500M in milestones through the deal | 8/7/15 |
Heptares Therapeutics (Welwyn Garden City, UK; subsidiary of Sosei Group Corp.; Tokyo) | Teva Pharmaceutical Industries Ltd. (Jerusalem) | $410.00 | Migraine partnership in which Teva is out-licensing its preclinical small-molecule calcitonin gene-related peptide antagonist program | Heptares will receive $10M up front and is to be funded to continue in-house discovery research in CGRP; in addition to $400M in research, development and commercialization milestones, Heptares will be eligible for royalties | 11/30/15 |
Horizon Discovery Group plc (Cambridge, U.K.) | Axol Bioscience Ltd. (Cambridge, U.K.) | ND | Partnership for the delivery of off-the-shelf and on-demand genomically modified and differentiated induced pluripotent stem cells for use in neuronal and cardiovascular disease research | Both companies will market and sell the products and services derived; financial terms were not disclosed | 11/25/15 |
Horizon Discovery Group plc (Cambridge, UK) | Definigen Ltd. (Cambridge, UK) | ND | Collaboration to develop a range of gene-engineered induced pluripotent stem-based cell lines for use in research | Horizon will perform genome engineering on the iPS cells, which will then be differentiated by Definigen | 6/11/15 |
Horizon Discovery Group plc (Cambridge, UK) | Redx Pharma plc (Liverpool, UK) | ND | Research collaboration to advance Redx's pan-RAF inhibitor program for out-licensing in oncology indications including colorectal cancer | Horizon and Redx will bear costs proportionate to respective research activities; Horizon also would share in the benefits of any potential partnering of the programs, gaining an unspecified percentage of any up-front payments, a share of future milestones and a share of future product royalties | 9/4/15 |
Horizon Discovery plc (Cambridge, UK) | Servier SA (Neuilly-sur-Seine, France) | $76.60 | In-licensing agreement for kinase inhibitors that Horizon will shape up for development as personalized medicines | Horizon will be in line for payments of more than £50M (US$76.6M) in development milestones plus royalties on sales of any products; Servier has the first option to license back the compounds | 10/8/15 |
Hutchison Whampoa Sinopharm Pharmaceuticals (Shanghai) Co. Ltd. (subsidiary of Hutchison China Meditech Ltd.; Hong Kong) | Astrazeneca (Wuxi) Trading Co. Ltd. (unit of Astrazeneca plc; London) | ND | Exclusive distribution agreement to distribute and market antipsychotic drug Seroquel (quetiapine) in China | Seroquel, which is approved for the treatment of schizophrenia and bipolar disorder, was launched in China in 2001 | 1/30/15 |
Hydra Biosciences Inc. (Cambridge, Mass.) | Boehringer Ingelheim GmbH (Ingelheim, Germany) | ND | Worldwide research collaboration and license agreement to identify small-molecule inhibitors of transient receptor potential, with a primary focus on treating renal diseases and disorders | Boehringer is responsible for global development and commercialization; Hydra will receive an up-front payment, research funding, milestone payments and tiered royalties | 4/14/15 |
Hyperion Therapeutics Inc. (Brisbane, Calif.) | Clal Biotechnology Industries Ltd. (Ramat Gan, Israel) and Yeda Research and Development Co. Ltd. | $6.00 | Hyperion amicably resolved its disputes, and entered a completion of phase III trial, option and mutual release agreement with Clal and Yeda Research and Development regarding Diapep277 | Hyperion will complete an ongoing DIA-AID 2 phase III trial of Diapep277 to treat new onset type 1 diabetes and will not take Diapep277 forward beyond completion of the trial; CBI will have an option, that expires Sept. 30, to acquire Andromeda, and will pay a nonrefundable option payment of $2.5M at signing, payable in shares of Hyperion stock currently held by CBI; if the option is exercised, CBI will pay an option exercise price of $3.5M, also payable in shares of Hyperion stock currently held by CBI; Andromeda will be obligated to pay Hyperion future contingent payments if and to the extent it or its shareholders receive revenues or certain other proceeds, which are capped at $36.5M | 2/18/15 |
Ibio Inc. (Newark, Del.) | Caliber Biotherapeutics LLC (Bryan, Texas) | ND | Agreement for Caliber to scale up and produce materials for clinical development of Ibio's anti-fibrosis product, IBIO-CFB03 | Financial terms were not disclosed | 4/28/15 |
Icura Vision Inc. (Los Angeles) | Undisclosed party | ND | Licensing agreement for the intellectual property portfolio and R&D program for an oral dry age-related macular degeneration medication | The company intends to place the first of the program's candidates, ICR-14967, into clinical development in 2016; under the terms of the licensing agreement, the National Institutes of Health's Blueprint Neurotherapeutics Network, which has funded the medication's discovery and early development, will continue to provide financial support through phase I | 1/29/15 |
Idera Pharmaceuticals Inc. (Cambridge, Mass.) | Glaxosmithkline plc (London) | $100.00 | Exclusive worldwide collaboration and license agreement | To research, develop and commercialize selected molecules from Idera's third-generation antisense platform for the treatment of selected targets in renal disease; Idera is eligible to receive about $100M in development and regulatory milestone payments, including a $2.5M up-front payment, plus royalties on all sales upon commercialization at varying rates up to 5% on annual net sales in excess of $500M | 11/24/15 |
IDT Australia Ltd. (Victoria, Australia) | Mayne Pharma Group Ltd. (Melbourne, Australia) | ND | Agreement to distribute IDT's generic temozolomide in the U.S. | Terms were not disclosed | 9/25/15 |
Igenica Biotherapeutics Inc. (Burlingame, Calif.) | Medimmune (unit of Astrazeneca plc; London) | ND | Oncology research agreement to evaluate the potential of antibody-drug conjugates targeting surface antigen in leukemia | Igenica will contribute its anti-SAIL antibodies, including IGN786, and its Snap ADC drug linker, and Medimmune will provide its antitumor payload; Medimmune will receive an option to an exclusive worldwide license to anti-SAIL antibodies and ADCs resulting from the collaboration; Igenica will receive an exclusive option fee and is eligible to receive an up-front license fee, milestones and royalties, if Medimmune exercises its option | 10/29/15 |
Ignyta Inc. (Jerusalem) | Teva Pharmaceutical Industries Ltd. (Jerusalem) | $14.90 | Ignyta acquired Teva's R&D oncology assets, picking up rights to four clinical and preclinical compounds | Concurrently, Ignyta raised $41.6M in an equity financing of 4.2M shares, of which 1.5M (US$14.9M) were purchased by Teva, which gains 6% of the company; deal includes no milestones or royalties, though Ignyta will be responsible for obligations to third parties, including milestones and royalties | 3/19/15 |
Ignyta Inc. (San Diego) | Eli Lilly and Co. (Indianapolis) | $40.00 | Exclusive license agreement for worldwide rights for the taladegib oncology development program | Lilly will receive an up-front payment of $2M in cash and approximately 1.2M shares of common stock; Ignyta is also obligated to pay to Lilly development and sales milestones related to taladegib products totaling up to approximately $38M, along with royalties on net sales | 11/10/15 |
Imaginab Inc. (Los Angeles) | Eli Lilly and Co. (Indianapolis) | ND | Preclinical research collaboration to study potential T-cell-based immuno-oncology therapies | Imaginab will conduct preclinical research using its immune imaging agent, IAB22M2C, a clinical anti-human CD8 probe, to detect T-cell trafficking, redirection and infiltration in response to Lilly oncology molecules | 10/14/15 |
Immune Pharmaceuticals Inc. (New York) | STC Biologics Inc. (Cambridge, Mass.) | ND | Strategic partnership to develop Nanomabs, a new generation of antibody nanoparticle conjugates, for targeted elivery of chemotherapeutics | Financial terms were not disclosed | 5/5/15 |
Immune Pharmaceuticals Inc. (New York) | Endo Pharmaceuticals Inc. (subsidiary of Endo International plc; Dublin) | ND | Amended 2003 licensing agreement in which Immune will transfer to Endo its previously licensed patents related to the use of topical lidocaine in acute and chronic back pain | Endo will give Immune a royalty-free, non-exclusive, fully transferable license to those patents; Endo will pay undisclosed milestones to Immune if Endo gains a back pain indication for a lidocaine-based product, according to terms of the original 2003 agreement; Immune will re-gain full exclusive rights to develop, commercialize and license Lidopain, a high-dose lidocaine patch for acute pain. Lidopain is in phase II development. | 7/9/15 |
Immune Pharmaceuticals Inc. (New York) | Atlante Biotech SAS | ND | Exclusive license for Atlante Biotech patents and know-how for a new format of bispecific antibodies | Terms were not disclosed | 12/29/15 |
Immune Therapeutics Inc. (Orlando, Fla.) | KRS Global Biotechnology Inc. | ND | Deal for the packaging and distributing of its naltrexone tablets | Terms were not disclosed | 1/26/15 |
Immuneering Corp. (Cambridge, Mass.) | Teva Pharmaceutical Industries Ltd. (Jerusalem) | ND | Agreement in which Teva will purchase a 51% equity share of the genomic analysis company | Immuneering uses advanced techniques to identify hidden signals and biological insights across an array of genetic, genomic and proteomic data that can direct research for enhanced discovery, development and clinical success | 8/4/15 |
Immunocellular Therapeutics Ltd. (London) | Pharmacell BV (Maastricht, the Netherlands) | ND | Agreement to provide contract manufacturing services for the European production of ICT-107, its dendritic cell-based cancer immunotherapy in development to treat glioblastomas | Immunocellular plans to initiate a phase III registration program for ICT-107 in the U.S. and in Europe this year; terms were not disclosed | 3/20/15 |
Immunocore Ltd. (Oxford, UK) | Medimmune (unit of Astrazeneca plc; London) | ND | Collaboration to conduct a phase Ib/II trial combining Medimmune's checkpoint inhibitors, MEDI4736 and/or tremelimumab, with IMCgp100, to treat metastatic melanoma | Medimmune has an exclusive relationship with Immunocore to develop IMCgp100 in combination with MEDI4736 and/or tremelimumab and will have first right of negotiation for future commercial development of combinations for tumors expressing gp100 | 4/17/15 |
Immunocore Ltd. (Oxford, UK) | Eli Lilly and Co. (Indianapolis) | ND | To explore the utility of Immunocore's IMC-GP100 in combination with Lilly's galunisertib (LY2157299) and merestinib (LY2801653) for the treatment of melanoma | Immunocore and Lilly will conduct two phase Ib/II studies, which Lilly will sponsor | 6/30/15 |
Immunogen Inc. | Takeda Pharmaceutical Co. Ltd. | $230.00 | Agreement to license exclusive rights to use the company's antibody-drug conjugate technology to develop and commercialize anticancer therapeutics for up to two undisclosed targets with an option on a third | Takeda's subsidiary Millennium Pharmaceuticals Inc. gains access to new DNA-acting IGN payload agents, which disrupt DNA to kill cells; Takeda is responsible for development, manufacturing and marketing of any ADC products resulting, and will owe up to $210M in milestones, plus $20M up front and royalties on net sales | 3/24/15 |
Immunomic Therapeutics Inc. | Astellas Pharma Inc. (Tokyo) | $300.00 | Exclusive global licensing and development deal in which Astellas is building on a single vaccine deal it struck with Immunomic earlier this year | Astellas is capturing rights to ITI's full portfolio of allergy-focused DNA vaccines; the deal carries $300M for ITI up front plus 10% royalties of net sales of potential products, leaving ITI with all rights to additional applications of the LAMP-vax technology | 10/12/15 |
Immunomic Therapeutics Inc. (Hershey, Pa.) | Astellas Pharma Inc. (Tokyo) | $70.00 | Exclusive license agreement to develop and commercialize JRC2-LAMP-vax, Immunomic's vaccine candidate to treat allergies induced by Japanese red cedar pollen, in Japan | Immunomic is set to receive $15M up front and up to $55M in potential development and regulatory milestone and technology transfer payments, as well as tiered double-digit royalties on net product sales; Astellas will assume responsibility for developing and commercializing JRC2-LAMP-vax in Japan, where Japanese red cedar pollinosis is endemic | 2/2/15 |
Immunovaccine Inc. (Halifax, Nova Scotia) | Incyte Corp. (Wilmington, Del.) | ND | Nonexclusive clinical trial collaboration to evaluate the combination of Immunovaccine's T-cell activating immunotherapy, Dpx-Survivac, with Incyte's INCB24360 | Immunovaccine and Incyte will co-fund and conduct a multicenter, open-label phase Ib study to evaluate the safety, tolerability and efficacy of the combination in platinum-sensitive ovarian cancer patients who are at high risk of recurrence | 6/26/15 |
Immunovaccine Inc. (Halifax, Nova Scotia) | Pharmathene Inc. (Annapolis, Md.) | $50.00 | Exclusive worldwide license agreement to develop and commercialize a recombinant protective antigen anthrax vaccine candidate using Immunovaccine's Depovax platform | Pharmathene will fund product development and make annual payments to Immunovaccine of $200,000, plus up to $8M in development and regulatory milestone and initial product sales payments and up to $42M in payments for the achievement of undisclosed sales targets; Immunovaccine also is eligible to receive a royalty on net sales | 7/9/15 |
Imprimis Pharmaceuticals Inc. (San Diego) | Urigen Pharmaceuticals Inc. (Walnut Creek, Calif.) | ND | Agreement in which Imprimis obtained exclusive U.S. commercial rights to the patented compounded alkalinized lidocaine and heparin formulation to treat interstitial cystitis | Imprimis received nonexclusive U.S. licensing rights for the product from Urigen | 4/29/15 |
Imprimis Pharmaceuticals Inc. (San Diego) | Advanced Dosage Forms Inc. | ND | License agreement to expand its ophthalmic injectable and combination topical compounded formulations into Canada | The license agreement includes an initial cash license fee, and a per-unit royalty of the greater of $50 or 20% of the gross purchase price paid to Advanced Dosage | 8/13/15 |
Incyte Corp. (Wilmington, Del.) | Jiangsu Hengrui Medicine Co. Ltd. (Shanghai) | $795.00 | License and collaboration agreement to develop and commercialize anti-PD-1 monoclonal antibody SHR-1210 | Incyte gained exclusive global rights outside China, Hong Kong, Macau and Taiwan, in exchange for $25M up front and up to $770M in milestone payments; Hengrui is entitled to tiered royalties on net sales | 9/3/15 |
Index Pharmaceuticals AB (Stockholm) | Almirall SA (Barcelona) | ND | Terminated license agreement relating to the drug Kappaproct for the treatment of ulcerative colitis, leading Index to regain European rights to the drug | The termination follows Almirall's recent repositioning of its R&D organization; the drug missed the primary endpoint of induction of clinical remission according to the Clinical Activity Index in a phase III study that read out in June 2014 | 7/1/15 |
Infinity Pharmaceuticals Inc. (Cambridge, Mass.) | Takeda Pharmaceutical Co. Ltd. (Osaka, Japan) | $52.50 | Exercised option to buy out future royalty obligations due to Takeda for sales of duvelisib (IPI-145), Infinity's dual inhibitor of phosphoinositide-3 kinase-delta and P13K-gamma in oncology indications | Infinity paid an exercise fee of $52.5M for the option, purchased in July 2014 from Takeda's Millennium unit for $5M; exercising the option eliminates the future obligation to pay Takeda tiered royalties ranging from 7% to 11% on worldwide net sales of duvelisib in oncology indications | 4/1/15 |
Ingenza Ltd. (Midlothian, UK) | Glaxosmithkline plc (London) | ND | Collaboration on a research project; Ingenza specializes in the application of industrial biotechnology and synthetic biology | Terms were not disclosed | 7/21/15 |
Innate Pharma SA (Marseille, France) | Sanofi SA (Paris) | ND | Collaboration to apply site-specific conjugation technology to develop new antibody-drug conjugates | Sanofi-Aventis Recherche & Developpement will evaluate site-specific payload conjugation to enhance ADC pharmacokinetics, efficacy and safety and has the option to enter a licensing agreement with Innate on that technology | 4/17/15 |
Innate Pharma SA (Marseille, France) | Astrazeneca plc (London) | $1,275.00 | Agreement to in-license Innate's IPH2201, a natural killer cell-activating antibody, which is in phase II | The product will be developed both as a monotherapy and in combination with MEDI4736, an anti-PD-L1 immune checkpoint inhibitor being developed by Astrazeneca's Medimmune; Innate gets $250M up-front, $100M at the start of phase III development, $925M in regulatory and sales-related milestones, plus royalties on sales; it also has rights to co-promote and take 50% of profits on products marketed in Europe | 4/27/15 |
Innovent Biologics Inc. | Eli Lilly and Co. (Indianapolis) | $456.00 | Agreement to develop and manufacture a portfolio of potential cancer therapies | The deal's value could exceed $456M if an Innovent-contributed preclinical immuno-oncology molecule hits key milestones, while other projects in the collaboration could yield a biosimilar of the blockbuster Rituxan (rituximab, Biogen Idec Inc. and Roche AG), a cMet monoclonal antibody to treat non-small-cell lung cancer and several bispecific immuno-oncology molecules; over the next decade, Innovent will lead the development and manufacturing for the China market while Lilly will be responsible for commercialization of the three potential medicines; Innovent also has co-promotion rights; deal includes $56M up-front, $400M in milestone payments, as well as sales royalties and other payments | 3/23/15 |
Innovent Biologics Inc. (Shanghai) | Eli Lilly and Co. (Indianapolis) | $1,000.00 | Immuno-oncology deal for up to three preclinical bispecific monoclonal antibodies based on PD-1 | The deal is worth $1B in milestone and royalty payments; Lilly will exercise global rights excluding China, to develop, manufacture and commercialize these cancer treatment candidates; the deal gives Innovent China rights to develop, manufacture and commercialize these candidates, subject to a Lilly opt-in right for co-development and commercialization | 10/12/15 |
Inovio Pharmaceuticals Inc. (Plymouth Meeting, Pa.) | Geneone Life Science Inc. (Seoul) | ND | Agreement for Inovio to advance its DNA vaccine for Middle East respiratory syndrome into a phase I trial in healthy volunteers | The companies will conduct a phase I trial funded by Geneone in return for milestone-based co-ownership of the immunotherapy | 5/28/15 |
Inovio Pharmaceuticals Inc. (Plymouth Meeting, Pa.) | Astrazeneca plc's (London) Medimmune unit | $727.50 | Exclusive license to Inovio's INO-3112 immunotherapy, which targets cancers caused by human papillomavirus types 16 and 18, plus a broader discovery partnership to develop up to two additional DNA-based cancer vaccine products that Medimmune will have exclusive rights to develop and commercialize | Inovio is set to receive an up-front payment of $27.5M and up to $700M in development and commercial milestones for the INO-3112 deal, while Medimmune assumes future development costs; Inovio also is entitled to tiered double-digit royalties; for the discover-stage programs Inovio will receive development, regulatory and commercial milestones and be eligible for royalties of related cancer vaccine products | 8/11/15 |
Insys Therapeutics Inc. (Phoenix) | Gold Coast Therapeutics Inc. (Illinois) | ND | Exclusive sublicense to develop a combination of cromolyn sodium and cetirizine (Zyrtec, Johnson & Johnson) to treat patients with chronic prostatitis/chronic pelvic pain syndrome | Design work is under way for preclinical and clinical studies to be conducted at Northwestern University, which developed intellectual property around the use of agents targeting mast cells as potential therapies for pelvic pain; Gold Coast exclusively licensed the technology that it sublicensed to Insys | 2/25/15 |
Insys Therapeutics Inc. (Phoenix) | Senzer Ltd. (UK) | ND | Exclusive agreement and partnership for the development of inhaled synthetic pharmaceutical cannabinoid products, incuding dronabinol and cannabinol using Senzer's inhalation delivery technology | Financial terms were not disclosed | 9/25/15 |
Intarcia Therapeutics Inc. (Boston) | Numab AG (Wadenswil, Switzerland) | ND | Collaboration focused on the development of once- or twice-yearly monospecific and multispecific antibodies addressing diabetes, obesity and autoimmune indications | Numab is eligible to receive undisclosed up-front and contingent milestone payments, as well as tiered single to low double-digit royalties on any sales resulting from collaborative efforts; Intarcia has the option to extend the collaboration beyond the initial assets and targets as well as the opportunity to purchase a strategic interest in Numab at a pre-defined time point; Intarcia will be responsible for the development, manufacturing and commercialization of all products stemming from the collaboration | 3/20/15 |
Intas Pharmaceuticals Ltd. (Ahmedabad, India) | Combino Pharma (Barcelona, Spain) | ND | Agreement under which Intas acquired the hospital drugs business in Spain and Portugal from Combino through its Accord Healthcare subsidiary | The deal gives Accord certain rights over Combino's hospital portfolio in a number of European and non-European countries while complementing Accord's existing business in Spain | 3/19/15 |
Intellia Therapeutics Inc. (Cambridge, Mass.) | Novartis AG (Basel, Switzerland) | ND | Collaboration to accelerate the ex vivo development of new CRISPR/Cas9-based therapies using chimeric antigen receptor T cells (CARTs) and hematopoetic stem cells (HSCs) | Novartis receives exclusive rights to develop all collaboration programs focused on engineered CARTs; within HSCs, Novartis and Intellia will jointly advance multiple programs, and have agreed to a process for assigning development and ownership rights, which will enable Intellia to develop its own proprietary internal HSC pipeline | 1/8/15 |
Intellicell Biosciences Inc. (New York) | Invigorcell | ND | Licensing agreement for the indication of diabetes mellitus | Invigorcell will be filing an investigational new drug application with the FDA; Intellicell focuses on regenerative medicine using adult autologous stromal vascular cells derived from the blood vessels found in adipose tissue | 1/28/15 |
Intellipharmaceutics International Inc. (Toronto) | Teva Pharmaceuticals USA Inc. (North Wales, Pa.) | ND | Agreement granting Teva and exclusive license to market in the U.S. an undisclosed extended-release drug product candidate | Under the agreement with Teva, subject to certain conditions, Intellipharmaceutics has agreed to manufacture and supply the product exclusively for Teva and Teva has agreed that Intellipharmaceutics will be its sole supplier of the product to be marketed in the U.S. | 2/3/15 |
Interleukin Genetics Inc. (Waltham, Mass.) | Isis Pharmaceuticals Inc. (Carlsbad, Calif.) | ND | Agreement to provide genetic testing services for a phase II study of ISIS-APO(a)Rx in patients with high lipoprotein | Patients with high levels of Lp(a) have an increased risk of atherosclerosis, coronary heart disease, aortic stenosis, heart attack and stroke | 1/8/15 |
Interleukin Genetics Inc. (Waltham, Mass.) | Isis Pharmaceuticals Inc. (Carlsbad, Calif.) | ND | Agreement for Interleukin Genetics to provide Isis with testing kits and prepare DNA, run genotypes and provide data for SNP genotypes for the IL-1 and LP(a) SNPs for Isis' phase I study evaluating ISIS-APO(a)-LRx | The company said that the phase I study is the second Isis clinical study to incorporate Interleukin's genetic test into the trial design to add genetic information at the earliest phases of testing | 3/10/15 |
Interprotein Corp. (Osaka, Japan) | Ipsen SA (Paris) | $177.00 | Research collaboration and option agreement to develop and commercialize therapeutic peptides for serious endocrinology conditions such as Cushing's disease | Should Ipsen exercise its option to fully develop the compounds, combined up-front and milestone payments to Interprotein could reach up to €165M (US$177M), with additional royalties on global net sales | 11/20/15 |
Intralytix Inc. (Baltimore) | Ferring Pharmaceuticals SA (Saint Prex, Switzerland) | ND | Collaboration in its development program for a bacteriophage-based therapy for inflammatory bowel disease | Intralytix will assist Ferring in formulating and manufacturing the bacteriophages for use in clinical trials; financial details were not disclosed. | 7/14/15 |
Intrexon Corp. (Germantown, Md.) | Ziopharm Oncology Inc. (Boston) | $100.00 | Broad exclusive licensing agreement to develop nonviral adoptive cellular cancer immunotherapies | The deal includes an exclusive sublicensing agreement through MD Anderson Cancer Center for intellectual property developed at the University of Minnesota; the companies committed to provide $15M to $20M annually over three years for additional research and technology development; the companies will provide $50M each in their common shares to MD Anderson | 1/15/15 |
Intrexon Corp. (Germantown, Md.) | Merck Serono (unit of Merck KgaA; Darmstadt, Germany) | $941.00 | Agreement focused on CAR T-cell research targeting both hematological and solid tumors using a plasmid-based delivery system, as opposed to the viral vector delivery in use by competitors | The $115M up-front fee will be split equally between Intrexon and partner Ziopharm Oncology Inc., who have worked together since 2011 on genetically modified chimeric antigen receptor (CAR) T cells; Merck Serono will nominate specific targets, two to start, and will provide research funding; Intrexon will develop the programs into preclinical products; the deal includes up to $826M in milestones, again split evenly with Ziopharm, plus tiered royalties; Intrexon also is eligible for technology development milestones | 3/31/15 |
Intrexon Corp. (Germantown, Md.) | Oragenics Inc. (Tampa, Fla.) | ND | Exclusive channel collaboration to pursue development of biotherapeutics for oral mucositis and other diseases and conditions of the oral cavity, throat and esophagus, including clinical advancement of the Actobiotic AG013 | Oragenics will have access to Intrexon's technologies and expertise to develop products for the treatment of OM or products containing genetically modified Lactococcus lactis-expressing trefoil factors in the oral cavity, throat and esophagus for a technology access fee and will reimburse Intrexon for the research and development costs; deal also includes commercial and regulatory milestone payments to Intrexon, as well as a low double-digit percentage royalty | 6/11/15 |
Intrexon Corp. (Germantown, Md.) | Synthetic Biologics Inc. (Rockville, Md.) | ND | Exclusive channel collaboration to pursue development and commercialization of biotherapeutics to treat patients with phenylketonuria | The firms plan to use Intrexon's Actobiotics platform providing a method of delivering therapeutic proteins and peptides to the gastrointestinal tract through food-grade microbes | 8/11/15 |
Intrexon Corp. (Germantown, Md.) | Ziopharm Oncology Inc. (Boston) | ND | Collaboration focused on addressing the undelrying pathologies of graft-vs-host disease and the discovery of immunotherapies | Intrexon will receive a technology access fee of $10M in cash and reimbursement for all research and development costs; the deal also provides for equal sharing of operating profits | 9/30/15 |
Intrexon Corp. (Germantown, Md.) | Janssen Pharmaceutica NV (Beerse, Belgium; part of Johnson & Johnson) | ND | Collaborative agreement to research and develop Actobiotics therapies for type 2 diabetes, obesity and metabolic disorders that are related to energy dysregulation | The collaboration will also work on preventing diabetes from progressing from early stages by using the Actobiotics platform | 12/23/15 |
Inventra Inc. (Madison, Wis.) | Oxford Biotherapeutics Ltd. (Oxford, UK) | ND | Collaboration to identify and characterize a panel of fully human therapeutic monoclonal antibodies against a cancer target that OBT has identified utilizing its Oxford Genome Anatomy Project discovery platform | OBT will make an initial payment to Invenra upon successful delivery of a panel of MAbs confirmed to meet mutually agreed design goals and specifications; OBT will be responsible for all further development of the therapeutic product candidates; Invenra could receive further milestone payments and royalties on net sales of therapeutic and diagnostic products | 6/26/15 |
Iroko Pharmaceuticals LLC (Philadelphia) | Litha Healthcare Group (Gauteng, South Africa) | ND | Licensing agreement for the exclusive rights to market and sell Zorvolex (diclofenac) capsules in Angola, Botswana, Lesotho, Madagascar, Malawi, Mauritius, Mozambique, Namibia, Republic of South Africa, Seychelles, Swaziland, Tanzania and Zambia | Lithia will be responsible for obtaining regulatory and pricing approval, and will provide marketing and distribution | 5/7/15 |
Iroko Pharmaceuticals LLC (Philadelphia) | Laboratorios Saval SA (Santiago, Chile) | ND | Licensing agreement for exclusive marketing and sales rights to Zorvolex (diclofenac) capsules in Bolivia, Chile, Ecuador, Paraguay and Peru | Saval will obtain regulatory and pricing approval and provide marketing and distribution in those countries | 7/16/15 |
Ironwood Pharmaceuticals Inc. (Cambridge, Mass.) | Exact Sciences Corp. (Madison, Wis.) | ND | Agreement to co-promote Exact Sciences' Cologuard, a noninvasive stool DNA screening test for colorectal cancer | The nonexclusive co-promotion deal, in which Ironwood's clinical sales specialists will expand the promotion efforts of Cologuard in the U.S., covers an initial one-year term with the opportunity for extension; Ironwood will be compensated from the net sales generated from the physicians on whom its sales reps call | 3/11/15 |
Ironwood Pharmaceuticals Inc. (Cambridge, Mass.) | Allergan plc (Dublin) | ND | Deal for the U.S. co-promotion of Viberzi (eluxadoline), Allergan's treatment for adults with irritable bowel syndrome with diarrhea | The arrangement calls for Ironwood's sales specialists to detail Viberzi to the roughly 25,000 health care practitioners they currently reach for Linzess and colon cancer test Cologuard; promotional efforts will be compensated based on the volume of calls delivered by Ironwood's sales force, as well as agreed-upon performance metrics; Allergan will be responsible for all other costs relating to the commercialization of Viberzi and the co-promotion will begin as soon as the product is commercially available | 8/6/15 |
Ironwood Pharmaceuticals Inc. (Cambridge, Mass.) | Allergan plc (Dublin) | ND | Deal for the U.S. co-promotion of Viberzi (eluxadoline), Allergan's treatment for adults with irritable bowel syndrome with diarrhea | The arrangement calls for Ironwood's sales specialists to detail Viberzi to the roughly 25,000 health care practitioners they currently reach for Linzess and colon cancer test Cologuard; promotional efforts will be compensated based on the volume of calls delivered by Ironwood's sales force, as well as agreed-upon performance metrics; Allergan will be responsible for all other costs relating to the commercialization of Viberzi and the co-promotion will begin as soon as the product is commercially available | 8/6/15 |
ISA Pharmaceuticals BV (Leiden, the Netherlands) | Shin Nippon Biomedical Laboratories Ltd. (Tokyo) | ND | Research and development agreement to explore a new nasal delivery for ISA's cervical cancer immunotherapeutic | ISA's Synthetic Long Peptide immunotherapeutic ISA101 will be administered via SNBL's nasal drug delivery technology; both parties expect to obtain basic research data on a potential antigen-specific immune response | 3/4/15 |
Isis Pharmaceuticals Inc. (Carlsbad, Calif.) | Janssen Biotech Inc. (unit of Johnson & Johnson; New Brunswick, N.J.) | $835.00 | Agreement to discover and develop antisense drugs to treat autoimmune disorders of the gut | Janssen committed to pay up to $835M in the deal, $35M up front and the rest in development, regulatory and sales milestones, as well as tiered royalties that on average are double digits; the deal gives Janssen options to license three therapeutic candidates in an area where it has established broad expertise with drugs such as Remicade while helping Isis continue to expand the breadth of antisense therapy's utility, further developing its potential for oral administration and local action | 1/6/15 |
Isis Pharmaceuticals Inc. (Carlsbad, Calif.) | Bayer Healthcare (Leverkusen, Germany) | $155.00 | Alliance for potential first-in-class factor XI inhibitor | Isis gains $100M up front and another $55M could come upon advancement of antisense oligonucleotide ISIS-FXIrx following a phase II trial in compromised kidney function; the deal also includes milestone payments and tiered royalties in the low to high 20% range | 5/5/15 |
Isis Pharmaceuticals Inc. (Carlsbad, Calif.) | Astrazeneca plc (London) | $65.00 | Deal for Isis to discover and develop drugs for cardiovascular, metabolic and kidney diseases | Astrazeneca will pay Isis $65M up front, as well as development and regulatory milestone payments; Isis will be in line to earn double-digit royalties on net sales | 8/4/15 |
Islet Sciences Inc. (Raleigh, N.C.) | Brighthaven Ventures | $116.85 | License agreement for exclusive rights to develop and commercialize SGLT2 inhibitor remogliflozin etabonate, which is in phase IIb development in type 2 diabetes and non-alchoholic steatohepatitis | Islet gets exclusive global rights outside of Japan, Korea, Taiwan, China and Latin America in exchange for $5M up front and up to $35.1M in pre-regulatory approval milestones and up to $76.75M in post-regulatory approval milestones, as well as royalties | 3/4/15 |
Janssen Pharmaceuticals Inc. (Raritan, N.J.; part of Johnson & Johnson) | Bavarian Nordic A/S (Copenhagen) | ND | Collaborative and licensing agreement, which involves using Bavarian's MVA-BN technology along with Janssen's Advac technology to develop a heterologous prime-boost vaccine for human papillomavirus chronic infections that can lead to cancer | Janssen will conduct clinical development and, subject to regulatory approval, will be responsible for registration, distribution and commercialization of a combination vaccine worldwide | 12/22/15 |
Janus Biotherapeutics Inc. (Boston) | Roche AG (Basel, Switzerland) | ND | Collaboration for the development of a small-molecule Toll-like receptor inhibitor with the potential to address several autoimmune diseases | Janus will receive an undisclosed up-front cash payment and R&D funding over a collaboration period; following achievement of certain milestones, Roche will have the option to acquire Janus; if exercised, Janus' shareholders will be eligible to receive an acquisition fee and development milestones | 8/21/15 |
Jazz Pharmaceuticals plc (Dublin) | EUSA Pharma (Hemel Hempstead, UK) | ND | EUSA acquired five approved specialty hospital product from Jazz | The company is supported by significant funding raised from health care growth equity investor Essex Woodlands; the products had annual sales of approximately $27 million last year | 3/24/15 |
Johnson & Johnson (New Brunswick, N.J.) | Washington University, Wuxi Apptec, Karolinska Intitutet, MaRS Innovation, the Lead Discovery Center, Emulate Inc., Novo Nordisk A/S, the BIO5 Institute at the University of Arizona, Uniquest, Carna Biosciences, Brim Biotechnology Inc., the University of the Witwatersrand in South Africa, Depuy Synthes Products and Arcturus Therapeutics Inc. | ND | J&J announced 17 new collaborations | The deals include an alliance for the Disease Interception Accelerator, a research agreement with Washington University to identify the root cause of type 1 diabetes and enable the development of interventions that halt progression to disease | 6/12/15 |
Juno Therapeutics Inc. (Seattle) | Fate Therapeutics Inc. (San Diego) | $13.00 | Partnership to discover mechanisms to modulate the properties of Juno's immuno-oncology candidates to improve their therapeutic potential in both the chimeric antigen receptor and T-cell receptor cellular immunotherapy programs | Juno will pay Fate $5M up front, purchase 1M of Fate's common shares at $8 apiece and fund activities related to the collaboration through the exclusive four-year research term, which carries a two-year extension option | 5/7/15 |
Juno Therapeutics Inc. (Seattle) | Editas Medicine Inc. (Cambridge, Mass.) | $277.00 | Agreement focused on chimeric antigen receptor T (CAR-T) cell therapies employing Editas' CRISPR | Juno will provide Editas with $25M up front, up to $22M in research support over the next five years across three programs, milestones of more than $230M associated with each program, plus tiered royalties | 5/28/15 |
Kadmon Corp. LLC (New York) | Jinghua Pharmaceutical Co. Ltd. (China) | $50.00 | Collaboration and license agreement to discover, develop and commercialize Kadmon's fully human anti-VEGFR2 and anti-PD-L1 monoclonal antibodies exclusively for Greater China | Kadmon also licensed to Jinghua its technology and know-how to discover fully human monoclonal antibodies to develop further products for commercialization in the Chinese market; Kadmon received a $10M equity investment and has the potential to receive more than $40M more upon achievement of key milestones, as well as 10% royalties | 11/23/15 |
Kairos Therapeutics Inc. (Vancouver, British Columbia) | Var2 Pharmaceuticals ApS (Bronshoj, Denmark) | ND | Partnership to advance Kairos' technology, used to attach novel toxins to VAR2CSA, a protein produced by a mosquito-borne parasite, into clinical trials | Studies showed that the same sugar molecule is found on the majority of cancer cell types, and that more than 95% of tumor cell lines were successfully treated by Kairos' technology | 10/14/15 |
Kamada Ltd. (Ness Ziona, Israel) | Baxalta Inc. (Deerfield, Ill.) | $50.00 | Disclosed the third extension to supply Glassia to Baxalta under its strategic agreement with Baxter originally executed in August 2010 | Kamada secured about $50M in additional minimum revenues of Glassia | 10/19/15 |
Kancera AB (Stockholm) | Acturum Life Science AB (Stockholm) | ND | Agreement allowing Kancera to evaluate and develop the fractalkine inhibitor, AZD8797 | Kancera will evaluate preclinically the efficiency of AZD8797 in halting tumor growth and relieving pain, with subsequent rights to acquire the project | 9/9/15 |
Kanyos Bio Inc. (Cambridge, Mass.; spinout of Anokion SA; Ecublens, Switzerland) | Astellas Pharma Inc. (Tokyo) | $760.00 | Development alliance in autoimmune disease that includes an option to buy the company outright | By creating the spinout, Anokion will continue to advance its technology on immunological tolerance to protein drugs; the deal is worth up to $760M in R&D funding, option exercise payments and milestones | 6/3/15 |
Kezar Life Sciences (South San Francisco) | Onyx Pharmaceuticals Inc. (South San Francisco; subsidiary of Amgen Inc.) | ND | Licensing agreement for intellectual property related to Onyx's immunoproteasome program | Financial terms were not disclosed | 6/17/15 |
Kinemed Inc. (Emeryville, Calif.) | Camino Partnership LLC | ND | Strategic partnership to locate and acquire control of a portfolio of new drug and targeted drug candidates; once acquired, Kinemed's proteomics technology will be applied to carry out proof-of-concept clinical studies for subsequent out-licensing to pharmaceutical companies | Up to six compounds will be involved over a three-year period, and the initial therapeutic areas of focus will be oncology, neurodegenerative disorders, muscle wasting and fibrosis; financial terms were not disclosed | 4/24/15 |
Kinemed Inc. (Emeryville, Calif.) | Biopharma Forest Inc. (Tokyo) | ND | Agreement to develop and commercialize synthetic ghrelin | Kinemed will develop the late-stage appetite-stimulating agent, synthetic ghrelin, for indications associated with muscle wasting | 9/25/15 |
Kite Pharma Inc. | Alpine Immune Sciences Inc. (Seattle) | $535.00 | Exclusive licensing agreement for two programs from an immunomodulatory technology developed by Alpine | The R&D agreement includes $5M up front and additional research funds; the partners will leverage the technology to better engineer Kite's next-generation chimeric antigen receptor and T-cell receptor candidates; in addition to up-front and R&D funding, AIS is eligible to receive milestone payments based on achieved milestones totaling $530M, plus low single-digit royalties | 10/28/15 |
Kite Pharma Inc. (Santa Monica, Calif.) | Bluebird Bio Inc. (Cambridge, Mass.) | ND | Agreement to co-develop and co-commercialize second-generation T-cell receptor product candidates in human papillomavirus type 16 E6 oncoprotein utilizing gene editing and lentiviral technologies | Kite will lead the program in the U.S., and Bluebird will have the option to lead the program in the EU; both will share overall costs, including R&D and sales and marketing expenses, and profits will be equally split; Kite will have a co-promotion option in the EU, and Bluebird will have a co-promotion option in the U.S. | 6/23/15 |
Kite Pharma Inc. (Santa Monica, Calif.) | GE Global Research (centralized R&D hub for GE) | ND | Research collaboration to develop a next-generation, functionally integrated and automated manufacturing system for engineered T-cell therapy | Kite and GE Global Research will each contribute resources and relevant expertise to the partnership | 12/4/15 |
Knight Therapeutics Inc. (Montreal) | Neuraxon Inc. (Mississauga, Ontario) | $1.75 | Partnership to commercialize products in development by Neuraxon in Canada, Israel, South Africa and Russia | Knight will pay $1.75M in cash and provide additional funding to develop the products | 1/5/15 |
Knight Therapeutics Inc. (Montreal) | 60 Degrees Pharmaceuticals LLC (Washington) | $4.00 | Exclusive license agreement with an option to develop and commercialize 60Ps products in Canada, Israel and Russia | Knight extended the first tranche of a fully secured loan of up to $4M to 60 Degrees; Knight will receive an undisclosed share of proceeds from approval of 60P's products in the U.S. and elsewhere | 12/14/15 |
Kura Oncology Inc. (La Jolla, Calif.) | Janssen Pharmaceutica NV (Beerse, Belgium; part of Johnson & Johnson) | ND | Agreement for an exclusive license to develop and commercialize tipifamib in multiple oncology indications | Terms were not disclosed | 3/30/15 |
Kura Oncology Inc. (La Jolla, Calif.) | Janssen Pharmaceutica NV (Beerse, Belgium; part of Johnson & Johnson) | ND | Agreement for an exclusive license to develop and commercialize tipifarnib, a farnesyl transferase inhibitor, in multiple oncology indications | As a result their common stock is quoted on the OTCQB, under the symbol KURO | 10/22/15 |
Kymab Ltd. (Cambridge, UK) | Provenance Biopharmaceuticals Corp.'s founder and CEO Stephen Gillies (Waltham, Mass.) | ND | Collaboration focused on developing new immunocytokine-based drugs that seek to exploit the synergistic potential of combining antibodies directed against immuno-oncology drug targets with the antitumor activity of selected cytokine molecules | Terms were not disclosed | 1/13/15 |
Kyowa Hakko Kirin Co. Ltd. (Tokyo) | Bristol-Myers Squibb Co. (New York) | ND | Clinical trial collaboration agreement to conduct a phase I/II combination study with mogamulizumab, an anti-CCR4 antibody, and Opdivo (nivolumab), a PD-1 immune checkpoint inhibitor | The study will be conducted in the U.S. and will focus on safety, tolerability and antitumor activity of the regimen in advanced or metastatic solid tumors | 7/31/15 |
Kythera Biopharmaceuticals Inc. (Westlake Village, Calif.) | Actelion Pharmaceuticals Ltd. (Allschwil, Switzerland) and the University of Pennsylvania | $27.00 | License agreements for a new method of treating hair loss, giving Kythera Holdings Ltd., a wholly owned Bermuda subsidiary, worldwide rights to setipiprant, a clinical-stage selective oral antagonist to the prostaglandin D2 receptor | Actelion will be eligible to receive up to $27M in potential development and regulatory milestones, as well as royalties on sales | 2/12/15 |
Laboratory Corp. of America Holdings (Burlington, N.C.) | Shandong Xuanzhu Pharma Co. Ltd. (subsidiary of Sihuan Pharmaceutical Holdings Group Ltd.; Beijing) | ND | Long-term partnership in which Covenace Drug Development, now part of Labcorp, will support the global development of Sihuan Pharmaceutical's drug candidate pipeline, which includes compounds to treat cardiovascular, metabolic, infectious disease, oncology and urology indications | Covance will provide Sihuan Pharmaceutical with global drug development and regulatory expertise, particularly in efforts to achieve dual or multiple filings for regulatory approvals such as investigational new drug applications and new drug applications in China and internationally | 4/2/15 |
Lead Discovery Center GmbH (Dortmund, Germany) | Astrazeneca plc (London) | ND | Agreement to discover new medicines to treat human diseases with high unmet medical need | Through a two-year collaboration, Astrazeneca will add 250,000 high-quality compounds to LDC's internal screening collection to pursue projects in the areas of oncology, neuroscience, respiratory and inflammation, cardiovascular, gastrointestinal and infection research | 4/15/15 |
Lead Pharma Holding BV (Nijmegen, the Netherlands) | Sanofi SA (Paris) | ND | Deal for retinoic acid-related orphan receptor gamma-t inhibition | Lead Pharma will receive an up-front payment, as well as research, development and clinical milestones, while Sanofi takes on responsibility for clinical development and commercialization | 2/19/15 |
Legochem Biosciences Inc. (Daejeon, South Korea) | Fosun Pharma (Shanghai, China; par of the Fosun Pharma Group) | $16.90 | License and commercialization agreement for one of Legochem's next-generation antibody-drug conjugate products and related technology for the Greater china market | The deal is for KRW20B (US$16.9M); they also signed a memorandum of understanding for three other ADC targets | 8/20/15 |
Lexicon Pharmaceuticals Inc. (The Woodlands, Texas) | Ipsen SA (Paris) | $5.00 | Agreement for Ipsen, upon regulatory approval, to commercialize telotristat etiprate in Canada, with a focus on the treatment of carcinoid syndrome | The agreement marks an expansion of the companies' 2014 licensing deal and calls for Lexicon to be eligible for up to $5M in up-front and pre-commercialization milestones; net sales in Canada will be aggregated with those in Europe and other territories licensed to Ipsen for purposes of the royalties and sales milestones to be paid to Lexicon; under the expanded alliance, Lexicon retains sole rights to commercialize the phase III-stage small-molecule inhibitor of tryptophan hydroxylase in the U.S. and Japan | 3/19/15 |
Lexicon Pharmaceuticals Inc. (The Woodlands, Texas) | Sanofi SA (Paris) | $1,700.00 | Licensing deal for sotagliflozin, an oral dual inhibitor of sodium-glucose co-transporters 1 and 2 | Deal includes $300M up front and up to $1.4B in milestones, plus tiered, escalating, double-digit royalties | 11/9/15 |
Ligand Pharmaceuticals Inc. (La Jolla, Calif.) | Sermonix Pharmaceuticals LLC (Columbus, Ohio) | $45.00 | Licensing agreement for development and commercialization of oral lasofoxifene in the U.S. and additional territories | Ligand received an undisclosed initial payment and is entitled to receive up to $45M in potential regulatory and commercial milestone payments and tiered royalties of 6% to 10% on future net sales; lasofoxifene is an estrogen partial agonist for the treatment of osteoporosis and other diseases | 2/4/15 |
Ligand Pharmaceuticals Inc. (San Diego) | Selexis SA (Geneva) | $4.00 | Ligand added rights to potential future milestone and royalty payments on 15 biologic development programs for Selexis for $4M in cash | The deal builds on an April 2013 agreement that took Ligand into the protein-based therapeutics space, paying $4.6M for a portfolio of future milestone and royalty payment rights on a separate set of more than 15 Selexis commercial license agreement programs; royalty rates in both agreements are in the low single-digit range | 5/12/15 |
Ligand Pharmaceuticals Inc. (San Diego) | Sanofi SA (Paris) | ND | Global license and supply agreement to utilize Captisol in the development and commercialization of SAR-125844, a MET kinase inhibitor | Ligand will be eligible to receive potential milestone payments and royalties; Sanofi will be responsible for costs | 7/31/15 |
Ligand Pharmaceuticals Inc. (San Diego) | Sage Therapeutics Inc. (Cambridge, Mass.) | ND | Expanded global license and supply agreements to cover the use of Captisol in the development and commercialization of SAGE-689 | Ligand received a licensing fee and will be eligible to receive potential milestone payments, tiered royalties on future net sales and revenue from Captisol material sales; SAGE will be responsible for all costs related to the program | 9/30/15 |
Lion Biotechnologies Inc. (New York) | Medimmune (unit of Astrazeneca plc; London) | ND | Collaboration to conduct clinical and preclinical research in immuno-oncology | Lion will fund and conduct two phase IIa trials combining Medimmune’s investigational PD-L1 inhibitor durvalumab with Lion’s tumor-infiltrating lymphocytes for the treatment of patients with metastatic melanoma, and head and neck cancer; Medimmune will supply durvalumab for the clinical trials | 12/22/15 |
Lipid Therapeutics GmbH (Heidelberg, Germany) | Nestle Health Science (part of Nestle SA; Vevey, Switzerland) | ND | Agreement to give Nestle exclusive worldwide licensing rights to Lipid's LT-02 compound (phosphatidylcholine), excluding Europe and Australia | The compound is a barrier function therapy for mild to moderate ulcerative colitis; terms include an up-front fee, milestones payments and royalties | 9/17/15 |
Liquidia Technologies Inc. (Research Triangle Park, N.C.) | Glaxosmithkline plc (London) | ND | Exercised option under a 2012 agreement to exclusively license the right to research, develop and commercialize inhaled therapeutics derived from Liquidia's Print technology | Liquidia is set to receive an option fee, continued R&D funding and potential product-based development and regulatory milestone payments | 10/1/15 |
Lonza Group Ltd. (Basel, Switzerland) | Benitec Biopharma Ltd. (Sydney) | ND | Service agreement to develop a manufacturing process for Benitec's DNA-directed RNA interference-based, adeno-associated virus (AAV)-delivered therapeutic products | Lonza will design and develop a cost-effective, scalable suspension culture based platform to produce material needed for AAV-based gene therapeutics to treat diseases such as hepatitis C | 10/8/15 |
Luc Therapeutics Inc. (Cambridge, Mass.) | Novartis AG (Basel, Switzerland) | ND | Exclusive license and collaboration agreement focused on accelerating develoment of Luc's subtype selective NMDA receptor negative allosteric modulators to treat depression | Luc exclusively licensed to Novartis intellectual property for compounds that selectively negatively modulate NR2B-containing NMDA receptors; Novartis will fund all research and development for the program and will pay an up-front fee to Luc, as well as development and sales milestones and royalties | 10/20/15 |
Lucerne Biosciences LLC (Wilmington, Del.) | LCS Group LLC (New Haven, Conn.) | ND | Exclusive license agreement for rights to commercialize U.S. Patent No. 8,318,813 and U.S. Patent Application No. 14/465,249, both titled "Method of Treating Binge Eating Disorder" | LCS Group's commercialization is planned through Dublin-based Shire plc's U.S. group's national marketing campaign of the drug lisdexamfetamine dimesylate to treat BED | 5/15/15 |
Lupin Ltd. (Mumbai) | Boehringer Ingelheim GmbH (Ingelheim, Germany) | ND | Alliance to co-market Boehringer's linagliptin, a DPP-4 inhibitor, in India | Lupin will market and sell the drug under the brand Ondero (monotherapy) and Ondero Met (fixed-dose combination with metformin), using its 400-strong diabetes specialty field force; Boehringer will continue selling the drug under the brand Tradjenta and Trajentaduo through its existing sales force and network | 10/15/15 |
Lycera Corp. (Ann Arbor, Mich.) | Celgene Corp. (Summit, N.J.) | $105.00 | Exclusive global collaboration focused on advancing Lycera's preclinical RORgamma agonists for cancer immunotherapy and a clinical-stage candidate, LYC-30937, in development for inflammatory bowel disease | Lycera stands to receive $82.5M up front, including an exclusive option for Celgene to license its portfolio of ex vivo RORgamma agonist compounds; Lycera may bank $22.5M more in near-term payments tied to the ex vivo licensing option; Celgene holds the exclusive right to acquire Lycera at the end of the option period | 6/10/15 |
Lysogene SA (Neuilly-sur-Seine, France) | Alcyone Lifesciences Inc. (Lowell, Mass.) | ND | Collaboration to evaluate the intraparenchymal delivery of Lysogene's recombinant adeno-associated virus to treat patients with mucopolysaccharidosis type IIIA, also known as Sanfilippo A | They will use the Alcyone MEMS Cannula targeted delivery platform; terms were not disclosed | 7/22/15 |
Mabspace Biosciences Co. Ltd. (Suzhou, China) | Jiangsu Hengrui Medicine Co. Ltd. (Lianyungang, China) | ND | Collaboration to co-develop antibody therapeutics on two targets | Mabspace will be responsible for the discovery and selection of humanized lead antibodies, while Hengrui will get exclusive global rights on the resulting therapeutic candidates for the nominated targets and will further develop the selected candidate molecules | 5/20/15 |
Mabspace Biosciences Co. Ltd. (Suzhou, China) | Genor Biopharma Co. Ltd. (Shanghai) | ND | Collaboration for a therapeutic antibody | Mabspace will discover and select fully human lead antibodies, while Genor will handle further development and will own exclusive global rights; Mabspace gets up-front R&D funding, regulatory milestones and royalties on global sales | 5/22/15 |
Macrogenics Inc. (Rockville, Md.) | Merck & Co. Inc. (Kenilworth, N.J.) | ND | Collaboration to evlauate the combination of Macrogenics' anti-HER2 product candidate, margetuximab, with Merck's anti-PD-1 therapy, Keytruda (pembrolizumab), in a phase Ib/II trial in patients with advanced gastric cancer | The agreement includes a provision where the parties may extend the collaboration to include a potential phase III trial | 10/23/15 |
Macrogenics Inc. (Rockville, Md.) | Les Laboratoires Servier SA (Paris) | ND | Les Laboratoires will not exercise its option to license regional rights for enoblituzumab (MGA271), a clinical-stage monoclonal antibody targeting B7-H3, resulting in global rights to programs within the B7-H3 franchise reverting to Macrogenics | Macrogenics said Servier's decision will enable it to integrate development and potential commercialization of enoblituzumab into its internal R&D efforts, including advancement of MGD009 into the clinic | 10/29/15 |
Malin Corp. plc (Dublin) | HVP (North Carolina) | $15.00 | Investment of $15M, and possibly $20M, in HVP | Malin plans to use HPV to connect with major universities in the southeast, such as Duke, University of North Carolina, Vanderbilt and Wake Forest University | 8/25/15 |
Manros Therapeutics SA (Roscoff, France) | Cyclacel Ltd. (Dundee, UK; subsidiary of Cyclacel Pharmaceuticals Inc.) | ND | Exclusive licensing and supply agreement to develop and commercialize oral seliciclib capsules for the treatment of cystic fibrosis | Cyclacel will rececive an undisclosed up-front payment, as well as milestone payments and tiered royalties if seliciclib is commercialized | 6/30/15 |
Marathon Pharmaceuticals LLC (Northbrook, Ill.) | Medline Industries Inc. (Mundelein, Ill.) | ND | Collaboration to market and distribute Zingo (lidocaine hydrochloride monohydrate, 0.5 mg) powder intradermal injection system | The needle-free product delivers local anesthetic to manage venous access pain in as little as one to three minutes; terms were not disclosed | 2/20/15 |
Marina Biotech Inc. (Bothell, Wash.) | Hongene Biotechnology Ltd. (Shanghai) | ND | License agreement giving Hongene exclusive rights to develop, supply and commercialize certain oligonucleotide amidites using Marina's Conformationally Restricted Nucleotide chemistry and granting Marina royalties from the sale of CRN-based reagents | The deal will establish a ready supply of CRN amidites for Marina's therapeutic research and development endeavors | 9/29/15 |
Medday Pharmaceuticals SAS (Paris) | DSM Nutritional Products | ND | Partnership and co-investment for the manufacturing of pharmaceutical grade D-Biotin for Medday's MD1003 | The partnership also will cover the full support from DSM for regulatory filings in Europe and the U.S. as well as an investment in a dedicated production facility at a DSM manufacturing site in Europe for the industrial scale production of pharmaceutical grade D-Biotin | 6/18/15 |
Medigene AG (Martinsried, Germany) | Syncore Biotechnology Co. Ltd. (Taipei, Taiwan) | $12.20 | Asset purchase agreement for the complete transfer of Endotag to Syncore, replacing and terminating the license agreement from May 2013 | In addition to licensing payments and proceeds from issued Medigene shares totaling €6.3M (US$6.8M) already received, Medigene will receive a payment of €5M (US$5.4M) from Syncore to be paid in five annual installments and Medigene also is eligible to milestone payments and royalties for Endotag-1 | 12/18/15 |
Medigene AG (Martinsried, Germany) | Amgen Inc. (Thousand Oaks, Calif.) | $10.50 | Intellectual property licensing deal involving spin-off company Catherex Inc., which Amgen is acquiring for $10.5M up front plus regulatory and sales-based milestones and single-digit royalties on Imlygic (talimogene laherparepvec) sales | The agreement, which runs until 2020, covers both the U.S., where Imlygic received FDA approval in October, and Europe, where Imlygic received formal approval from the European Commission in the past week | 12/22/15 |
Medimmune (Gaithersburg, Md.) | Tanabe Research Laboratories U.S.A. Inc. (subsidiary of Mitsubishi Tanabe Pharma Corp.; Osaka, Japan) | ND | Strategic collaboration and licensing agreement under which TRL will use Medimmune's pyrrolobenzodiazepine-based warhead and linker technology to generate monospecific and bispecific antibody-drug conjugates for various cancers | TRL will exclusively license MedImmune's next-generation PBDs in exchange for an up-front payment, development and commercial milestone payments and single-digit royalties; MTPC will handle preclinical research, development, manufacturing and later-stage activities, including global commercialization, while Medimmune retains an option for the development and commercialization in the U.S. | 9/24/15 |
Medimmune (Gaithersburg, Md.; biologics research arm of Astrazeneca plc) | Juno Therapeutics Inc. (Seattle) | ND | Collaboration to conduct combination clinical trials in immuno-oncology with one of Juno's CD19-directed chimeric antigen receptor (CAR) T-cell candidates and Medimmune's MEDI4736; both companies will explore the safety, tolerability and preliminary efficacy of the combination therapy as a treatment for non-Hodgkin's lymphoma, as well as the combination of MEDI4736 with a next-generation, Juno-developed fully human CD19-directed CAR T-cell candidate | The companies will co-fund the initial phase Ib study; specific financial terms were not disclosed | 4/24/15 |
Medivation Inc. (San Francisco) | Biomarin Pharmaceutical Inc. (San Rafael, Calif.) | $570.00 | Agreement for global rights to Biomarin's BMN-673 (talazoparib), a phase III poly ADP ribose polymerase inhibitor for BRCA-mutated breast cancer and other malignancies | The $410M up-front deal also includes $160M in milestones and mid-single-digit royalties | 8/25/15 |
Medivir AB (Stockholm) | GVK Biosciences Private Ltd. (Hyderabad, India) | ND | Partnership to deliver enhanced efficiency and quality within its portfolio of research projects while over time reducing overall research costs and enhancing future cost flexibility | Terms were not disclosed | 6/17/15 |
Medivir AB (Stockholm) | Cancer Research Technology (London) and Transmit GmbH (Germany) | ND | Medivir will terminate its ADAM8 inhibitor program to treat pancreatic cancer | The move dissolves the collaboration and license agreement between the companies | 11/18/15 |
Meiji Seika Pharma Co. Ltd. (Tokyo) and Fedora Pharmaceuticals Inc. (Canada) | Roche AG (Basel, Switzerland) | $750.00 | Licensing agreement for phase I candidate, OP0595, a beta-lactamase inhibitor that targets beta-lactamase enzymes in combination with new or existing beta-lactam antibiotics for use in difficult-to-treat bacterial infections | The deal means up to $750M in combined up-front, development, regulatory and sales-based milestone payments to Meiji Seika and Fedora; the companies also are entitled to tiered royalties; Roche gains global rights to develop and commercialize OP0595 except in Japan, where Meiji will retain sole commercialization rights | 1/14/15 |
Melinta Therapeutics Inc. (New Haven, Conn.) | Eurofarma Laboratorios SA (Sao Paolo, Brazil) | $15.00 | Commercialization and distribution agreements for delafloxacin, an investigational fluoroquinolone | Eurofarma will be responsible for obtaining regulatory approval in Brazil and will then have the right to market, sell and distribute delafloxacin in that country for the treatment of acute bacterial skin and skin structure infections; Melinta will receive a combined up-front cash and equity payment of $15M, as well as milestones and royalties on future sales of delafloxacin | 1/9/15 |
Merck & Co. Inc. (Whitehouse Station, N.J.) | Medicines Patent Pool | ND | Agreement to license its pediatric formulations of raltegravir for use in treating HIV-1 infection in infants and children, ages 4 weeks to younger than 12 years, in developing countries | The deal also allows for the development of pediatric formulations of raltegravir and novel combinations; Raltegravir is marketed by Merck as Isentress | 2/25/15 |
Merck KGaA (Darmstadt, Germany) | Bristol-Myers Squibb Co. (New York) | ND | Agreement for BMS to transfer full responsibility for the promotion of Erbitux (cetuximab) in Japan effective May 1 | Erbitux was launched in collaboration with BMS in Japan in September 2008 to treat metastatic colorectal cancer, followed by an additional indication in head and neck cancer in December 2012 | 2/17/15 |
Merck KGaA (Darmstadt, Germany) | Pfizer Inc. (New York) | ND | Agreement allowing the companies to co-promote Pfizer's anaplastic lymphoma kinase inhibitor Xalkori (crizotinib) in an effort to establish a sales force in advance of the potential launch of avelumab | Xalkori will be co-promoted in two waves, first in the second and third quarters of 2015 in the U.S., Canada, Japan and five European Union countries, then in 2016 in China and Turkey; Merck will receive a reimbursement for promotion of Xalkori this year, after which the companies will split profits, with 80% accruing to Pfizer and 20% going to Merck starting in 2016 | 4/8/15 |
Mereo Biopharma Ltd. (London) | Novartis AG (Basel, Switzerland) | ND | Agreement for Mereo to acquire three clinical-stage programs from Novartis | Novartis maintains an interest through an equity stake in Mereo, and will receive milestones and royalties; the programs include BPS-804 for osteogenesis imperfecta, BCT-197 for acute exacerbations of chronic obstructive pulmonary disease, and BGS-649 for hypogonadotopric hypogonadism | 7/30/15 |
Mersana Therapeutics Inc. (Cambridge, Mass.) | Takeda Pharmaceutical Co. Ltd. (Osaka, Japan) | ND | Expanded partnership to create Fleximer antibody-drug conjugate drug candidates to include additional oncology-relevant targets | Mersana is eligible to receive additional up-front and milestone payments potentially worth more than $300M under the revised deal, subject to future success; the original agreement was announced in April 2014 | 1/13/15 |
Merus Labs International Inc. (Toronto) | Novartis Pharma AG (Basel, Switzerland) | $29.50 | Agreement to acquire rights to manufacture, market and sell Salagen for xerostomia and Sjogren's syndrome and transdermal estradiol product Estraderm MX in certain European and other markets | Novartis is divesting the products for $29.5M; Merus will fund the acquisition with available cash | 5/26/15 |
Mesoblast Ltd. (Melbourne, Australia) | Celgene Corp. (Summit, N.J.) | $45.00 | Agreement giving Celgene a six-month right of first refusal to Mesoblast's mesenchymal lineage adult stem cell product candidates to prevent and treat acute graft vs. host disease, certain oncologic diseases, inflammatory bowel diseases, and organ transplant rejection | Celgene will purchase 15.3M shares for A$58.5M (US$45M) at A$3.82 per share | 4/14/15 |
Microchips Biotech Inc. (Lexington, Mass.) | Teva Pharmaceutical Industries Ltd. (Jerusalem) | $35.00 | Partnering deal to develop a tiny implantable chip capable of storing and releasing hundreds of therapeutic doses of drug for periods ranging from months to years | The deal includes a $35M up-front payment as well as development and commercial milestones, plus potential royalties on future product sales; Teva will be responsible for mid-to-late-stage development and regulatory filings | 6/19/15 |
Midasol Therapeutics LP (a joint venture between Midatech Pharma Ltd., of London, and Monosol Rx LLC, of Warren, N.J.) | Undisclosed international pharmaceutical company | ND | Six-month research collaboration to evaluate the preclinical effectiveness of Midasol's gold-nanoparticle and Pharmafilm transbuccal strip technologies for needle-free delivery of an approved diabetes drug | The terms include an up-front payment and performance-driven milestones | 3/9/15 |
Midatech Pharma plc (Abingdon, UK) | Centurion Pharma Iiac (Istanbul) | ND | Supply agreement for Q-Octreotide in the Turkish market | Midatech will receive up-front, milestone and royalty payments | 12/15/15 |
Midatech Pharma plc (Oxford, U.K.) | Galena Biopharma Inc. (Portland, Ore.) | ND | Acquisition of Galena's Zuplenz (ondansetron) | Terms were not disclosed | 12/31/15 |
Mimetogen Pharmaceuticals Inc. | Allergan plc (Dublin) | $50.00 | Exlcusive license agreement to develop and commercialize tavilermide (MIM-D3), a topical formulation of a small-molecule TrkA agonist to treat dry eye disease | Allergan paid $50M up front for the licenses, and will fund all phase III development and pay more as it hits pre-agreed milestones; Allergan plans to launch it in 2019 and expects it to achieve peak sales of $500M to $750M annually | 11/5/15 |
Minerva Biotechnologies Inc. (Waltham, Mass.) | ID Pharma Co. Ltd. (Ibaraki, Japan) | ND | Agreement granting Minerva worldwide rights to use and commercialize ID's non-integrating Sendai virus vectors together with Minerva's technology for generating induced pluripotent stem cells | Sendai virus enables delivery of genes into a host cell without permanently altering the cell's chromosome, which is critical for stem cell therapies | 8/28/15 |
Mirati Therapeutics Inc. (San Diego) | Astrazeneca plc (London) | ND | Agreement to pair spectrum-selective histone deacetylase (HDAC) blocker mocetinostat with the anti-programmed death-ligand 1 (PD-L1) candidate durvalumab (also known as MEDI4736) from Astrazeneca | Under the terms of their research deal, Mirati will conduct and pay for the first phase I/II study in non-small-cell lung cancer (NSCLC), expected to start next year, with Astrazeneca's Medimmune arm providing supply of durvalumab | 8/6/15 |
Moberg Pharma AB (Stockholm) | Berlin-Chemie AG (Berlin; a member of the Menarini Group) | ND | Exclusive rights agreement to market and sell Emtrix in Russia and Ukraine | Emtrix is an over-the-counter topical product for the local treatment of onychomycosis | 2/10/15 |
Moberg Pharma AB (Stockholm) | Colep | ND | Development agreement for MOB-015, Moberg's topical formulation of terbinafine for onychomycosis, or nail fungus | Colep will be responsible for scale-up of manufacturing, stability programs and clinical trial material for a phase III study for MOB-015, as well as required documentation to file for marketing authorization in the U.S. and the EU | 11/4/15 |
Moderna Therapeutics Inc. (Cambridge, Mass.) | Merck & Co. Inc. (Whitehouse Station, N.J.) | $100.00 | Three-year license and collaboration deal that gives Merck rights to commercialize five product candidates for viral diseases using modified messenger RNA | In addition to $50M up front and a $50M equity investment for Moderna, Merck will provide per-product development and commercial milestone, along with tiered royalties | 1/14/15 |
Morphosys AG (Martinsried, Germany) | Celgene Corp. (Summit, N.J.) | $818.00 | Terminated agreement for MOR202, which is in a phase I/Iia trial in relapsed or refractory multiple myeloma | The potential $818M co-development and co-promotion agreement was signed in 2013 | 3/27/15 |
Morphosys AG (Martinsried, Germany) | Sosei Group Corp. (Tokyo) | ND | Exercised option to initiate a therapeutic antibody program arising from the alliance the companies entered in February 2013 | The program will levarage Morphosys's Ylanthia antibody library to generate antibody leads, and it addresses a GPCR target for which Heptares has engineered a Star antigen; Morphosys will receive a licensing fee and R&D funding from Heptares and is eligible to receive milestone payments and royalties | 7/31/15 |
Morphosys AG (Martinsried, Germany) | G7 Therapeutics AG (Zurich, Switzerland) | ND | Collaboration agreement on antibody therapeutics targeting G protein-coupled receptors and possibly other disease-related transmembrane proteins such as ion channels | G7 will generate disease-relevant receptors that have been proposed by Morphosys, and Morphosys will utilize its Ylanthia antibody library to discover and develop antibody therapeutics against the receptors; Morphosys will have the right to sublicense access to those targets to third parties | 8/5/15 |
Morphosys AG (Martinsried, Germany) | Immatics Biotechnologies GmbH (Tuebingen, Germany) | ND | Collaboration to develop antibody-based therapeutics for a number of cancer antigens recognized by T cells | The agreement will give Morphosys access to several tumor-associated peptides, called TUMAPs, that were discovered via Immatics' Xpresident platform; the companies will pay each other milestones and royalties | 8/26/15 |
Morphotek Inc. (Exton, Pa.) | Blaze Bioscience Inc. (Seattle) | ND | License agreement under which Morphotek will provide an exclusive, worldwide, royalty-bearing license to develop, license and commercialize a potential tumor-targeting chlorotoxin derivative linked to a near-infrared diagnostic agent, which may help visualize cancer cells during surgery | Morphotek received an undisclosed up-front payment from Blaze and is eligible to receive scheduled development and sales milestone payments, as well as royalties on future net sales of licensed products. Morphotek retains all rights to develop chlorotoxin derivative products not covered by the terms of the license agreement | 11/12/15 |
Morphotek Inc. (Exton, Pa.; subsidiary of Eisai Inc.) | Biocare Medical LLC | ND | Second collaboration and license deal, to develop and commercialize an immunohistochemical diagnostic kit | It will use Morphotek's monoclonal antibody to specifically detect mesothelin with Biocare's Intellipath Automated Stainer | 12/18/15 |
Motif Bio plc (Salisbury, UK) | Covance | ND | Clinincal trials agreement to test iclaprim, an antibiotic for multidrug-resistant bacteria, including MRSA | Covance will run two phase III randomized, double-blind trials to evaluate intravenous iclaprim vs. intravenous vancomycin to treat acute bacterial skin and skin structure infections | 10/19/15 |
Multicell Immunotherapeutics Inc. (Woonsocket, Pa.) | Oxis Biotech Inc. (Tampa, Fla.) | $14.38 | Research and development and product license agreement to create three antibody-drug conjugates containing Oxis' lead candidates using Multicell's ADC platform technology for use in triple-negative breast cancer and multiple myeloma and associated osteolytic lesions | Oxis paid MCIT a license fee of $500,000 and will reimburse MCIT up to $1.125M in development costs for the three candidates; Oxis also will pay up to $12.75M in clinical development milestones and was granted an option to purchase manufacturing rights to the drugs upon payment of an additional $10M; Oxis was granted a worldwide exclusive license to sell the three ADCs, with MCIT to receive a 3% royalty on net yearly sales | 3/13/15 |
Mundipharma International Corp. Ltd. (Cambridge, Mass.) | Medical Developments International Ltd. (Victoria, Australia) | $54.50 | License, development and commercialization agreement under which Mundipharma will have exclusive rights to Penthrox (low-dose methoxyflurane), a self-inhaled analgesic to treat emergency pain, in 39 European markets, excluding Hungary, the Republic of Ireland, and the UK | First country launches may begin in 2016; Mundipharma will pay up to $54.5M in up-front and milestone payments | 9/15/15 |
Munipharma Laboratories GmbH (Cambridge, UK) and Purdue Pharmaceuticals LP (Stamford, Conn.) | Laboratorios Esteve SA (Barcelona, Spain) | $1,000.00 | Global multiprogram discovery and development collaboration to bring to market next-generation products to manage pain | Mundipharma and Purdue could potentially make payments to Esteve exceeding $1M if all development, regulatory and sales milestones are met across programs | 1/13/15 |
Myriad Genetics Inc. (Salt Lake City) | Astrazeneca plc (London) | ND | Expanded companion diagnostic collaboration for use of Myriad's BRACAnalysis test to prospectively identify which patients with metastatic pancreatic cancer may respond to treatment with Lynparza (olaparib) | Terms were not disclosed | 4/2/15 |
Nabsys Inc. (Providence, R.I.) | Ariana Pharmaceuticals SA (Paris) | ND | Collaboration to identify sets of DNA structural variants linked to prostate and breast cancers and to the clinical outcome of patients with those diseases through the analysis of public genome databases | The companies will develop a single database for the analysis of prostate adenocarcinomas and breast cancer | 1/14/15 |
Naia Ltd. (Greenbrae, Calif.) | Amunix Operating Inc. (Mountain View, Calif.) | ND | In-licensing agreements for its GLP-1 and GLP-2 Xten receptor agonist product candidates, plus a licensing agreement with Cedars-Sinai Medical Center in Los Angeles | The agreement with Cedars-Sinai pertains to a use patent for GLP-1 | 1/6/15 |
Nanocarrier Co. Ltd. (Chiba, Japan) | Chugai Pharmaceutical Co. Ltd. (Tokyo) | $4.19 | Joint research agreement for siRNA drugs | Nanocarrier has resolved to conduct a third-party allotment of shares to Chugai, valued at ¥500M (US$4.19M) to further strengthen the relationship and enhance the partnership | 2/25/15 |
Nanostring Technologies Inc. (Seattle) | Merck & Co. Inc. (Kenilworth, N.J.) | ND | Clinical research collaboration to develop an assay that will optimize immune-related gene expression signatures and evaluate the potential to predict benefit from Merck's anti-PD-1 therapy, Keytruda (pembrolizumab), in multiple tumor types | The collaboration will use Nanostring's Ncounter Analysis System to optimize gene expression signatures as part of the clinical development program | 5/29/15 |
Nanotherapeutics Inc. | Takeda Pharmaceutical Co. Ltd. | ND | Agreement providing Takeda with expanded commercialization and technology rights to Vero cell technology, a manufacturing platform that's key to Takeda's flu vaccines and its aspirations to further develop its global vaccines business in other markets | Financial terms were not disclosed | 8/28/15 |
Nantcell LLC (Los Angeles) | Amgen Inc. (Thousand Oaks, Calif.) | ND | Licensing agreement for AMG-479 (ganitumab), a fully human monoclonal antibody that targets type 1 insulin-like growth factor receptor | Nantcell acquired the exclusive rights to develop and commercialize the drug worldwide, excluding Japan | 1/15/15 |
Nanthealth (subsidiary of Nantworks; Culver City, Calif.) | Allscripts (Chicago) | $200.00 | Advanced partnership through two cross-investments, including Allscripts' purchase of a 10% equity stake in Nanthealth for $200M in cash | Nantcapital LLC, the personal investment vehicle of Patrick Soon-Shiong, founder of Nanthealth, has made a $100M investment in Allscripts | 7/1/15 |
Nantpharma LLC (Los Angeles; subsidiary of Nantworks LLC) | Amgen Inc. (Thousand Oaks, Calif.) | ND | Deal in which Nantpharma acquired exclusive global rights - excluding Japan, Russia and certain other Central Asian countries – to develop and commercialize AMG 337, a phase II small-molecule inhibitor of the cell surface enzyme c-Met | Earlier this year, Nantworks and Amgen entered an exclusive license agreement on the immunotherapeutic antibody ganitumab (AMG 479); the agreement extends that strategic relationship to drive precision cancer care with molecules targeting oncogenic drivers of the disease | 9/15/15 |
Nantworks Inc. (Culver City, Calif.) | Sorrento Therapeutics Inc. (San Diego) | $110.00 | Expanded their December 2014 collaboration with a deal to discover and develop cancer immunotherapies derived from Sorrento's G-MAB library against Nantworks-identified neoepitopes of tumor-specific antigens | Under terms of the new deal, Nantworks subsidiary Nantcell LLC will pay Sorrento $10M in cash, provide a $100M share of Nantcell equity and an unspecified share of profits from the partnership in exchange for an exclusive license to any antibodies or immunotherapies the pair produces | 3/17/15 |
Navidea Biopharmaceuticals Inc. (Dublin, Ohio) | Alseres Pharmaceuticals Inc. (Hopkinton, Mass.) | ND | Terminated sublicense agreement dated July 31, 2012, for research, development and commercialization of NAV5001 in phase III development for early detection of Parkinson's disease | Navidea previously said it intended to decrease its expenses by divesting its non-core neuroimaging assets; Alseres gains all rights to NAV5001, and Navidea will receive a milestone payment for NDA approval and a royalty on net sales | 4/28/15 |
Nektar Therapeutics Inc. (San Francisco) and Astrazeneca plc (London) | Daiichi Sankyo Inc. (Tokyo) | $825.00 | U.S. co-commercialization agreement for Movantik (naloxegol) to treat opioid-induced constipation in adults with chronic noncancer pain | Daiichi Sankyo will pay $200M up front and subsequent sales-related payments of up to $625M; Astrazeneca will oversee manufacturing, book all sales and make sales-related commission payments to Daiichi Sankyo; the companies will be jointly responsible for commercial activities | 3/20/15 |
Nemucore Medical Innovations Inc. (Worcester, Mass.) | Pfenex Inc. (San Diego) | ND | Agreement for a nonexclusive license to a production strain derived from Pfenex's Expression Technology protein production platform to develop and produce NMI-8000 for cancer associated with the female reproductive system | Financial terms were not disclosed | 12/15/15 |
Neon Therapeutics Inc. (Cambridge, Mass.) | Bristol-Myers Squibb Co. (New York) | ND | Clinical trial collaboration to evaluate the combination of Neon's personalized neoantigen vaccine, NEO-PV-01, and Opdivo (nivolumab), a PD-1 immune checkpoint inhibitor | The study will evaluate the safety, tolerability and preliminary efficacy of NEO-PV-01 in patients receiving Opdivo in melanoma, smoking-associated non-small-cell lung cancer and bladder cancer, and it will evaluate neoantigen-specific immune responses in peripheral blood and tumor tissue, as well as other indicators of immune response such as PD-L1 expression; Neon plans to initiate the study in 2016 | 12/16/15 |
Neostem Inc. (New York) | Invetech Pty Ltd. | ND | Agreement to develop a new closed processing system for cell therapy manufacturing | Invetech will provide system design and engineering, while Neostem will develop applications for performing closed cell processing manipulations such as separation | 1/13/15 |
Neovacs SA (Paris) | Chong Kun Dang Pharmaceutical Corp. (Seoul, South Korea) | $5.45 | Licensing agreement to market IFNa-Kinoid for lupus and dermatomyositis in South Korea | Neovacs will receive €5M (US$5.45M) in total, including a €1M down payment and milestone payments until the first sales; royalties on sales and a margin within the transfer price will also be paid to the company | 12/16/15 |
Neurocrine Biosciences Inc. (San Diego) | Mitsubishi Tanabe Pharma Corp. (Osaka, Japan) | $115.00 | Exclusive collaboration and licensing agreement to develop and commercialize its VMAT2 inhibitor, NBI-98854, in Japan and other Asian markets | Neurocrine is set to receive $30M up front and is eligible for up to $85M in development and commercial milestone payments, plus royalties on related product sales from Mitsubishi Tanabe's territories in Asia, which include China, South Korea, Philippines, Indonesia, Taiwan, Singapore, Malaysia, Thailand and Hong Kong | 4/2/15 |
Neurorx Inc. (Wilmington, Del.) | Wuxi Apptec | ND | Partnership under which Wuxi will formulate and manufacture cyclurad for an upcoming study in acute suicidal crisis associated with bipolar depression | Neurorx intends to file an investigational new drug application in the first quarter of 2016 and plans to start the trial in the second half of the year | 12/17/15 |
Neurovive Pharmaceutical AB (Stockholm) | Oncore Biopharma Inc. (Doylestown, Pa.) | $48.00 | Exclusive worldwide licensing agreement related to the development of commercialization of NVP018 for oral treatment of hepatitis B virus | The deal includes an up-front licensing fee of $1M and up to $47M in clinical development and regulatory milestones per indication | 2/6/15 |
Neurovive Pharmaceutical AB (Stockholm) | Isomerase Therapeutics Ltd. (Cambridge, UK) | ND | Collaboration for NVP014 to treat ischemic stroke | The collaboration replaces one with To-BBB Technologies BV, which liquidated at the end of 2014; the parties will develop new molecules and a more effective method for penetrating the blood-brain barrier | 4/20/15 |
Neurovive Pharmaceutical AB (Stockholm) | Sanofi SA (Paris) | ND | Collaboration agreement to develop and commercialize Ciclomulsion in South Korea | Neurovive will receive an undisclosed up-front payment, a conditional milestone payment and royalties on potential future sales in South Korea | 5/22/15 |
Nextera AS (Norway) | Janssen Biotech Inc. (part of Johnson & Johnson) | ND | Research agreement in which Nextera will use its technology platform to perform verification studies with the goal of determining the proper applications of its platform within rheumatoid arthritis | Janssen will fund the research, and will have an option for an exclusive worldwide license to the Nextera technology platform within RA | 9/22/15 |
NGM Biopharmaceuticals Inc. | Merck & Co. Inc. (Whitehouse Station, N.J.) | $450.00 | Multiyear, potential multiproduct collaboration for several preclinical candidates, including NP201, in development for diabetest, obesity and nonalcoholic steatohepatitis | Merck also gains an option to license additional programs emerging from NGM's preclinical pipeline following human proof-of-concept trials; Merck agreed to pay $94M up front and will purchase a 15% equity stake in NGM for $106M, as well as provide $250M in fixed commitments to fund efforts over the initial five years | 2/24/15 |
Nicox SA (Sophia Antipolis, France) | Insite Vision Inc. (Alameda, Calif.) | ND | License agreement for the development, manufacture and commercialization of Insite's innovative ophthalmic therapeutics Azasite, Bromsite and Azasite Xtra | The agreement grants Nicox exclusive rights to all three products in Europe, Middle East and Africa | 2/3/15 |
Nicox SA (Sophia Antipolis, France) | Fera Pharmaceuticals LLC (Locust Valley, N.Y.) | $35.00 | Exclusive license agreement for the development and commercialization of Nicox's naproxcinod, a CINOD cyclooxygenase-inhibiting nitric oxide-donating) anti-inflammatory candidate, in the U.S. | Fera's initial focus will be the signs and symptoms of osteoarthritis; Nicox will be eligible to receive up to $35M in sales-based milestones, plus 7% royalties based on net sales of naproxcinod in the U.S.; Fera is eligible to receive an undisclosed royalty | 11/11/15 |
Nimbus Therapeutics Inc. (Cambridge, Mass.) | Genentech (part of Roche AG; Basel, Switzerland) | ND | Exclusive worldwide license agreement to discover and develop small-molecule inhibitors of interleukin-1 receptor-associated kinase 4 | Nimbus will receive an undisclosed up-front payment and is eligible to receive milestone payments and royalties; Genentech will be responsible for all preclinical and clinical development, manufacturing and commercialization | 10/22/15 |
NMT Pharmaceuticals Pte Ltd. (Singapore) | Cao Pharmaceuticals Inc. (Houston) | ND | Agreement to acquire exclusive worldwide licensing rights to further develop and market CZ-48, an anticancer product that was co-developed by NMT and Cao | CZ-48 is an analogue of camptothecin, which is stable and resistant to inactivation while circulating in the bloodstream; the two companies will secure funding for Cao for its operations and clinical trials in the U.S. | 8/25/15 |
Northern Biologics Inc. (Toronto) | Celgene Corp. (Summit, N.J.) | $30.00 | Collaboration for discovery and development of first-in-class therapeutic antibodies in oncology and fibrosis | Northern Biologics received $30M up front and has the right to receive additional payments to advance its portfolio; Celgene has options to in-license drug candidates and to acquire Northern Biologics at the end of the collaboration | 4/30/15 |
Novabay Pharmaceuticals Inc. (Emeryville, Calif.) | Sarmedic Ltd. (Israel) and Alpha Pharma LLC (Ukraine) | ND | Distribution agreements to market its topical non-antibiotic antimicrobials in international markets | Sarmedic will have exclusive rights to market and distribute Novabay's eye care product Avenova in Israel while Alpha Pharma will have exclusive rights to market and distribute the company's wound cleanser Neutrophase in the Ukraine | 3/10/15 |
Novabay Pharmaceuticals Inc. (Emeryville, Calif.) | Amerisourcebergen Corp. (Chesterbrook, Pa.) | ND | U.S. distribution agreement for Avenova, its prescription lid and lash hygiene product | The product is designed to manage eye conditions such as blepharitis, Meibomian gland dysfunction and associated dry eye | 4/2/15 |
Novacyt (Paris) | Leica Biosystems (Cambridge, UK) | ND | Exclusive distribution deal in greater China markets of Novacyt's NOVAPrep cytology platform | NOVAPrep was recently approved by the CFDA; the deal includes mainland China, Hong Kong, Macau and Taiwan | 3/5/15 |
Novamedica LLC (Moscow) | Ferring Pharmaceuticals SA (Saint-Prex, Switzerland) | ND | Agreement giving Novamedica the rights to commercialize a range of Ferring's line of innovative gastroenterological prescription drug products to treat inflammatory bowel disease in the Russian market | Financial terms were not disclosed | 6/3/15 |
Novartis AG (Basel, Switzerland) | Glaxosmithkline plc (London) | $834.00 | Agreement for Novartis to acquire all remaining rights to ofatumumab, a CD20-targeting antibody, for relapsing-remitting multiple sclerosis and other autoimmune indications | Novartis gained rights to the drug, marketed as Arzerra, for oncology indications in 2014; Novartis will make a $300M up-front payment and $200M in a milestone payment following the start of the phase III study; GSK could earn contingent payments of up to $534M and royalties of up to 12% on sales in autoimmune indications | 8/24/15 |
Novartis AG (Basel, Switzerland) | Glaxosmithkline plc (London) | $1,034.00 | GSK is selling the rights to Arzerra (ofatumumab) in autoimmune diseases | Novartis will pay $1.034B, including $300M up front, $200M once a phase III study gets under way and further milestone payments of $534M; Novartis also will pay royalties of up to 12% | 8/25/15 |
Novera Therapeutics Inc. (Toronto) | Janssen Biotech LLC (Johnson & Johnson unit; New Brunswick, N.J.) | $346.00 | Novera will receive an undisclosed up-front payment from the deal focused on new compounds discovered through an ongoing collaboration between the Ontario Institute for Cancer Research (OICR) and University Health Network | The deal also includes potential preclinical, clinical, regulatory and commercial milestone payments of up to C$450M (US$346M) for Novera; through an exclusive global licensing option, Janssen can secure global rights to human uses of any candidates identified through the partnerships if it wants them; once triggered, the option would shift responsibility for subsequent preclinical and clinical work to Janssen; deal includes tiered royalties | 10/15/15 |
Novimmune SA (Geneva) | Baxalta Inc. (Bannockburn, Ill.) | ND | Research collaboration to develop bispecific antibodies for an unspecified indication | Financial terms were not disclosed | 9/3/15 |
Novo Nordisk A/S (Bagsvaerd, Denmark) | Johnson & Johnson (New Brunswick, N.J.) | ND | Deal for an exclusive global license to further develop and commercialize a clinical program focused on therapy within autoimmune diseases | The program targets modulation of certain immune cells via a cell surface receptor, specifically the NKG2D receptor | 5/22/15 |
Novo Nordisk A/S (Bagsvaerd, Denmark) | IBM Watson Health | ND | Agreement | To work together to create diabetes solutions built on the Watson Health Cloud | 12/11/15 |
Nuevolution A/S (Copenhagen) | Janssen Biotech Inc. (unit of Johnson & Johnson; New Brunswick, N.J.) | ND | Deal using Nuevolution's Chemetics drug discovery platform | The multitarget collaboration will focus on discovery and development of new medical entities to treat oncological, infectious and inflammatory diseases; no specific financial terms were disclosed, but Nuevolution will get an up-front payment, research funding, milestones and royalties | 10/20/15 |
Numedii Inc. (Palo Alto, Calif.) | Allergan plc (Dublin) | ND | Research alliance to explore new therapeutic options for the potential treatment of psoriasis | The companies will use Numedii's predictive big data intelligence platform technology, and Numedii will provide Allergan with proprietary, de-risked therapeutic candidates for psoriasis that are compatible with the 505b2 drug development regulatory pathway; they may select and evaluate lead candidates in proof-of-concept disease models for potential further development | 9/30/15 |
Nuo Therapeutics Inc. (Gaithersburg, Md.) | Rohto Pharmaceutical Co. Ltd. (Osaka, Japan) | ND | Exclusive licensing and distribution agreement for the Aurix system, a platelet and plasma therapy system approved to manage ulcers and wounds | Nuo will receive an up-front payment in exchange for an exclusive license and the right to develop and commercialize Aurix in the Japanese market, plus royalty payments and an additional future cash payment if milestones are met; Nuo will pay a one-time fee to Millenia Holdings to terminate a September 2009 license and distribution agreement | 1/12/15 |
OBI Pharma Inc. (Taipei, Taiwan) | Merck & Co. Inc. (Kenilworth, N.J.) | $3.00 | Deal for the development and commercialization in Taiwan of OBI's narrow-spectrum macrocyclic antibiotic Dificid (fidaxomicin) | OBI will receive an up-front payment of $3M, with additional undisclosed royalty and other payments for reaching certain milestones | 10/7/15 |
Ocata Therapeutics Inc. (Marlborough, Mass.) | Allele Biotechnology and Pharmaceuticals Inc. (San Diego) | ND | Agreement for use of Allele's technology platform for generating human-induced pluripotent stem cells | Ocata recently confirmed proof of concept in the creation of photoreceptors, which are capable of preventing blindness and restoring vision in established animal models | 3/25/15 |
Omnis Pharmaceuticals Inc. (Rochester, Minn.) | Medimmune (unit of Astrazeneca plc; London) | ND | Licensing agreement that will allow Medimmune to combine key agents from its immunotherapy portfolio with Omnis' lead oncolytic virus program | MedImmune has the license to develop and, if successful, to commercialize Omnis's lead oncolytic virus program; financial terms were not disclosed | 1/13/15 |
Oncogenex Technologies Inc. (subsidiary of Oncogenex Pharmaceuticals Inc.; Bothell, Wash.) | Teva Pharmaceuticals Ltd. (Jerusalem) | $23.20 | Terminated agreement allowing Oncogenex to regain rights to custirsen, which is in phase III for prostate and lung cancers | The agreement includes a $23.2M payment from Teva, and Oncogenex will take over all expenses, including those related to the ENSPIRIT trial | 4/28/15 |
Oncomed Pharmaceuticals Inc. (Redwood City, Calif.) | Eli Lilly and Co. (Indianapolis) | ND | Agreement to supply Alimta (pemetrexed for injection) for Oncomed's ongoing phase II DENALI trial testing its anti-Delta-like ligand 4 antibody, demcizumab, in combination with Alimta and carboplatin in first-line advanced non-small-cell lung cancer | Terms were not disclosed | 4/3/15 |
Onconova Therapeutics Inc. (Newtown, Pa.) | Baxter Healthcare SA | ND | Baxter decided not to pursue additional trials or the submission of a drug approval application for the oral formulation of rigosertib in lower-risk myelodysplastic syndrome patients | The agreement between the ocmpanies remains in place, but the financials from the potential $565M deal now are lower | 2/4/15 |
Open Monoclonal Technology Inc. (Palo Alto, Calif.) | Celgene Corp. (Summit, N.J.) | ND | License agreement for unlimited access to OMT's Omnirat, Omnimouse and Omniflic platforms for generation of human antibody therapeutics | Financial terms were not disclosed | 3/11/15 |
Open Monoclonal Technology Inc. (Palo Alto, Calif.) | Seattle Genetics Inc. (Bothell, Wash.) | ND | License providing Seattle Genetics with access to its Omnirat, Omnimouse and Omnilic human antibody generation platforms | Terms were not disclosed | 11/3/15 |
Opexa Therapeutics Inc. (The Woodlands, Texas) | EMD Serono (part of Merck KGaA; Darmstadt, Germany) | ND | Revised development and commercialization agreement for its investigational compound for treating secondary progressive multiple sclerosis, Tcelna (imilecleucel-T) | Serono will pay Opexa $3M to support the phase IIb trial (Abili-T Trial) in patients with SPMS | 3/10/15 |
Ophthotech Corp. (New York) | Midatech Pharma plc (Abingdon, UK) | ND | Deal to explore the feasibility of using Midatech's Q Sphera microencapsulation technology for sustained delivery formulations of select Ophthotech products to treat wet age-related macular degeneration and other ocular indications | Financial terms were not disclosed | 8/14/15 |
Oramed Pharmaceuticals Inc. (Jerusalem) | Sinopharm Capital Management Co. Ltd. and Hefei Life Science & Technology Park Investments and Development Co. Ltd. | $50.00 | Nonbinding letter of intent for an investment and license agreement for exclusive rights in China to ORMD-0801 | The transaction calls for Sinopharm and Hefei to purchase a stake of approximately 10% (1.16M shares) in Oramed for $12M and to acquire rights for oral insulin in China for $38M, including $18M when the license agreement is signed and $20M following completion and reporting of data from Oramed's phase IIb trial of the oral insulin candidate; deal includes 10% royalties on related product sales | 7/8/15 |
Oramed Pharmaceuticals Inc. (Jerusalem) | Hefei Tianhui Incubator of Technologies Co. Ltd. | $50.00 | Licensing and investment agreements to market ORMD-0801, Oramed's oral insulin capsule, in China, Hong Kong and Macau | Payments include a $3M fee upon execution of the agreement, $8M in near-term payments and $39M in milestone payments, plus a 10% royalty on net sales | 12/1/15 |
Orca Pharmaceuticals Ltd. (Oxford, UK) | Astrazeneca plc (London) | $122.50 | Alliance to leverage retinoic acid-related orphan nuclear receptor gamma inhibitors to address autoimmune diseases | The exclusive collaboration, adopting Orca's full ROR? pipeline, carries up-front and milestone payments of up to $122.5M for the Oxford, UK-based company and will likely yield a candidate by year-end ahead of possible 2016 first-in-human studies; Astrazeneca gains an option to acquire the compounds at the end of the collaboration | 2/26/15 |
Orexigen Therapeutics Inc. | Takeda Pharmaceutical Co. Ltd. | $105.00 | Company settled a dispute with North American partner Takeda | The argument with Takeda, over which company would pay for a pricey cardiovascular outcomes clinical trial, was resolved through an amendment agreement under which Orexigen will foot the bill, up to $210M, after which costs will be split equally; the new agreement added up to $105M in success-based milestones for Orexigen | 8/7/15 |
Orexigen Therapeutics Inc. | Kwang Dong Pharmaceutical Co. Ltd. (South Korea) | $7.00 | Kwang Dong will seek to market on Orexigen's behalf in South Korea | Should Kwang Dong begin marketing Contrave in the second half of 2016, as planned, Orexigen can look forward to a 35% to 40% cut of net sales, and the arrival of potential sales-based milestones; deal includes $7M up front | 8/7/15 |
Orexigen Therapeutics Inc. | Kwang Dong Pharmaceutical Co. Ltd. (South Korea) | $7.00 | Kwang Dong will seek to market on Orexigen's behalf in South Korea | Should Kwang Dong begin marketing Contrave in the second half of 2016, as planned, Orexigen can look forward to a 35% to 40% cut of net sales, and the arrival of potential sales-based milestones; deal includes $7M up front | 8/7/15 |
Orgenesis Inc. (Germantown, Md.) | Biosequel LLC | ND | Collaboration agreement for conducting clinical trials in Russia | Financial terms were not disclosed | 11/25/15 |
Orgenesis Inc. (White Plains, N.Y.) | Curecell Co. Ltd. (Seoul, South Korea) | ND | Nonbinding memorandum of understanding with Curecell as an initial step for finalizing a joint venture to develop and bring to market Orgenesis' Autologous Insulin Producing cell therapy product in Korea | Terms were not disclosed | 4/10/15 |
OSE Pharma SA (Paris) | Rafa Laboratories Ltd. (Jerusalem) | ND | Exclusive long-term agreement for the registration, marketing, distribution and sale of Tedopi, which combines 10 neo-epitopes directed against five tumor-associated antigens | The product is about to enter a pivotal phase III study in patients with advanced non-small-cell lung cancer who express HLA-A2 and failed first-line therapy; Rafa will submit the drug for approval in Israel, market and distribute it, and will pay an up-front fee and milestone payments, equally sharing profits | 5/14/15 |
Ovid Therapeutics Inc. (New York) | H. Lundbeck A/S (Valby, Denmark) | ND | Exclusive worldwide license for gaboxadol to treat neurological diseases Angelman syndrome and Fragile X syndrome | Ovid obtained exclusive global development and commercialization rights for OV101, in return for a minority stake by Lundbeck and undisclosed milestone payments and sales royalties | 4/17/15 |
Oxford Biomedica plc (Oxford, UK) | Glaxosmithkline plc (London) | ND | GSK exercised an option to obtain a nonexclusive license for two rare orphan disease indications under Oxford's Lentivector platform technology patents, under an agreement signed in December 2013 | Further terms were not disclosed | 10/29/15 |
Oxford Biotherapeutics plc (Oxford, UK) | Boehringer Ingelheim GmbH (Ingelheim, Germany) | ND | Exercised option to receive exclusive rights to an oncology target discovered with Oxford's OGAP system | Boehringer Ingelheim will be responsible for development and commercialization of antibody products to the target; Oxford Biotherapeutics will receive development and regulatory milestone payments, and royalties on sales | 1/15/15 |
Padlock Therapeutics Inc. (Cambridge, Mass.) | Glaxosmithkline plc (London) | ND | Agreement to license intellectual property and a collection of assets targeted at protein-arginine deiminases from GSK | Padlock plans to use the assets to expand its chemistry portfolio to create new treatments for autoimmune disease by targeting the PAD enzymes; it will receive exclusive rights to the assets, and GSK gets an undisclosed equity grant and board observer rights | 5/29/15 |
Pain Therapeutics Inc. (Austin, Texas) | Pfizer Inc. (New York) | ND | Under terms of a letter agreement with Pfizer, Pain Therapeutics is taking back responsibility for Remoxy | The two companies agreed to implement a detailed transition plan involving an orderly transfer of a large amount of data, materials, capital equipment and other assets related to Remoxy | 4/22/15 |
Palatin Technologies Inc. (Cranbury, N.J.) | Gedeon Richter plc (Budapest, Hungary) | ND | Terminated the license and collaborative deal for bremelanotide in the treatment of female sexual dysfunction | All rights and licenses granted to Richter will revert back to Palatin; Palatin received $9.8M in total up-front payments from Richter, and a milestone amount of $3.1M upon initiation of its U.S. phase III trial; there are no payment or reimbursement obligations | 9/22/15 |
Palobiofarma SL (Barcelona, Spain) | Novartis AG (Basel, Switzerland) | $15.00 | Licensing deal based on targeting adenosine signaling in cancer immunotherapy | Palobiofarma will get $15M up front, plus undisclosed clinical and commercial milestones and tiered single- to double-digit royalties | 10/22/15 |
Panoptes Pharma Ges.mbH (Vienna) | Mediolanum Laboratoires Leurquin SA (France; subsidiary of Meiolanum Farmaceutici SpA; Italy) | ND | Mediolanum will acquire marketing rights to PP-001, a small molecule in preclinical development for several inflammatory eye diseases | Panoptes received an up-front payment, and is eligible for developmental and sales milestones and royalties on net sales; Mediolanum will have marketing rights over two main European countries, while Panoptes will retain marketing rights in all other countries | 2/11/15 |
Panther Biotechnology Inc. (Chicago) | Faulk Pharmaceuticals Inc. (Raleigh, N.C.) | ND | Closed definitive agreements to acquire Faulk’s pharmaceuticals technology assets | Panther gains a ligand-drug conjugate technology platform and a pipeline of drug product candidates in oncology, autoimmune, antiviral and other disease indications, including TRF-DOX; Panther will issue 50,000 shares of common stock and agreed to a tiered royalty payment | 7/17/15 |
Paras Biopharmaceuticals Finland Oy (Oulu, Finland) | Novozymes A/S (Bagsvaerd, Denmark) | ND | Partnership to use the Novozyme's Veltis technology to develop a biobetter of teriparatide | Financial terms were not disclosed | 11/25/15 |
Paxvax Inc. (Redwood City, Calif.) | Various unnamed companies | ND | Commercial partnerships and distribution agreements for its typhoid vaccine Vivotif | Financial terms were not disclosed | 4/23/15 |
PCT LLC (subsidiary of Caladrius Biosciences Inc.; New York) | Immunocellular Therapeutics Ltd. (Calabasas, Calif.) | ND | PCT will produce ICT-107 for a pivotal phase III trial in patients with newly diagnosed glioblastoma | PCT will provide manufacturing services, including processing, packaging, labeling, quality control testing, release, shipping and storage, as well as process requalification, for ICT-107 | 6/16/15 |
PDL Biopharma Inc. (Incline Village, Nev.) | Acelrx Pharmaceuticals Inc. (Redwood City, Calif.) | $65.00 | Agreement in which PDL acquired a portion of the royalties on expected sales of Acelrx's Zalviso (sufentanil sublingual tablet system) in the European Union, Switzerland and Australia by its commercial partner, Grunenthal | PDL has provided Acelrx with $65M in gross proceeds, and in exchange, it will receive 75% of the royalties Acelrx received from Grunenthal as well as 80% of the first four commercial milestones subject to a capped amount | 9/22/15 |
PEP-Therapy (Paris) | Clevexel Pharma (Maisons-Alfort, France) | ND | Agreement to co-develop a peptide as a targeted therapy in oncology based on technology involving bifunctional peptides | The partnership will take the product through to its clinical proof of concept | 6/10/15 |
Peptidream Inc. (Tokyo) | Novartis AG (Basel, Switzerland) | ND | Exercised option under a 2012 strategic alliance agreement to obtain a nonexclusive license to Peptidream's Peptide Discovery Platform System technology | Peptidream will receive multistage up-front technology access payments and will be eligible for development milestones and royalties on related product sales | 4/3/15 |
Peptidream Inc. (Tokyo) | Merck & Co. Inc. (Kenilworth, N.J.) | ND | Multitarget discovery and optimization collaboration in which Peptidream will use its Peptide Discovery Platform System technology to generate macrocyclic/constrained peptides against multiple targets of interest selected by Merck | Merck will have the right to develop and commercialize therapeutic peptides resulting from the collaboration, with an option to nonexclusively license the PDPS technology at a future date; Peptidream is set to receive an undisclosed up-front payment and research funding and will be eligible for milestone payments and sales royalties | 5/4/15 |
Peptidream Inc. (Tokyo) | Sanofi SA (Paris) | ND | Multi-target discovery and optimization collaboration in which Peptidream will use its Peptide Discovery Platform System technology to generate macrocyclic/constrained peptides against multiple targets of interest selected by Sanofi | Sanofi will have the right to develop and commercialize any therapeutic peptides resulting; Peptidream will receive an undisclosed up-front payment, research funding and will be eligible for payments associated with the achievement of certain preclinical and clinical development milestones; the ocmpany is eligible to receive royalties on sales | 9/15/15 |
Peptidream Inc. (Tokyo) | Teijin Pharma Ltd. (Tokyo) | ND | Multi-target discovery and optimization collaboration in which Peptidream will use its Peptide Discovery Platform System technology to generate macrocyclic/constrained peptides against multiple targets of interest selected by Teijin | Peptidream will receive an undisclosed up-front payment, research funding and will be eligible for payments associated with achievement of certain preclinical and clinical development milestones, plus royalties | 9/29/15 |
Peptidream Inc. (Tokyo) | Genentech (unit of Roche AG; Basel, Switzerland) | ND | Multitarget discovery and optimization collaboration to use its Peptide Discovery Platform System technology to identify macrocyclic/constrained peptides against multiple targets of interest selected by Genentech, and will optimize hit peptides into therapeutic peptides or small-molecule products | Genentech will have the right to develop and commercialize all molecules; Peptidream will receive an undisclosed up-front payment, research funding and is eligible for payments associated with the achievement of certain preclinical and clinical development milestones; Peptidream is eligible to receive royalties on sales | 12/22/15 |
Peptidream Inc. (Tokyo) | Genentech (unit of Roche AG; Basel, Switzerland) | ND | Multitarget discovery and optimization collaboration to use its Peptide Discovery Platform System technology to identify macrocyclic/constrained peptides against multiple targets of interest selected by Genentech, and will optimize hit peptides into therapeutic peptides or small-molecule products | Genentech will have the right to develop and commercialize all molecules; Peptidream will receive an undisclosed up-front payment, research funding and is eligible for payments associated with the achievement of certain preclinical and clinical development milestones; Peptidream is eligible to receive royalties on sales | 12/22/15 |
Peregrine Pharmaceuticals Inc. (Tustin, Calif.) | Astrazeneca plc (London) | ND | Agreement to evaluate Peregrine's phosphatidylserine-signaling pathway inhibitor, bavituximab, in combination with Astrazeneca's anti-PD-L1 immune checkpoint inhibitor, durvalumab (MEDI4736) | The initial trial will be conducted by Peregrine; financial terms were not disclosed | 8/25/15 |
Peregrine Pharmaceuticals Inc. (Tustin, Calif.) | Astrazeneca plc (London) | ND | Expanded cancer immunotherapy clinical collaboration to include a second, later-stage trial | The companies will now also evaluate the immunotherapy combination of Peregrine’s phosphatidylserine (PS)-targeted immune-activator, bavituximab, and Astrazeneca’s anti-PD-L1 immune checkpoint inhibitor, durvalumab (MEDI4736), in a phase II study in patients with previously treated squamous or nonsquamous non-small-cell lung cancer | 10/16/15 |
Perrigo Co. plc (Dublin) | Glaxosmithkline plc (London) | ND | Deal to acquire a portfolio of over-the-counter brands from GSK | Perrigo will pick up rights to GSK's Niquitin nicotine replacement therapy, several assorted OTC brands such as Coldrex cold and flu treatment and Nezeril, a nasal decongestant, as well as Novartis' cold sore management products | 6/3/15 |
Perrigo Co. plc (Dublin) | Matawan Pharmaceuticals LLC (Cranford, N.J.) | ND | Acquisition of a portfolio of generic dosage forms and strengths of acne vulgaris treatment Retin-A (tretinoin) | Terms were not disclosed | 12/18/15 |
Pfenex Inc. (San Diego) | Hospira Inc. | $341.00 | Deal to advance PF582, a biosimilar of Lucentis (ranibizumab injection) for diabetic retinopathy | Pfenex will receive $51M up front and is eligible for $291M in development and sales-based milestone payments, plus tiered double-digit royalties; the parties will share costs on a phase III equivalence trial of PF582 vs. Lucentis in wet AMD, with costs to Pfenex capped at $20M | 2/11/15 |
Pfenex Inc. (San Diego) | Glide Technologies Ltd. (Oxfordshire, UK) | ND | Extended contract between the companies as a result of the National Institute of Allergy and Infectious Diseases exercising an option for Pfenex's recombinant protective antigen, Px563L-mrPA, which uses Glide's solid dose formulation technology as an alternative delivery method for the anthrax vaccine | Terms were not disclosed | 3/10/15 |
Pfizer Inc. (New York) | Glaxosmithkline plc (London) | $130.00 | Agreement for Pfizer to expand its global reach in preventing mengingococcal disease by acquiring two meningitis vaccines for $130M | Pfizer plans to buy Nimenrix and Mencevax, which are single-dose meningococcal vaccines; the transaction is expected to be completed in the second half of this year | 6/23/15 |
Pfizer Inc. (New York) | Glaxosmithkline plc (London) | ND | Multiyear collaboration for the development of next-generation equipment design | The collaboration is aimed at building on Pfizer's existing portfolio for continuous, miniature and modular prototype for oral solid dose pharmaceutical development and manufacturing; terms were not disclosed | 10/30/15 |
PGI Drug Discovery LLC (Tarrytown, N.Y.) | Sunovion Pharmaceuticals Inc. (Marlborough, Mass.) | ND | Drug discovery and development collaboration extended for another four years | The original 2007 deal was focused on identifying a new generation of treatments for neuropsychiatric disorders; the companies have expanded the scope, which led to the identification of potential drug candidates including a compound in clinical development | 9/15/15 |
Phagelux Inc. (Nanjing, China) | Iveria Technologies Inc. (Delaware) | ND | Deal to acquire several biodegradable polymer delivery systems for its phage technologies being developed for human and agricultural uses | Terms were not disclosed | 1/7/15 |
Pharma Major Lupin Ltd. (Mumbai, India) | Temmler Pharma GmbH (Marburg, Germany) | ND | Strategic asset purchase agreement to acquire Temmler's specialty product portfolio | Terms were not disclosed | 7/27/15 |
Pharmacosmos A/S (Holbaek, Denmark) | Helsinn Group (Lugano, Switzerland) | $130.00 | Agreement for exclusive U.S. commercialization rights to Monofer, an intravenous iron replacement therapy in development for iron deficiency anemia | Pharmacosmos is eligible for milestone payments of up to $130M as well as further payments for the manufacture and supply of Monofer to Helsinn in the U.S. | 1/9/15 |
Pharmamar SA (Madrid) | TTY Biopharm Co. Ltd. (Taipei, Taiwan) | ND | Exclusive license and commercialization agreement to market and distribute the drug candidate Aplidin (plitidepsin) in Taiwan | Pharmamar will receive an up-front payment, royalties and additional remunerations for regulatory milestones; it will retain exclusive production rights and will supply the finished product to TTY Biopharm for commercial use | 7/24/15 |
Pharmanest AB (Princeton, N.J.) | Karolinska Development | $43.35 | Karolinska is divesting its shareholding in Pharmanest | Pharmanest has been acquired by a consortium of investors, who simultaneously are putting in SEK38M (US$43.35M) for further clinical development | 7/13/15 |
Pharmaxis Ltd. (Frenchs Forest, Australia) | Boehringer Ingelheim GmbH (Ingelheim, Germany) | $601.40 | Exercised option to in-license PXS4728A from Pharmaxis | Boehringer Ingelheim is paying $31.4M up front and $570M in milestones tied to approval in nonalcoholic steatohepatitis and chronic obstructive pulmonary disease | 5/19/15 |
Pharmaxis Ltd. (Sydney) | Synairgen plc (Southampton, UK) | ND | Agreement to co-develop a selective inhibitor to the lysyl oxidase type 2 enzyme to treat the fatal lung disease idiopathic pulmonary fibrosis | Synairgen will fund further activity of the program at Pharmaxis, use its Biobank and in vitro lung model platform, and collaborate with the IPF research team at the University of Southampton to complete preclinical and early clinical development | 8/6/15 |
Philogen SpA (Siena, Italy) | Boehringer Ingelheim GmbH (Ingelheim, Germany) | ND | Collaboration to investigate treatment approaches for acute myeloid leukemia and have agreed on an exploratory trial investigating immunotherapy concepts for relapsed AML patients | Financial terms were not disclosed | 10/16/15 |
Phosplatin Therapeutics Inc. (New York) | U.S.-based pharmaceutical company with operations in China | ND | Regional license for Phosplatin's platinum agent, PT-112, for development and commercialization in China and certain adjacent territories | The agreement grants the partner the rights to develop and market it in China, Hong Kong SAR, the Macau SAR, and Vietnam for oncology indications; the partner also has options to add Taiwan and South Korea; Phosplatin is eligible for up-front, milestone and tiered royalty payments | 8/20/15 |
Phylogica Ltd. (Perth, Australia) | Phoremost Ltd. (Cambridge, UK) | ND | Licensing agreement under which Phylogica grants to Phoremost a worldwide nonexclusive license to use certain Phylomer libraries solely for phenotypic screening to identify novel targets involved in diseases such as cancer, and then to identify and develop small-molecule drugs against those targets | The license includes certain preference conditions that cap the number of similar phenotypic deals that Phylogica may enter during an 18-month option period; Phylogica will retain all commercial rights, and will obtain a 7.5% equity stake | 4/8/15 |
Pieris Pharmaceuticals Inc. (Boston) | Roche AG (Basel, Switzerland) | $416.00 | Partnering deal in immuno-oncology involving a single target against which Pieris will deploy its anticalin scaffold technology | The deal is worth up to CHF415M (US$416M), with CHF6.5M coming in the form of an up-front payment; the figure also includes some research funding and Pieris also would receive tiered mid single-digit to low double-digit sales royalties | 12/9/15 |
Plasmatech Biopharmaceuticals Inc. (New York) | Unemed Corp. (Omaha) | ND | Licensing agreement for an adeno-associated virus gene therapy program targeting the lysosomal storage disease, juvenile Batten disease, from Unemed | Terms were not disclosed | 6/9/15 |
Pluristem Therapeutics Inc. (Haifa, Israel) | United Therapeutics Corp. (Silver Spring, Md.) | ND | Terminated licensing agreement for the development of PLX-PAD for the treatment of pulmonary arterial hypertension | Pluristem will regain full rights to PLX-PAD in that indication, as well as all clinical data and regulatory submissions | 12/9/15 |
Polyphor Ltd. (Alschwil, Switzerland) | Pari Pharma (Starnberg, Germany) | ND | Licensing agreement to use the Eflow technology nebulizer to administer POL6014 to treat rare lung diseases such as alpha-1 antitrypsin deficiency and cystic fibrosis | The start of phase I studies of POL6014 is planned for this year | 1/12/15 |
Polyphor Ltd. (Alschwil, Switzerland) | Taisho Pharmaceutical Co. Ltd. (Tokyo) | ND | Collaboration to identify drug candidates based on Polyphor's macrocycle platform | Financial details were not disclosed | 9/18/15 |
Portola Pharmaceuticals Inc. (South San Francisco) | Ora Inc. (Andover, Mass.) | ND | Collaboration to develop Portola's Syk inhibitor, PRT2761, in ophthalmic diseases | Ora will lead clinical development and the companies will share expenses until proof of concept | 5/6/15 |
Poseida Therapeutics Inc. | Janssen Biotech Inc. (unit of Johnson & Johnson; New Brunswick, N.J.) | ND | Global license agreement to discover, develop, manufacture and commercialize chimeric antigen receptor T-cell-based therapies | The plan includes a deal Janssen signed last year with Transposagen Biotherapeutics Inc., which spun out Poseida; it originally called for Transposagen to receive up to $292M per CAR T therapeutic from Janssen; the new deal gives Poseida the right to screen Janssen's Centyrin library and to identify and develop molecules against cancer antigens that Poseida identifies or licenses; Poseida will pay an undisclosed up-front fee and potential milestone payments | 8/12/15 |
Poseida Therapeutics Inc. (San Diego) | Johnson & Johnson (New Brunswick, N.J.) | $292.00 | Transferred drug development and license agreement between Transposage Biopharmaceuticals Inc., of Lexington, Ky., and J&J to Transposagen's spinout Poseida | The agreement will focus on developing at least two allogeneic CAR T product candidates; Poseida will receive milestone payments of up to $292M per product candidate and tiered royalty payments | 6/2/15 |
Potenza Therapeutics Inc. (Cambridge, Mass.) | Astellas Pharma Inc. (Tokyo) | ND | Exclusive research and development collaboration in which Potenza will be advancing a portfolio of candidates that target immune checkpoint pathways, co-stimulatory signals and regulatory T cells | Astellas holds an option to buy out Potenza; under the terms, Potenza will lead drug discovery activities and hand over development prospects to Astellas, which will handle clinical development and commercialization; financial terms were not detailed but also include an equity investment, option fee, research funding and milestone payments | 4/23/15 |
Poxel SA (Lyon, France) | Enyo Pharma SAS (Lyon, France) | ND | License agreement under which Enyo will gain access to Poxel's FXR (farnesoid X receptor) agonist compounds for infection-related indications with Poxel retaining rights for cardiovascular and metabolic indications among others | Financial terms were not disclosed | 5/7/15 |
Poxel SA (Lyon, France) | Enyo Pharma SAS (Lyon, France) | ND | Agreement to allow Enyo access to Poxel's patent to use FXR agonist technology for the development of hepatitis B treatments | The technology was discovered and patented by Poxel and its academic partners, which are represented by Inserm Transfert, and Edelris, of Lyon | 11/18/15 |
PPF Group (Amsterdam the Netherlands) | Cytune Pharma SAS (Nantes, France) | ND | Deal under which PPF Group acquired a significant minority stake in cytune, which is focused on new therapies for immune modulation for cancer and infectious diseases | PPF also committed to funding Cytune R&D activities related to its lead compound as well as to other developments based on its novel platform | 2/5/15 |
Prasco Laboratories Inc. (Cincinnati) | Takeda Pharmaceutical Co. Ltd. (Osaka, Japan) and its subsidiary | ND | Distribution and supply agreement for rights to distribute authorized generic colchicine tablets, a version of Colcyrs (colchicine, URL Pharma Inc.) | Terms were not disclosed | 1/13/15 |
Precision Biologics Inc. (Texas) | EMD Millipore (unit of Merck KGaA; Darmstadt, Germany) | ND | Agreement for providing upstream process development services to advance NEO-201 | NEO-201 is a preclinical monoclonal antibody which binds to a tumor-specific antigen found in several forms of cancer | 2/3/15 |
Presage Biosciences Inc. (Seattle) | Piramal Enterprises Ltd. (Chennai, India) | ND | In-licensing agreement for Piramal's voruciclib | Terms of the licensing were not disclosed | 11/25/15 |
Primary Peptides Inc. (Vancouver, British Columbia) | Yabao Pharmaceutical Co. (Beijing) | ND | Exclusive license to develop and commercialize products targeting PTEN nuclear translocation for the treatment of stroke | Yabao gets rights to develop and commercialize in China, Taiwan and Hong Kong, while Primary Peptides retains rights in all other markets | 9/16/15 |
Pro Bono Bio (London) | Knight Therapeutics Inc. (Westmount, Quebec) | $15.00 | Exclusive distribution agreement to accelerate the global launches of Flexiseq and Sequaderma dermatology products, as well as help fund its nanotechnology research and development programs | In return for its $15M in funding, Knight receives the immediate and exclusive distribution rights to Flexiseq, Flexiseq Sport and Sequaderma within the province of Quebec and Israel, as well as the exclusive rights to Pro Bono Bio's pipeline of hematology and diagnostic device products across all of Canada and Israel | 6/29/15 |
Probiodrug AG (Halle, Germany) | QPS Austria Neuropharmacology | ND | Agreement to license the TBA2.1 Mouse to contract research organization QPS Austria | Terms were not disclosed | 9/2/15 |
Probiodrug AG (Halle, Germany) | Rentschler Biotechnologie GmbH (Laupheim, Germany) | ND | Agreement to develop PBD-C06, a pGlu-Abeta-specific monoclonal antibody | The agreement covers all stages of production and processing; financial details were not disclosed | 10/8/15 |
Probiogen AG (Berlin) | Tizona Therapeutics Inc. (South San Francisco) | ND | Commercial license and service agreement for cell line and process development | Probiogen will develop Tizona's immuno-oncology antibody up to GMP manufacturing, applying Probiogen's Glymaxx cell line to boost the antibody's ADCC anti-tumor activity; manufacturing of clinical study material will be conducted at Probiogen's new facility which will house two additional 1,000L single-use bioreactors in its GMP suites | 10/2/15 |
Probiogen AG (Berlin) | Zymeworks Inc. (Vancouver, British Columbia) | ND | Agreement under which Probiogen will complete cell line development of a Zymeworks bi-specific antibody product candidate, applying its Glymaxx technology to enhance antibody-dependent cell-mediate cytotoxicity | Terms were not disclosed | 10/15/15 |
Probiogen AG (Berlin) | Bio Farma (Bandung, West Java, Indonesia) | ND | Agreement for the development of a biosimilar trastuzumab for cancer treatment | Probiogen will develop a manufacturing process based on a specifically designed recombinant CHO-cell line, conduct engineering runs and the industrial scale-up; the turnkey process, including state-of-the-art analytics, will then be transferred to Indonesia to enable local market production | 10/29/15 |
Prometic Life Sciences Inc. (Laval, Quebec) | Emergent Biosolutions Inc. (Rockville, Md.) | $100.00 | Strategic manufacturing agreement giving Prometic access to additional cGMP capacity in an FDA-licensed facility in Winnipeg, Manitoba | Prometic plans to develop and manufacture plasma-derived biopharmaceuticals using its Plasma Protein Purification System; Prometic will make an initial annual minimum payment of $4M per year, rising to $7M per year in 2018 and $9 million per year in 2021, with minimum fees exceeding $100M over the life of the contract | 5/20/15 |
Prometic Life Sciences Inc. (Laval, Quebec) | Omnio AB (Umea, Sweden) | ND | Strategic agreement under which Prometic secured exclusive license rights to both issued and pending patents for the use of plasminogen related to wound healing | The agreement also provides Prometic access to extensive preclinical data as well as unique proof-of-concept efficacy data in patients | 11/12/15 |
Prometic Life Sciences Inc. (Laval, Quebec) | Prothera Biologics Inc. (East Providence, R.I.) | ND | Partnership for the development and commercialization of human plasma-derived inter-alpha inhibitor proteins | The agreements provide Prometic with global, exclusive intellectual property rights to commercialize products for two orphan clinical indications and gives both companies a strategic interest in the other's IAIP-related therapeutic areas through a royalty-bearing cross-license agreement | 11/20/15 |
Prometic Life Sciences Inc. (Laval, Quebec) | Glaxosmithkline plc (London) | ND | Supply agreement renewed | The renewed agreement follows the original supply agreement entered in 2009; details were not disclosed | 12/7/15 |
Protalix Biotherapeutics Inc. (Carmiel, Israel) | Pfizer Inc. (New York) | $46.00 | Protalix sold its share in the collaboration for Elelyso (taliglucerase alfa) to commercialization partner Pfizer for $46M, including $36M in cash and a $10M investment in exchange for about 5.6M of Protalix' common shares | Pfizer and Protalix shared revenues and expenses for the development and commercialization of Elelyso on a 60-40 basis globally, excluding Israel and Brazil; Pfizer now assumes responsibility for expenses and will be entitled to global revenues outside Brazil, where Protalix will bear expenses and retain product revenues | 10/14/15 |
Proteros Biostructures GmbH (Martinsried, Germany) | Merck & Co. Inc. (Kenilworth, N.J.) | $126.00 | Drug discovery agreement for an undisclosed epigenetic cancer target | Proteros will be responsible for the delivery of lead compounds, and Merck for development and commercialization; the deal includes up to $126M in up-front and research funding, milestone payments, tiered royalties on product sales | 10/8/15 |
Provectus Biopharmaceuticals Inc. (Knoxville, Tenn.) | Boehringer Ingelheim (China) Investment Co. Ltd. (Shanghai) | ND | Letter of intent to lay a foundation to collaborate in bringing PV-10 to market for cancer in mainland China, Hong Kong and Taiwan | Boehringer will provide commercial support, and Provectus will grant Boehringer the first priority to be the exclusive collaborator of Provectus in China for PV-10 in the event that PV-10 is successfully registered and approved | 7/6/15 |
Proximagen Ltd. (unit of Upsher-Smith Laboratories Inc.; Maple Grove, Minn.) | Roche AG (Basel, Switzerland) | ND | Worldwide agreement for further development of an oral small-molecule inhibitor of vascular adhesion protein 1, or VAP-1, a cell-adhesion molecule that may be effective in the treatment of inflammatory disease | Proximagen granted Roche an exclusive license to develop and commercialize the compound, which is in phase II development; Proximagen will receive an up-front payment, along with downstream development, regulatory and sales milestones, plus tiered royalties | 12/2/15 |
Proximagen Ltd. (unit of Upsher-Smith Laboratories Inc.; Maple Grove, Minn.) | Roche AG (Basel, Switzerland) | ND | Worldwide agreement for further development of an oral small-molecule inhibitor of vascular adhesion protein 1, or VAP-1, a cell-adhesion molecule that may be effective in the treatment of inflammatory disease | Proximagen granted Roche an exclusive license to develop and commercialize the compound, which is in phase II development; Proximagen will receive an up-front payment, along with downstream development, regulatory and sales milestones, plus tiered royalties | 12/2/15 |
Psivida Corp. (Watertown, Mass.) | Unnamed pharmaceutical company | ND | Technology evaluation agreement for Psivida's Durasert technology for delivering a compound to treat ophthalmic disease | Terms were not disclosed | 5/13/15 |
Pulmatrix Inc. (Lexington, Mass.) | Mylan NV (Potters Bar, UK) | ND | Inked an ex-U.S. development agreement for PUR0200 | Pulmatrix will lead the development work and pharmacokinetic clinical study with collaborative support from Mylan, which has an option for PUR0200 ex-U.S. based on successful completion of the clinical study; financial terms were not disclosed | 6/17/15 |
Purdue Pharma LP (Stamford, Conn.) | VM Pharma LLC (Fremont, Calif.) | $213.00 | Deal in which Purdue acquired VM-902A as well as the backup compounds and associated intellectual property for the potential treatment of chronic pain from VM Pharma | VM Pharma received an up-front payment and could receive development, regulatory and commercial milestone payments, which together with the up-front payment, could total up to $213M, as well as royalties | 9/9/15 |
Q Biomed Inc. (New York) | Mannin Research Inc. (Toronto) | ND | Agreement to in-license and ultimately acquire the assets of Mannin Reearch | Q Biomed's primary target indication is for a first-in-class therapeutic eye-drop for the treatment of glaucoma in adults and children; company execs said they expect to be conducting first-in-human clinical trials by 2017 | 9/22/15 |
Quest Pharmatech Inc. (Edmonton, Alberta) | Oncoquest Inc. (subsidiary of Quest) | $2.00 | Quest Pharmatech sold its immuno-photodynamic therapy assets to Oncoquest for $2M | The immuno-photodynamic therapy patent protects the use of photodynamic therapy for enhancing the effects of any immunotherapeutic agents for treatment of diseases when used in combination | 12/11/15 |
Radius Health Inc. (Waltham, Mass.) | Eisai Co. Ltd. (Tokyo) | ND | Agreement for full global rights to develop and commercialize its investigation drug RAD 1901 being studied for metastatic breast cancer and vasomotor symptoms | In June 2006 Radius had acquired the ex-Japan rights to RAD1901 from Eisai; terms were not disclosed | 3/10/15 |
Rani Therapeutics Inc. (San Jose, Calif.) | Novartis AG (Basel, Switzerland) | ND | Collaboration to evaluate its oral biotherapeutics drug delivery platform | The companies agreed to begin feasibility studies to evaluate how selected Novartis' biologics can be delivered into the bloodstream using Rani's oral route of administration | 5/28/15 |
Raptor Pharmaceutical Corp. (Novato, Calif.) | Tripex Pharmaceuticals LLC | $418.40 | Raptor is buying global rights to Quinsair for adult cystic fibrosis patients | It will pay Tripex $68.4M up front and as much as $350M more in milestone payments; the deal includes a single-digit royalty for Tripex on global sales | 8/24/15 |
Redhill Biopharma Ltd. (Tel Aviv) | Resprotect GmbH (Dresden, Germany) | $0.13 | Extended an exclusive option agreement to acquire global rights to RP101 in all indications except pancreatic cancer in South Korea | If Redhill exercises the option, Resprotect is set to receive $100,000 along with potential milestone payments and tiered royalties ranging from single digits to mid-teens; Redhill agreed to pay $25,000 for a one-year extension of the option agreement | 7/16/15 |
Redhill Biopharma Ltd. (Tel Aviv, Israel) | Apogee Biotechnology Corp. (Hummelstown, Pa.) | $5.50 | Exclusive global license agreement for the development and commercialization rights to phase II candidate, ABC294640, an orally administered sphingosine kinase-2 inhibitor targeting multiple inflammatory, gastrointestinal and oncology indications | The agreement included additional intellectual property for all indications; Redhill will pay Apogee $1.5M up front and $4M in potential milestone payments plus tiered royalties starting in the low double digits | 4/3/15 |
Redvax GmbH (spin-off from Redbiotec AG; Zurich-Schlieren, Switzerland) | Pfizer Inc. (New York) | ND | Pfizer acquired a controlling interest in Redvax | The transaction provides access to a preclinical human cytomegalovirus vaccine candidate, as well as intellectual property and a technology platform related to a second, undisclosed vaccine program | 1/6/15 |
Regeneron Pharmaceuticals Inc. (Tarrytown, N.Y.) | Sanofi SA (Paris) | $2,200.00 | Collaboration to jointly develop and commercialize the programmed cell death protein-1 inhibitor REGN-2810 and other new immuno-oncology antibodies | The five-year deal includes $640M up front for Regeneron and reallocates some money from a 2009 antibody deal; it covers both monoclonal antibodies and new bispecific antibodies; they will together invest $1B for discovery through proof-of-concept development, $250M from Regeneron and $750M from Sanofi; worldwide profits will be shared equally; they also will invest $325M each in developing REGN-2810, and Sanofi will make a milestone payment of $375M if sales exceed $2B in 12 months; the companies also agreed to re-allocate $75M over three years for immuno-oncology antibodies from Sanofi's $160M annual contribution to their existing antibody collaboration | 7/29/15 |
Regeneron Pharmaceuticals Inc. (Tarrytown, N.Y.) | Mitsubishi Tanabe Pharma Corp. (Osaka, Japan) | $325.00 | Exclusive development and commercial rights agreement for fasinumab (REGN475) to treat musculoskeletal pain in Japan, Korea and nine other Asian countries, excluding China | Deal includes $55M up front; Regeneron also is entitled to receive up to $170M in R&D reimbursement and development milestones, and is eligible for one-time purchase price adjustement payments totaling up to $100M upon achieving sales targets | 10/5/15 |
Regenerx Biopharmaceuticals Inc. (Rockville, Md.) | G-treebnt Co. Ltd. (Korea) | $1.00 | Agreements to develop RGN-259 for dry eye syndrome and neurotrophic keratitis in the U.S. | G-treebnt will be responsible for conducting and funding all clinical trials and product development through approval of a new drug application (NDA); Regenex granted the joint venture under the agreement an exclusive, royalty-bearing license to market and sell RGN-259 in the U.S.; G-treebnt will hold a majority equity stake in the JV that will increase as it successfully reaches development milestones; Regenerx will receive a total of $1M in two tranches, as well as royalties ranging from high single digits to low double digits, depending on medical indications approved and if the JV's ophthalmic product candidates are commercialized internally or through a third party | 1/29/15 |
Regenxbio Inc. (Rockville, Md.) | Wuxi Apptec Inc. (Shanghai) | ND | Strategic manufacturing collaboration to establish efficient, scalable manufacturing processes within current good manufacturing practice guidelines for the production of adeno-associated virus gene therapy treatments incorporating NAV Technology | Terms were not disclosed | 6/12/15 |
Regulus Therapeutics Inc. (La Jolla, Calif.) | Glaxosmithkline plc (London) | ND | Collaboration and formulation development agreement in which they will conduct a phase II study to evaluate RG-101 with GSK2878175 to treat hepatitis C virus | Regulus will be responsible for conducting an open-label phase II study to evaluate the potential to achieve sustained viral responses post-treatment with a single subcutaneous administration of 4 mg/kg of RG-101 in combination with daily oral administrations of 20 mg of GSK2878175 for up to 12 weeks in treatment-naive patients chronically infected with HCV genotypes 1 and 3; the study is planned to begin in the first quarter of 2016 | 11/4/15 |
Relief Therapeutics SA (Geneva) | Merck Serono (unit of Merck KgaA; Darmstadt, Germany) | ND | In-licensing agreement giving Relief worldwide, exclusive rights to develop and commercialize atexakin alfa, a human recombinant version of interleukin-6 | Financial terms were not disclosed | 9/9/15 |
Relypsa Inc. (Redwood City, Calif.) | Sanofi SA (Paris) | ND | Two-year detailing agreement for patiromer | Relypsa will use Sanofi's nephrology sales force to complement its own commercial efforts; Sanofi will be paid a service fee and is eligible for incentive payments | 8/12/15 |
Relypsa Inc. (Redwood City, Calif.) | Vifor Fresenius Medical Care Renal Pharma Ltd. (Glattbrugg, Switzerland) | $165.00 | Exclusive partnership to commercialize patiromer for oral suspension to treat hyperkalemia | Relypsa will receive an up-front cash payment of $40M and will be eligible to receive payments of up to $125M in regulatory and sales milestones, plus double-digit royalties | 8/12/15 |
Reset Therapeutics Inc. (San Francisco) | 23andme Inc. (Mountain View, Calif.) | ND | Research agreement to study circadian clock genes and to improve therapeutic development for diseases related to molecular clocks | Through the collaboration, the Reset team will be able to conduct research from more than 650,000 23andMe customers who have consented for their de-identified aggregated data to be a part of research; terms of the agreement are not disclosed | 1/8/15 |
Resilience Therapeutics Inc. (Boston) | PGI Drug Discovery LLC (Psychogenics) (Tarrytown, N.Y.) | ND | Partnership to discover and optimize novel treatments for post-traumatic stress disorder and related conditions | Psychogenics, which has made a strategic investment in Resilience, is providing access to its Smartcube system, and expertise for the development of therapeutics for PTSD and other stress-related disorders | 3/3/15 |
Resverlogix Corp. (Calgary, Alberta) | Emerald Logic | ND | Research collaboration using Emerald's FACET (Fast Collective Evolution Technology) to study the dataset from Resverlogix's phase II trials, ASSERT, SUSTAIN and ASSURE, related to major adverse cardiac events | The research produced a number of proprietary models and deduced both binary and continuous variables, previously unidentified, that contribute to drug efficacy, adverse events as well as the observed reduction in MACE incidence in response to treatment with Resverlogix's RVX-208 | 3/5/15 |
Resverlogix Corp. (Calgary, Alberta) | Hepalink Pharmaceutical Co. Ltd. (Shenzhen, China) | $400.00 | Agreement for rights in all indications to RVX-208, a small-molecule BET bromodomain inhibitor, in China, Hong Kong, Taiwan, and Macau | The product is being studied in cardiovascular disease, diabetes mellitus and low high-density lipoprotein; Hepalink is investing about $28.9M in Resverlogix, and if RVX-208 reaches annual sales milestones, Resverlogix gets sales-based payments ranging from $5M to $90M, along with royalties, with a total payout of more than $400M | 4/28/15 |
Resverlogix Corp. (Calgary, Alberta) | Shenzhen Hepalink Pharmaceutical Co. Ltd. (Shenzhen, China) | $90.00 | License agreement and stock purchase agreement | Terms of the license call for Resverlogix to receive milestone payments ranging from $5M to $90M based on sales of the small-molecule BET bromodomain inhibitor, RVX-208, in China, Hong Kong, Taiwan and Macau, plus a 6% royalty on net sales in the territories | 7/9/15 |
Retrophin Inc. (New York) | Asklepion Pharmaceuticals LLC (Baltimore) | $78.00 | Agreement under which Retrophin acquired the exclusive right to purchase all worldwide rights, titles and ownership of cholic acid to treat bile acid synthesis defects | Retrophin will pay Asklepion an up-front payment of $5M and up to $73M in milestones based on approval and net product sales, plus tiered royalties on future net sales | 1/13/15 |
Retrophin Inc. (San Diego) | Sanofi SA (Paris) | $245.00 | Retrophin is selling its rare pediatric disease priority review voucher to Sanofi | Retrophin received the voucher when the FDA approved Cholbam for bile acid synthesis disorders due to single enzyme defects, and for those with peroxisomal disorders; Sanofi will pay $150M, followed by two equal installments of $47.5M in 2016 and 2017 | 5/28/15 |
Retrophin Inc. (San Diego) | Sanofi SA (Paris) | $245.00 | Agreement for Retrophin to sell its rare pediatric disease priority review voucher to Sanofi | Retrophin received a payment of $150M and is set to receive two additional payments of $47.5M each in 2016 and 2017; Retrophin received the voucher in March as part of a deal with Asklepion Pharmaceuticals LLC, of Baltimore, after Asklepion's drug, Cholbam, was approved by the FDA to treat rare bile acid synthesis disorders | 7/8/15 |
Rich Pharmaceuticals Inc. (Beverly Hills, Calif.) | Theradex Systems Inc. (Princeton, N.J.) | ND | Development agreement | Theradex will be responsible for finalizing the investigational drug application with the FDA for Rich's drug RP-323 to treat acute myeloid leukemia | 10/8/15 |
Rigel Pharmaceuticals Inc. (South San Francisco) | Bristol-Myers Squibb Co. (New York) | $339.00 | Agreement focused on transforming growth factor beta receptor kinase inhibitors | The deal brings $30M right away to Rigel plus the promise of development and regulatory milestone rewards that could mean more than $309M for a successful compound approved in multiple indications, along with tiered royalties | 2/24/15 |
Rigel Pharmaceuticals Inc. (South San Francisco) | Aclaris Therapeutics Inc. (Malvern, Pa.) subsidiary | $98.00 | Exclusive global license agreement to develop and commercialize specified Rigel JAK inhibitors to treat alopecia areata and other dermatological conditions | Rigel will receive an up-front payment of $8M, and will be eligible to receive various milestone payments of up to $90M based on global development and multiple indications, as well as tiered royalties | 9/10/15 |
Roche AG (Basel, Switzerland) | Qiagen NV (Venlo, the Netherlands) | ND | Agreement that includes a provision of nonexclusive licenses to recently granted Roche patents pertaining to the detection of mutations in the EGFR pathway, including in the KRAS gene | Financial details were not disclosed | 1/15/15 |
Roche Molecular Diagnostics (division of Roche AG; Basel, Switzerland) | Global Fund | ND | Roche was selected to provide HIV-1 viral load and early infant diagnostic technologies for the Global Fund, a partnership designed to accelerate the end of AIDS, tuberculosis and malaria as epidemics | The HIV-1 tests eligible for the collaboration use a dual-target design to simultaneously amplify and detect two HIV-1 genome regions, which are not subject to selective drug pressure; for early infant diagnostics, the dual-target HIV-1 qualitative test works with plasma and dried blood spot collection cards, does not need refrigeration, reduces the volume of blood required, and makes transportation easy | 6/19/15 |
Rodes Inc. (Paoli, Pa.) | Ligand Pharmaceuticals Inc. (San Diego) | ND | Exclusive global license and supply agreements for three Captisol-enabled programs | For each program Ligand will be eligible to receive development and commercial milestone payments, revenue from the sales of Captisol, and royalties of 8% to 11% on future net sales; Rodes will be responsible for all costs related to the development and commercialization of the programs | 12/9/15 |
R-Pharm US LLC (Princetong, N.J.; part of R-Pharm; Moscow) | Bristol-Myers Squibb Co. (New York) | ND | R-Pharm acquired Ixempra | It is indicated for metastatic or locally advanced breast cancer in refractory tumors | 8/18/15 |
R-Tech Ueno Ltd. (Tokyo) | Sucampo Pharmaceuticals Inc. (Bethesda, Md.) | ND | Terminated licensing agreement for the eye drug unoprostone isopropyl | Sucampo returned the rights in the wake of a phase III study in which the drug failed to meet its primary endpoint of improving mean retinal sensitivity in people with retinitis pigmentosa vs. a placebo with statistical significance | 3/10/15 |
R-Tech Ueno Ltd. (Tokyo) | Santen Pharmaceutical Co. Ltd. (Osaka, Japan) | ND | Deal for R-Tech to acquire the right to develop and commercialize DE-105 | DE-105 is a treatment targeting at persistent corneal epithelial defects that Santen has been developing currently in a phase I trial in the U.S. and phase II trial in Japan | 4/28/15 |
Rugen Therapeutics Inc. (Shanghai) | Allergan plc (Dublin) | ND | Exclusive collaboration to support the discovery and development of therapies for autism spectrum disorders and obsessive compulsive disorders | Rugen received an up-front initiation fee and is entitled to development-stage initiation and success-based milestone payments for advancing compounds; Allergan will have the exclusive option to acquire all rights, including the worldwide intellectual property rights and other assets, related to the compounds following clinical proof-of-concept studies | 11/30/15 |
Rxi Pharmaceuticals Corp. (Marlborough, Mass.) | Hapten Pharmaceuticals LLC (Princeton, N.J.) | $0.10 | Global license agreement for the therapeutic use of Samcyprone, which is in phase IIa trials for the treatment of alopecia areata, warts and cutaneous metastases of malignant melanoma | Hapten received a one-time up-front cash payment of $100,000 and 200,000 shares of Rxi's common stock; Hapten also is entitled to receive future milestone payments tied to the achievement of certain clinical and commercial objectives such as the enrollment of the first patient in a phase III trial and regulatory approval, and escalating royalties based on product sales | 2/6/15 |
Rxi Pharmaceuticals Corp. (Marlborough, Mass.) | Mirimmune LLC (Cambridge, Mass.) | ND | Exclusive license agreement to Rxi's sd-rxRNA technology for use in developing cell-based cancer immunotherapies | Mirimmune will be responsible for all research, development, manufacturing, regulatory and commercialization activities for the licensed products; RXi will receive an annual licensing fee, clinical milestone payments, sublicensing income and single digit royalties | 3/30/15 |
S1 Biopharma Inc. (New York) | Chong Kun Dang Pharmaceutical Corp. (Seoul, South Korea) | ND | Commercialization agreement for Lorexys (S1P-104) to treat hypoactive sexual desire disorder in women | CKD acquires rights to commercialize Lorexys throughout South Korea; terms include an undisclosed up-front payment to S1 Biopharma and additional payments based on milestones as well as royalties on future product sales; CKD also has right of first refusal for commercialization agreements related to additional potential indications for Lorexys | 12/9/15 |
Sangamo Biosciences Inc. (Richmond, Calif.) | Shire plc (Dublin) | ND | Agreement to revise the January 2012 license deal to expedite development of ZFP therapeutics for hemophilia A and B and Huntington's disease | Shire will return to Sangamo the exclusive worldwide rights to gene targets for the development, clinical testing and commercialization of ZFP therapeutics for hemophilia A and B, but will retain rights for Huntington's disease and a ZPF therapeutic for one additional gene target | 9/3/15 |
Scancell Holdings plc (Nottingham, UK) | Immunid Technologies SAS (Grenoble, France) | ND | Agreement to collaborate on a research project aimed at predicting which patients will respond best to SCIB1 treatment | The study will use Immunid's Imuntracker to assess the immune-modulatory effect of Scancell's SCIB1 Immunobody vaccine in patients with stage III/IV metastatic melanoma | 7/31/15 |
Scynexis Inc. (Research Triangle Park, N.C.) | Avista Pharma Solutions | ND | Asset purchase agreement for the sale of its contract research and development services business, which includes a screening platform and technology utilized by animal health companies, and GMP API, process chemistry and analytical service offerings to customers on a fee-for-service basis | The company said it is relocating to Jersey City, N.J. | 7/24/15 |
Seattle Genetics Inc. (Bothell, Wash.) | Bristol-Myers Squibb Co. (New York) | ND | Clinical trial collaboration agreement to evaluate the investigational combination of Seagen's antibody-drug conjugate Adcetris (brentuximab vedotin) and BMS' immunotherapy Opdivo (nivolumab) in two planned phase I/II trials | The first trial will evaluate the combination of Adcetris and Opdivo as a potential treatment option for patients with relapsed or refractory Hodgkin's lymphoma (HL), and the second trial will focus on patients with relapsed or refractory B-cell and T-cell non-Hodgkin's lymphoma (NHL), including diffuse large B-cell lymphoma; the studies are expected to begin in 2015, with Seagen conducting the HL trial and BMS conducting the NHL trial | 1/13/15 |
Seattle Genetics Inc. (Bothell, Washington) | Unum Therapeutics Inc. (Cambridge, Mass.) | $645.00 | Collaboration and license agreement to develop and commercialize antibody-coupled T-cell receptor therapies for cancer | Sgen agreed to pay $25M up front and make an equity investment of $5M in Unum's next financing round; the companies will initially develop two ACTR products incorporating Sgen's antibodies, and Sgen has an option to expand the collaboration to include a third ACTR product; Sgen also will provide Unum with funding to conduct preclinical research and development activities through phase I; they will co-develop and jointly fund programs after phase I unless either company opts out and then co-commercialize and share profits equally in the U.S.; Sgen will retain exclusive commercial rights outside the U.S., paying Unum high single- to mid-double-digit royalties on ex-U.S. sales; option fee and milestone payments to Unum may total up to $615M million across the three ACTR programs | 6/9/15 |
Selecta Biosciences Inc. (Watertown, Mass.) | Généthon (Evry, France) | ND | Deal to eliminate undesired immune responses to a common viral vector used in gene therapies | They will combine Généthon's expertise in gene therapy vectors and Selecta's SVP platform to co-develop and co-own gene therapies that result; the initial focus will be on muscular dystrophies and pediatric liver metabolic diseases that employ adeno-associated virus vectors | 5/14/15 |
Selecta Biosciences Inc. (Watertown, Mass.) | Sanofi SA (Paris) | $300.00 | Expanded collaboration in which Sanofi is exercising its option to license Selecta's antigen-specific immunotherapy platform for a program targeting celiac disease | The deal is part of a $900M November 2012 agreement, and Selecta is eligible for up to $300M in milestones and double-digit tiered royalties on net sales | 5/14/15 |
Sellas Life Sciences Group (Zug, Switzerland) | Trojantec Ltd. (UK) | ND | Exclusive global collaboration and license agreement to develop, market and commercialize TR-1 cancer therapeutic technology and drug | Terms were not disclosed | 4/16/15 |
Selvita SA (Krakow, Poland) | Merck Serono (unit of Merck KgaA; Darmstadt, Germany) | ND | Collaboration to discover small-molecule-based drugs to target proteins related to cancer cell metabolism | They will work toward discovering drug candidates for multiple oncology indications; Selvita will receive milestone payments if Merck Serono begins development programs or successfully commercializes drug candidates | 11/3/15 |
Serendex Pharmaceuticals A/S (Copenhagen) | CMC Biologics | ND | Agreement in which Serendex secured access to a form of factor VIIa, with exclusive rights to develop and commercialize factor VIIa for pulmonary administration | The therapeutic focus will be on acute bleeding of the lungs; CMC Biologics will develop, manufacture and supply factor VIIa bulk drug substance for acute pulmonary administration for preclinical and clinical studies as well as for commercialization on behalf of Serendex | 2/2/15 |
Serenus Biotherapeutics Corp. (Dublin and Johannesburg) | Hanmi Pharmaceutical Co. Ltd. (South Korea) | ND | Deal to supply amosartan (amlodipine camsylate/losartan potassium), Hanmi's combination therapy to treat hypertension, to patients in Africa | Terms were not disclosed | 10/29/15 |
Shanghai Life Biotech Co. Ltd. (Shanghai) | Clearbridge Biomedics Pte Ltd. (Singapore) | ND | Exclusive partnership for the contract research organization market in China | The two will jointly set up the Lide-Clearbridge CRO CTC Hub to provide circulating tumor cell, or CTC, processing services | 5/1/15 |
Shire plc (Dublin) | Sanquin Blood Supply (Amsterdam, the Netherlands) | ND | Agreement providing Shire access to its manufacturing technology and allowing Shire to source additional manufacturers to meet the growing demand for the compound | Terms involve payments to Sanquin on achievement of certain milestones | 8/26/15 |
Shuwen Biotech Co. Ltd. (Deqing, China) | Jiangsu Hengrui Medicine Co. Ltd. (Shanghai) | ND | Agreement to develop companion diagnostics | Shuwen Biotech will develop companion diagnostic assays and kits for an undisclosed cancer drug candidate Hengrui is developing and will also screen patients at its diagnostic reference labs using the diagnostic assays for Hengrui's trials | 7/29/15 |
Sigma-Tau Industrie Farmaceutiche Riunite SpA (Rome) | Pierre Fabre Pharmaceuticals (Castres, France) | ND | Agreement for marketing authorization for the anti-malarial Eurartesim (dihydroartemisin plus piperaquine) in 32 African countries | Pierre Fabre will register, distribute and promote Eurartesim in Senegal, Guinea, Mali, Ivory Coast, Burkina Faso, Niger, Madagascar, Togo, Benin, RDC, Congo, Chad, Gabon, Cameroon, Mauritania, Burundi, Nigeria, Ghana, Kenya, Tanzania, Uganda, Angola, Ethiopia, Malawi, Liberia, Sierra Leone, Mozambique, Zambia, Zimbabwe, Botswana, Swaziland and Namibia | 7/6/15 |
Signum Dermalogix Inc. (Princeton, N.J.) | Dermata Therapeutics LLC (San Diego) | ND | Agreement to develop a topical product to treat rosacea, SIG990 | Dermata has obtained an exclusive worldwide license to SIG990 and is responsible for the clinical development of the product; Dermalogix will receive milestone payments and royalties on revenues of the product | 3/26/15 |
Sinclair IS Pharma plc (London) | Alliance Pharma plc (Chippenham, UK) | $196.50 | Companies completed the strategic disposal of Sinclair's non-aesthetics business to Alliance | Deal includes up-front cash consideration of £132M (US$196.5M), as well as sales-related royalty payments relating to Flammacerium US | 12/18/15 |
Sistemic Ltd. (Glasgow, UK) | Roosterbio Inc. (Frederick, Md.) | ND | Commercial collaboration and signed memorandum of understanding whereby both companies will combine their technologies and work together toward advancing the field of mesenchymal stem/stromal cell regenerative technology | The companies will collaborate on utilizing microRNA-based cell characterization workflows and technologies to build more precise and relevant characterization panels for hMSC products and in process cell banks | 5/29/15 |
Skyepharma plc (London) | Mundipharma Laboratories GmbH (Basel, Switzerland) | ND | Feasibility and option agreement that may lead Mundipharma to be be the global development and commercialization partner for SKP-2076, a triple ICS/LABA/LAMA1 fixed-dose combination product in a pressurized metered-dose inhaler | Mundipharma would pay a nonrefundable option fee of "several hundred thousand euros;" includes substantial initial, development, launch and sales milestones, plus royalties on product sales | 12/24/15 |
Smartox Biotechnology (Saint Martin d'Heres, France) | Xenon Pharmaceuticals Inc. (Burnaby, British Columbia) | ND | Research collaboration to identify venom toxins that selectively modulate specific ion channels | Smartox gained an exclusive right to develop and sell venom toxins identified through the collaboration as research tools, therapeutics and diagnostics, with Xenon set to receive royalties on net sales of resulting diagnostic or therapeutic products; Smartox also granted Xenon a right of first negotiation concerning license or purchase agreements to develop and commercialize human therapeutics | 9/30/15 |
Solasia Pharma K.K. (Tokyo) | Meiji Seika Pharma Co. Ltd. (Tokyo) | ND | Exclusive global license for rights to commercialize, distribute and rpomote darinaparsin for patients with relapsed and refractory peripheral T-cell lymphoma in Japan in exchange for an undisclosed initial development payment | Meiji also obtained the right to develop and commercialize darinaparsin for other indications in Japan, the option to manufacture intravenous formulation of darinaparsin and a right of first negotiation relating to the formulations other than the intravenous formulation of darinaparsin | 1/21/15 |
Soligenix Inc. (Princeton, N.J.) | Emergent Biosolutions Inc. (Rockville, Md.) | ND | Development agreement to implement a commercially viable, scalable production technology for the Rivax drug substance protein antigen | Soligenix will transfer the manufacturing processes and analytics to Emergent to conduct process development work that could lead to a commercial manufacturing collaboration | 5/14/15 |
Somalogic Inc. (Boulder, Colo.) | Otsuka Pharmaceutical Co. Ltd. (Tokyo) | ND | Extended its collaboration agreement from May 2008 to continue developing several Somamer therapeutics | No other details were disclosed regarding specific products and financial terms; Somalogic was entitled to receive a royalty on any marketed products developed, and Otsuka had an option to acquire distribution rights in Asia for certain Somalogic clinical diagnostics products; Somalogic also received an equity investment from Otsuka | 8/11/15 |
Sorrento Therapeutics Inc. | Mabtech Ltd. (China) | ND | Exclusive licensing agreement to develop and commercialize multiple prespecified and undisclosed biosimilar or biobetter antibodies for antibody development and manufacturing firms | Sorrento will develop and market four monoclonal antibodies for the North American, European and Japanese market | 8/4/15 |
Sorrento Therapeutics Inc. (San Diego) | Nantworks Inc. (Culver City, Calif.) | $1,300.00 | Deal for phase III-stage albumin-bound paclitaxel, Cynviloq | A new drug application could be filed before the end of this year; Nantworks will take over a subsidiary of Sorrento, named Igdrasol Inc., for $90M up front, plus up to $600M in regulatory milestone payments, and $600M more if sales targets are hit; Sorrento also will collect transfer pricing payments from total unit sales, and holds a co-development and co-marketing option | 5/18/15 |
Sorrento Therapeutics Inc. (San Diego) and subsidiary TNK Therapeutics Inc. | Cytolumina Technologies Corp. and Fetolumina Technologies Corp. (Los Angeles) | ND | Agreement to exclusively license the Nanovelcro circulating tumor cell profiling assay | The licenses will cover the applications of the Nanovelcro CTC assay and its portfolio technologies for precision medicine diagnostics in conjunction with all cellular therapies and Sorrento antibody therapeutics | 8/12/15 |
Spark Therapeutics Inc. (Philadelphia) | Clearside Biomedical Inc. (Alpharetta, Ga.) | ND | Option agreement under which Spark acquired licensing rights to Clearside's microinjector technology to deliver gene therapies to the back of the eye | The companies will study the possibilities of using Clearside's microinjector technology to deliver viral vectors to the choroid and the retina through the suprachoroidal space | 4/30/15 |
Specialised Therapeutics Australia Pty Ltd. (Melbourne, Australia) | Pharmamar SA (Madrid) | ND | Exclusive license and commercialization deal to market and distribute oncology drug Aplidin (plitidepsin) in Australia and New Zealand | Pharmamar will receive an up-front payment, royalties and additional remunerations for regulatory and sales milestones | 8/21/15 |
Spectrum Pharmaceuticals Inc. (Henderson, Nev.) | Hanmi Pharmaceuticals Co. Ltd. (Kyungkido, South Korea) | ND | Licensing agreement to gain rights to cancer candidate poziotinib, an oral, quinazoline-based pan-HER inhibitor | Spectrum received an exclusive license to develop, manufacture and commercialize the drug worldwide, excluding Korea and China | 3/5/15 |
Spectrum Pharmaceuticals Inc. (Henderson, Nev.) | Mundipharma International Corp. Ltd. (Cambridge, UK) | $20.00 | Spectrum is divesting rights to radioimmunotherapeutic drug Zevalin in Japan and other countries in Asia Pacific (excluding China and India), Middle East, Africa and Latin America, to Mundipharma | Spectrum will receive an up-front payment of $15M plus $5M in profits on initial Zevalin | 11/19/15 |
Spepharm AG (afiliate of Norgine BV; London) | Navidea Biopharmaceuticals Inc. (Dublin, Ohio) | $7.00 | Exclusive sublicense agreement for the commercialization and distribution of the imaging agent Lymphoseek (tilmanocept) in the EU | Navidea will receive $2M up front and is eligible to receive up to $5M in milestones, as well as royalties | 3/6/15 |
Spring Bank Pharmaceuticals Inc. (Milford, Mass.) | Gilead Sciences Inc. (Foster City, Calif.) | ND | Clinical trial collaboration for a hepatitis B phase II study testing Spring Bank's SB 9200 in combination with Viread in patients with hepatitis B virus | SB 9200, which emerged from Spring Bank's small-molecule nucleic acid hybrid, or SMNH platform, is designed to selectively activate the host cellular proteins RIG I and NOD 2, which have been implicated in the body's immune response to viral infections | 11/20/15 |
Sprint Biosciences AB (Stockholm) | Bayer Healthcare (subsidiary of Bayer AG; Leverkusen, Germany) | $210.00 | Collaboration and license agreement for research, development and commercialization of cancer drug candidates | Sprint is licensing an early stage inhibitor program targeting tumor metabolism to Bayer, which will have full control over further development and worldwide commercialization rights for potential cancer therapeutics and diagnostics; Sprint is eligible to receive up to €190M (US$210M) in potential preclinical, clinical and net sales-based milestone payments, including an undisclosed up-front payment from Bayer upon signing of the agreement; Sprint is eligible to receive royalties on worldwide net sales of any resulting products under the collaboration. | 7/29/15 |
Sprout Pharmaceuticals Inc. (Raleigh, N.C.) | UPM Pharmaceuticals (division of Gregory Pharmaceutical Holdings Inc.) | ND | Deal in which UPM will manufacture flibanserin 100-mg tablets | Sprout has submitted a new drug application for the drug, a postsynaptic 5-HT1A agonist and 5-HT2A antagonist, seeking approval in hypoactive sexual desire disorder | 3/5/15 |
SQZ Biotech Inc. (Boston) | Roche AG (Basel, Switzerland) | $500.00 | Partnership to develop a cell therapy platform that would empower a patient's own immune cells to fight a broad range of cancers | The deal will involve SQZ's technology designed to engineer B cells as a therapeutic platform for oncology; terms call for more than $500M in up-front and potential clinical, regulatory and sales milestone-based payments for advancement of all products across all planned indications, in addition to royalties on potential future products | 12/8/15 |
Starpharma Holdings Ltd. (Melbourne, Australia) | Astrazeneca plc (London) | $124.00 | Licensing agreement covering a defined family of targets using its DEP drug delivery technology | The deal centers on using the platform for Starpharma's dendrimers; Starpharma is eligible to receive a signature payment of $2M and milestone payments ($62M) on one or more Astrazeneca DEP products, plus milestone ($60M) and royalty payments on net sales | 9/9/15 |
Steadymed Ltd. (San Ramon, Calif.) | Cardiome Pharma Corp. (Vancouver, British Columbia) | $12.25 | Exclusive license and supply agreement for Cardiome to commercialize Trevyent in certain regions outside the U.S., including Europe, Canada and the Middle East | Steadymed will receive $12.25M in connection with regulatory and sales milestones, including an up-front payment of $3M, and Cardiome will pay to Steadymed a transfer price on finished goods and a scaling double-digit royalty on future Trevyent sales | 6/30/15 |
Stem Cell Theranostics Inc. (Redwood City, Calif.) | Capellabio (San Francisco) | ND | Collaboration to discover drug therapies to prevent cardiotoxicity associated with various oncology drugs | Work will combine Capellabio's Smartr computational analysis platform with SCT's iPSC-derived cardiomyocyte discovery platform; advanced drug leads have been identified in the first program, targeting cardioprotective drugs to prevent anthracycline-induced cardiotoxicity | 12/17/15 |
Stemcell Technologies Inc. (Vancouver, British Columbia) | iPS Academia Japan Inc. (Kyoto, Japan) | ND | Patent license agreement to license and commercialize technologies for induced pluripotent stem cell, or iPS cell, research | It enables Stemcell to develop, manufacturer and distribute products optimized for cellular reprogramming | 8/26/15 |
Stemedica Cell Technologies Inc. (San Diego) | Universal Stabilization Technologies Inc. (San Diego) | ND | Agreement for an exclusive worldwide license to its Preservation by Vaporization technology to Stemedica subsidiary Stemprotein LLC for industrial scale stabilization of stem cells and stem cell derivatives | The license will allow Stemedica and Stemprotein to manufacture stem cell-secreted therapeutic proteins in a Vitrilife state, designed to remain shelf stable and therapeutically active at ambient temperatures for two or more years | 3/25/15 |
Stemline Therapeutics Inc. (New York) | Canbas Co. Ltd. (Shizuoaka, Japan) | ND | Exclusive license agreement to develop and commercialize an oral small-molecule reversible inhibitor of exportin-1, a nuclear transport target also known as chromosome region maintenance-1 | Stemline, which will call the molecule SL-801, acquired worldwide rights with the exception of Japan, Korea, Taiwan and China | 1/9/15 |
Sucampo Pharmaceuticals Inc. (Bethesda, Md.) | Harbin Gloria Pharmaceuticals Co. Ltd. (Harbin, China) | $1.50 | Exclusive license, development, commercialization and supply agreement for Amitiza (lubiprostone), a chloride channel activator that acts locally in the small intestine to restore motility and to address symptoms of constipation in China | Sucampo will receive $1.5M up-front and a milestone payment | 5/13/15 |
Sucampo Pharmaceuticals Inc. (Bethesda, Md.) and R-Tech Ueno Ltd. (Tokyo) | Par Pharmaceutical Inc. (Woodcliff Lake, N.J.) | ND | Stipulation and license agreement that would give Par a license for a generic version of the Rescula (unoprostone isopropyl ophthalmic solution) 0.15% product approved for the lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension prior to the latest expiration date of the patents, which is July 2021 | Par had previously submitted an abbreviated new drug application to FDA requesting approval to market, sell and use a generic version of Rescula. Under the license, Par will split with Sucampo the gross profits of the generic or authorized generic version sold during the term of the agreement, which continues until the last of Sucampo patents relating to Rescula expire | 2/13/15 |
Swedish Orphan Biovitrum AB (Stockholm) | Biogen Inc. (Cambridge, Mass.) | $10.00 | Swedish Orphan exercised its opt-in right to take over development and commercialization of Alprolix for treatment of hemophilia B for Europe, North Africa, Russia and certain Middle Eastern markets | Sobi will make a payment to Biogen of $10M, which will be held in escrow pending the EU regulatory approval of Alprolix | 7/17/15 |
Swedish Orphan Biovitrum AB (Stockholm) | Selexis SA (Geneva) | ND | Service agreement to use Selexis' Sure-Cho-Mplus Libraries to address issues with difficult-to-express proteins | Financial terms were not disclosed | 9/23/15 |
Sygnis AG (Heidelberg, Germany) | Nanodigmbio Co. Ltd. (Shanghai) | ND | Distribution agreement for the commercialization of its product portfolio in China | The company granted Nanodigmbio the rights to promote, market and sell all existing, as well as future, products including the Trueprime products for primer-free whole-genome amplification as well as Sunscript thermostable reverse transcriptase kits for the translation of RNA into DNA | 8/21/15 |
Symic Biomedical Inc. (San Francisco) | Nordic Bioscience A/S (Copenhagen) | ND | Strategic alliance to focus on the clinical development of its osteoarthritis program | Nordic will provide clinical development services to Symic on a shared-risk basis in exchange for a payment structure that includes service fees and equity in Symic's OA subsidiary; Symic retains responsibility for development and commercialization | 1/6/15 |
Symphogen A/S (Copenhagen) | Merck KGaA (Darmstadt, Germany) | $631.60 | Agreement in which Merck is giving back rights to Sym004 as it reprioritizes its pipeline | The parties entered the potential $631.6M deal in September 2012 | 1/30/15 |
Synaging SAS (Nancy, France) | Actelion Pharmaceuticals Ltd. (Allschwil, Switzerland) | ND | Extended drug discovery collaboration in neurodegenerative diseases to develop multiple lead series targeting an undisclosed G protein-coupled receptor to stop neuronal apoptosis | The collaboration started in 2010 with the aim of discovering neuroprotective small molecules for the treatment of age-related neurodegenerative diseases such as Alzheimer's and Parkinson's; the joint lead optimization process of the collaboration extension aims to deliver orally active molecules for clinical development | 11/5/15 |
Synartro AB (Stockholm) | Pharmalink (Stockholm) | ND | Asset purchase agreement giving Pharmalink a preclinical project in osteoarthritis, as well as a chemical conjugation platform that has wider applicability | Terms were not disclosed | 3/19/15 |
Syndax Pharmaceuticals Inc. (Waltham, Mass.) | Kyowa Hakko Kirin Co. Ltd. (Tokyo) | $100.00 | License agreement for the exclusive rights to develop and commercialize entinostat, a class one selective HDAC inhibitor, in Japan and Korea | Kyowa will pay Syndax a total of up to $100M, including an up-front fee of $25M with a certain amount of an equity investment and potential development and commercial milestone payments; Syndax will manufacture and supply the product to Kyowa | 1/9/15 |
Syndax Pharmaceuticals Inc. (Waltham, Mass.) | Merck & Co. Inc. (Whitehouse Station, N.J.) | ND | Clinical trial collaboration to evaluate the safety and efficacy of combining Syndax's entinostat, an epigenetic therapy, with Merck's Keytruda (pembrolizumab), the first anti-PD-1 therapy approved in the U.S. | The phase Ib/II study will evaluate that combination regimen in patients with either advanced non-small-cell lung cancer or melanoma; the study is expected to begin enrolling patients in the second half of this year | 4/1/15 |
Syndax Pharmaceuticals Inc. (Waltham, Mass.) | Roche AG (Basel, Switzerland) | ND | Collaboration to evaluate the safety, tolerability and preliminary efficacy of Syndax's entinostat, an oral small molecule that targets immune regulatory cells, in combination with Genentech's atezolizumab (MPDL3280A) in patients with triple-negative breast cancer | Terms were not disclosed | 8/27/15 |
Synpromics Ltd. (Edinburgh, U.K.) | Avalanche Biotechnologies Inc. (Menlo Park, Calif.) | ND | Collaboration under which Synpromics will develop synthetic promoters for use with Avalanche's Ocular Biofactory platform | Financial terms were not disclosed | 12/18/15 |
Synthetic Genomics Inc. (La Jolla, Calif.) | Lung Biotechnology PBC (subsidiary of United Therapeutics Corp.; Silver Spring, Md.) | $50.00 | Expanded multi-year R&D agreement to develop transplantation-ready pig organs using synthetic genomic advances | The partnership, initially focused on lung diseases, will add kidney diseases; SGI is set to receive undisclosed royalties and milestones from development and commercialization of the organs and, as part of the agreement expansion, an additional $50M equity investment by Lung Biotechnology, which previously invested $50 million in SGI preferred stock | 9/24/15 |
Synthon Biopharmaceuticals NV (Nijmegen, the Netherlands) | Pfizer Inc. (New York) | ND | Deal in which Pfizer acquired the exclusive commercialization rights in the U.S. to glatiramer acetate, a generic version of multiple sclerosis drug Copaxone (Teva Pharmaceutical Industries Ltd.) | Pfizer will have rights to both formulations and will be responsible for commercialization; Synthon is responsible for the clinical development, manufacture and supply of glatiramer acetate | 8/4/15 |
Synthon Biopharmaceuticals NV (Nijmegen, the Netherlands) | Pfizer Inc. (New York) | ND | Deal in which Pfizer acquired the exclusive commercialization rights in the U.S. to glatiramer acetate, a generic version of multiple sclerosis drug Copaxone (Teva Pharmaceutical Industries Ltd.) | Pfizer will have rights to both formulations and will be responsible for commercialization; Synthon is responsible for the clinical development, manufacture and supply of glatiramer acetate | 8/4/15 |
Syros Pharmaceuticals Inc. (Cambridge, Mass.) | TMRC Co. Ltd. (Tokyo) | ND | Exclusive license agreement to develop and commercialize tamibarotene, a selective agonist to retinoic acid receptor alpha in North America and Europe for cancer | Financial terms were not disclosed | 9/25/15 |
Taigen Biotechnology Co. Ltd. (Taipei, Taiwan) | Cellex GmbH and the University Hospital Carl Gustav Carus Dresden in Germany | ND | Agreement to collaborate in an investigator-initiated phase II clinical trial using burixafor in stem cell mobilization in healthy donors | Cellex will be responsible for obtaining clinical trial approval and conduct of the trial and assume all associated costs; Taigen will have the option to obtain and use the data for future development and filing of market authorization | 3/19/15 |
Taiho Pharmaceutical Co. Ltd. (Tokyo) | Les Laboratoires Servier SA (Suresnes, France) | $130.00 | Exclusive license agreement for the development and commercialization of TAS-102 in Europe and other countries | Taiho retains the right to develop and commercialize TAS-102 in the U.S., Canada, Mexico and Japan/Asia and to manufacture and supply the product; Taiho will receive $130M in an up-front payment and for MAA approval in the EU, plus further regulatory and sales event milestone payments and royalties on net sales | 6/16/15 |
Taiwan Liposome Co. Ltd. (Taipei, Taiwan) | Main Life Corp. Ltd. (Hong Kong) | ND | Distribution deal under which Main Life will be responsible for distribution of TLC's liposomal amphotericin B product, Ambil, in Hong Kong and Macau | This adds to Ambil's existing out-licensed territories of Europe, the U.S., Taiwan and Korea | 10/13/15 |
Takeda Pharmaceutical Co. Ltd. (Osaka, Japan) | Cour Pharmaceutical Development Co. Inc. (Chicago) | ND | Partnership to develop immune-modulating therapies for the potential treatment of celiac disease | The partnership will focus on using nanotechnologies based on Cour's Tolerizing Immune Modifying Nanoparticle platform, which can be extended to certain autoimmune and allergic conditions by inhibiting the abnormal immune responses that cause disease, without affecting the beneficial parts of the immune system; Cour will receive up-front and success-based milestone payments from Takeda leading to an exclusive option to acquire a global license to the TIMP-GLIA program after the completion of the phase IIa trial; Cour will also receive royalties on sales of any successful commercialized products resulting from the partnership | 12/9/15 |
Takeda Pharmaceutical Co. Ltd. (Osaka, Japan) | Astrazeneca plc (London) | $575.00 | Agreement for Astrazeneca to acquire the core respiratory assets of Takeda for $575M | The assets include expansion of rights to roflumilast (Daliresp in the U.S. and Daxas elsewhere), as well as commercial rights to Tudorza Pressair (aclidinium bromide inhalation powder) for Chronic obstructive pulmonary disease, and development rights in the U.S. and Canada for LAS40464 | 12/17/15 |
Taxus Cardium Pharmaceuticals Group Inc. (San Diego) | Dr. Reddy's Laboratories Ltd. (Hyderabad, India) | ND | Binding term sheet for an exclusive territorial license covering the co-development marketing and sales of the Generx (ad5FGF-4) angiogenic microvascular gene therapy, a phase III-stage product candidate for patients with refractory angina and myocardial ischemia due to cardiac microvascular insufficiency | The agreement initially covers certain territories and international markets, including Russia, the Commonwealth of Independent States, Venezuela, Vietnam and Myanmar, and provides the right of first refusal for Dr. Reddy's to negotiate additional exclusive license agreements to market and sell Generx in more than 30 other countries in Latin America and the Association of Southeast Asian Nations | 4/8/15 |
Telesta Therapeutics Inc. (formerly Bioniche Life Sciences Inc.; Montreal) | Ipsen SA (Paris) | $137.00 | Exclusive licensing agreement giving Ipsen the right to develop and commercialize MCNA1 to treat high-risk nonmuscle-invasive bladder cancer outside the U.S. | Telesta will be responsible for commercial launch in the U.S., while Ipsen will identify a regulatory path in Europe and other licensed territories; Telesta is set to receive $10M up front and regulatory and sales milestone payments of up to $127M, plue tiered double-digit royalties | 10/29/15 |
Telesta Therapeutics Inc. (Montreal) | BL&H Co. Ltd. (Korea) | $2.00 | Exclusive license, supply and distribution agreement for the commercialization of MCNA, a biologic therapy derived from the cell wall fractionation of a non-pathogenic bacteria for high-risk nonmuscle-invasive bladder cancer, in South Korea | Telesta will receive a combination of up-front payments, regulatory milestones and sales milestones in excess of $2M, in addition to a significant transfer price, allowing Telesta to receive a large proportion of the revenue related to MCNA sales in South Korea; Telesta will be responsible for the manufacturing and supply of the drug product, while BL&H will cover all costs for registration, sales and marketing in the territory; in addition, BL&H concurrently subscribed for a private placement in Telesta common shares for an amount of $200,000 at market price | 7/21/15 |
TES Pharma S.r.l. (Perugia, Italy) | Ecole Polytechnique Federale de Lausanne (Lausanne, Switzerland) | ND | Research and development collaboration on small molecule modulators of the kynurenine pathway as therapies for metabolic disorders and age-related diseases | Financial terms were not disclosed | 7/6/15 |
Tesaro Inc. (Waltham, Mass.) | Merck & Co. Inc. (Kenilworth, N.J.) | ND | Deal to evaluate the combination of Keytruda plus Tesaro's PARP inhibitor, nirraparib, in a phase I/II trial | The study will enroll patients with triple-negative breast cancer or ovarian cancer | 6/2/15 |
Tesaro Inc. (Waltham, Mass.) | Hengrui Medicine Co. Ltd. (Lianyungang, China) | ND | Exclusive license agreement to develop, register, manufacture and commercialize rolapitant in China | Hengrui will make undisclosed up-front and milestone payments to Tesaro subject to the achievement of certain events | 7/31/15 |
Tetragenetics Inc. (Arlington, Mass.) | Argen-x BV (Breda, the Netherlands), Crystal Bioscience Inc. (Emeryville, Calif.) and Sevion Therapeutics Inc. (San Diego) | ND | Partnership program to discover and develop therapeutic monoclonal antibodies directed against well-known ion channel drug targets implicated in a range of diseases, including pain and autoimmune disorders | The program will combine Tetragenetics' antigen production capabilities with each partner's antibody discovery platform | 12/18/15 |
Tetragenetics Inc. (Cambridge, Mass.) | Medimmune (arm of Astrazeneca plc; London) | ND | Collaboration on antibody drug discovery research in which Tetragenetics will use its ion channel production technology, Sionx, to produce up to five ion channel antigens for Medimmune's antibody drug discovery programs | Medimmune will get target ion channel antigens on a nonexclusive basis in exchange for undisclosed up-front license fees, research funding and milestone payments associated with preclinical and clinical development as well as potential product sales | 1/8/15 |
Tetralogic Pharmaceuticals Corp. (Malvern, Pa.) | Merck & Co. Inc. (Whitehouse Station, N.J.) | ND | Oncology clinical study collaboration for a phase I trial to evaluate birinapant, Tetralogic's SMAC-mimetic, in combination with Merck's PD-1 blocker Keytruda (pemrolizumab) | It will be studied in patients with relapsed or refractory solid tumors and is expected to start later this year | 4/21/15 |
Teva Pharmaceutical Industries Ltd. (Jerusalem) | G&W Laboratories Inc. (South Plainfield, N.J.) | ND | Agreement for Teva to sell its Sellersville, Pa.-based facility to G&W as part of Teva's plan to streamline operations by reducing excess manufacturing capacity | The transaction, set to close in March or April, includes the sale to G&W of about 25 products from the Teva portfolio and also grants to G&W exclusive rights to sell up to two additional Teva products, which Teva will continue manufacturing at its Zagreb, Croatia, facility; financial terms were not disclosed | 3/3/15 |
Teva Pharmaceutical Industries Ltd. (Jerusalem) | Takeda Pharmaceutical Co. Ltd. (Osaka, Japan) | ND | Agreement to establish a partnership for generic drugs in Japan | The business venture is expected to start operating in the second calendar quarter of 2016 | 12/1/15 |
TG Therapeutics Inc. (New York) | Checkpoint Therapeutics Inc. (subsidiary of Coronado Biosciences Inc.; Burlington, Mass.) | ND | Deal aimed at developing a portfolio of fully human immuno-oncology targeted antibodies licensed from the Dana-Farber Cancer Institute, including preclinical antibodies targeting PD-L1, GITR and CAIX | Under the terms, TG and Checkpoint will develop and commercialize the PD-L1 and GITR programs in the field of hematological malignancies; TG will make an undisclosed up-front payment as well as development and sales-based milestones, plus a tiered single-digit royalty on next sales | 3/5/15 |
The Lead Discovery Center GmbH (Dortmund, Germany) | Qurient Co. Ltd. (Gyeonggi-do, South Korea) | ND | License agreement giving Qurient exclusive worldwide rights to a series of highly selective CDK7 inhibitors to treat cancer, inflammation and viral infections | LDC will receive up-front and milestone payments, and Qurient will fund future development activities within the collaboration | 6/4/15 |
The Lead Discovery Center GmbH (Dortmund, Germany) | Infinity Pharmaceuticals Inc. (Cambridge, Mass.) | ND | Collaboration to select high-potential cancer drug discovery projects from the LDC's portfolio and its broad academic network | The partners will agree on the scope and terms of potential co-development partnerships on a project-by-project basis to ensure optimal project progress and a fair distribution of investments and potential returns; any revenue the LDC may receive from commercialization will be shared with the academic inventors and collaborating institutions | 9/30/15 |
The Medicines Co. (Parsippany, N.J.) | Sandoz Inc. (unit of Novartis AG; Basel, Switzerland) | ND | Deal for the distribution of an authorized generic of Angiomax (bivalirudin) in the U.S. | The antithromin product is indicated in patients undergoing percutaneous coronary intervention | 7/10/15 |
The Medicines Co. (Parsippany, N.J.) | Symbio Pharmaceuticals Ltd. (Tokyo) | $10.00 | Partnership for Ionsys (fentanyl iontophoretic transdermal system) in Japan | Symbio obtains an exclusive license in Japan to develop and commercialize the product; the deal includes a $10M up-front payment plus regulatory and commercial milestones and net sales royalties | 10/8/15 |
The Medicines Co. (Parsippany, N.J.) | Mallinckrodt plc (Dublin) | $410.00 | Agreement for The Medicines Co. to sell its global portfolio of three hemostasis products - Recothrom thrombin topical (recombinant), Preveleak and Raplixa (fibrin sealant) to subsidiaries of Mallinckrodt | The deal calls for $410M, with $175M up front, and $235M in future milestone payments | 12/21/15 |
Therapix Bio (Tel Aviv, Israel) | Dekel Pharmaceuticals Ltd. (Israel) | ND | Binding term sheet outlining a licensing and royalty agreement under which Dekel has granted Therapix exclusive worldwide right to develop, manufacture and commercialize combination drug therapies based on Dekel's technology | Dekel will receive an up-front license fee, cash or equity payments based on achievement of specific development milestones, and a time-limited option to purchase Therapix common stock, plus a royalty based on revenues of licensed products sold | 1/14/15 |
Theratechnologies Inc. (Montreal) | Aop Orphan Pharmaceuticals AG (Vienna) | $3.40 | Distribution and commercialization agreement for Egrifta (tesamorelin) covering several European countries | Aop will be responsible for all regulatory activities to obtain marketing authorizations for the HIV-associated lipodystrophy drug in Europe and will pay royalties on net sales of Egrifta over a certain price level; deal also includes milestone payments and an upfront payment of €150,000 (US$167,900) for Aop; the total deal value could reach a combined total of €3M (US$3.4M) | 3/2/15 |
Theratechnologies Inc. (Montreal) | BL&H Co. Inc. (Seoul, South Korea) | ND | Agreement to distribute and commercialize Egrifta (tesamorelin for injection) for HIV-associated lipodystrophy in South Korea | BL&H will pursue marketing approval in South Korea; Theratechnologies will manufacture and supply Egrifta to BL&H at a set transfer price; the deal has a 10-year term | 9/2/15 |
Theravance Biopharma Inc. (South San Francisco) | Mylan Inc. (Pittsburgh) | $265.00 | Partnership on the development and commercialization of TD-4208, an investigational once-daily nebulized long-acting muscarinic antagonist for chronic obstructive pulmonary disease and other respiratory diseases | Mylan will fund the U.S. program and will pay Theravance an initial fee of $15M, a $30M equity investment, potential development and sales milestones totaling $220M, with $175M associated with TD-4208 monotherapy and $45M for future potential combination products; in the U.S., Mylan will lead commercialization and Theravance will retain the right to co-promote the product under a profit-sharing arrangement; outside the U.S. (excluding China), Mylan will be responsible for development and commercialization and pay Theravance a royalty on net sales | 2/3/15 |
Theravance Biopharma Inc. (South San Francisco) | Sciclone Pharmaceuticals Inc. (Foster City, Calif.) | $6.00 | Development and commercialization agreement granting Sciclone exclusive development and commercial rights for the antibiotic Vibativ (telavancin) in China and certain adjacent territories | The companies will pursue development and commercialization in hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia; Sciclone gains exclusive rights in China, as well as the Hong Kong SAR, the Macau SAR, Taiwan and Vietnam, in exchange for up-front and regulatory milestone payments totaling $6M | 5/28/15 |
Threshold Pharmaceuticals Inc. (South San Francisco) | Merck KGaA (Darmstadt, Germany) | $440.00 | Co-promotion agreement for evofosfamide, pursuant to the companies' license and co-development agreement from Feb. 2, 2012 | Threshold may co-promote evofosfamide (previously known as TH-302) in the U.S. subject to FDA approval; the development milestone payment and royalty payment portions of the agreement remain the same; to date, Threshold has received up-front and milestone payments of $110M, and can earn additional potential milestone payments of up to $440M | 11/19/15 |
Tianyin Pharmaceutical Co. Inc. (Chengdu, China) | Undisclosed industrial partner | ND | Alliance to form an integrated platform based on Tianyin's modernized traditional Chinese medicine franchise and focused primarily on the cardiovascular agent Gingko mihuan | TPI's wholly owned subsidiary, Chengdu Tianyin Pharmaceutical, will own a majority stake in the alliance, which will integrate TPI's existing sales force with network resources from the undisclosed partner | 1/5/15 |
Tigenix NV (Leuven, Belgium) | Lonza Group AG (Basel, Switzerland) | ND | Agreement for the supply of Tigenix's adipose-derived stem cells product, Cx601 | Lonza will manufacture material for the phase III trial of Cx601 in the U.S. at Lonza's cell therapy production facility in Walkersville, Md.; Cx601 is a locally injected suspension of allogeneic expanded eASCs for the treatment of complex perianal fistulas in Crohn's disease patients, currently in phase III in Europe | 2/13/15 |
Tillotts Pharma AG (Rheinfelden, Switzerland) | Numab AG (Wadenswil, Switzerland) | ND | Exclusive global license to develop and commercialize antibody-based therapies that act against tumor necrosis factor-alpha in inflammatory bowel disease | Tillotts will develop and commercialize new formulations of anti-TNF-alpha antibody fragments identified by Numab, which is eligible for an undisclosed signing fee and, upon successful development, milestone payments and royalties escalating to double digits | 6/10/15 |
Tillotts Pharma AG (Rheinfelden, Switzerland; part of the Zeria Group) | Astrazeneca plc (London) | $215.00 | Agreement to acquire global rights for Entocort (budesonide), excluding U.S. rights, which will remain with Astrazeneca | Entocort is a locally acting glucocorticosteroid, currently approved in more than 40 countries for the treatment of Crohn's disease and, in some markets, ulcerative colitis; Tillotts will make an up-front payment of $215M | 7/10/15 |
Tiziana Life Sciences plc (London) | Nerviano Medical Sciences Group (Nerviano, Italy) | $41.80 | Exclusive license agreement for milciclib, which blocks the action of cyclin-dependent kinases, and is in phase II trials for thymic carcinoma | Tiziana will make an up-front cash payment of $3.5M for the license to Nerviano; Tiziana also will pay specified milestone payments of up to $35M and a royalty on net sales of any products containing milciclib; in addition, Tiziana will pay £2.14M (US$3.3M) to be satisfied by the issue of about 4.2M new ordinary shares in the company to Nerviano; Tiziana will be responsible for future development costs in thymoma and thymic epithelial tumors and in any additional indications, including hepatocellular carcinoma and breast cancer; Nerviano will handle manufacturing and the performance of clinical studies up to completion of phase II trials | 1/28/15 |
Tokai Pharmaceuticals Inc. (Cambridge, Mass.) | Qiagen NV (Venlo, the Netherlands) | ND | Expanded agreement for developing and commercializing Qiagen's AR-V7 companion diagnostic for use with galeterone, a small-molecule, oral drug for the treatment of castration-resistant prostate cancer that disrupts androgen receptor signaling | Under the new terms of the deal, Tokai will gain exclusive rights from Qiagen to its circulating tumor cell enrichment technology for use with galeterone, which will be incorporated into the companion diagnostic already under development by Qiagen | 3/18/15 |
Tolero Pharmaceuticals Inc. (Salt Lake City) | Eutropics Pharmaceuticals Inc. (Cambridge, Mass.) | ND | Exclusive license agreement to use the Praedicare Dx platform in the clinical development of alvocidib | Preliminary studies have suggested that the test can be used to identify acute myeloid leukemia patients with a high likelihood of responding to alvocidib; Tolero is currently initiating a randomized phase II study in previously treated AML patients | 11/11/15 |
Transgene SA (Paris) | Sillajen Inc. (Busan, South Korea) | $6.00 | Signed an amended agreement for the development and commercialization of Pexa-Vec | Sillajen will assume responsibility for conducting the phase III PHOCUS trial in hepatocellular carcinoma (HCC), while Transgene remains responsible for submitting for marketing approval and retains commercialization rights in its territories; Transgene will pay a total of $6M to Sillajen over four years beginning this year; Transgene will return rights to Sillajen for all Middle Eastern countries, Russia, Ukraine, Belarus and Turkey | 11/13/15 |
Transition Therapeutics Inc. (Toronto) | Eli Lilly and Co. (Indianapolis) | $101.00 | Exclusively licensed worldwide rights agreement to a small-molecule drug candidate | Lilly will receive contingent up-front consideration of up to $1M and will be eligible to receive up to $100M in commercial milestones and a mid-single-digit royalty on sales of TT701 products | 5/7/15 |
Transparency Life Sciences LLC (New York) | Senexta Therapeutics SA (Lugano, Switzerland) | ND | Agreement for an exclusive option to develop and commercialize Senexta's selective, long-acting clinical-stage cholinesterase inhibitor | Financial details of the agreement were not disclosed | 12/18/15 |
Treeway BV (Rotterdam, the Netherlands) | Uniqure NV (Amsterdam) | ND | Collaboration to develop a gene therapy treatment for amyotrophic lateral sclerosis | Uniqure granted Treeway an exclusive license to Uniqure's relevant AAV5 viral vector and glial cell-derived neurotrophic factor intellectual property; Treeway is responsible for preclinical and clinical development, and Uniqure will provide manufacturing capabilities; the parties will jointly commercialize any resulting ALS gene therapy with defined geographical rights for commercialization assigned to each company | 1/15/15 |
Twi Biotechnology Inc. (subsidiary of Twi Pharmaceuticals Inc.; Taipei, Taiwan) | Castle Creek Pharmaceuticals LLC | ND | Development and commercialization agreement for Twi's lead drug candidate, AC-203, for the treatment of epidermolysis bullosa | Castle Creek gets an exclusive worldwide license for AC-203, with the exception of Asia but including Australia and New Zealand, in exchange for an undisclosed up-front payment and milestone payments based on achievement of predefined clinical and regulatory events; Twi also is eligible for double-digit royalties after product launch | 12/18/15 |
Twi Pharmaceuticals Inc. (Taipei, Taiwan) | Teva Pharmaceuticals Industries Ltd. (Jerusalem) | ND | Agreement that will transfer the U.S. sales and distribution rights of Twi's generic versions of Megace ES and Lidoderm from Teva to Twi | Twi will distribute both products through its wholly owned subsidiary, Twi Pharmaceuticals USA | 2/25/15 |
Two privately held biotech companies | TNK Therapeutics Inc. (subsidiary of Sorrento Therapeutics Inc.; San Diego) | ND | Acquisition of multiple preclinical and clinical-stage chimeric antigen receptor, or CAR, T immunotherapy programs, as well as underlying CAR T technology | The CAR T programs focus on targeting solid tumors as well as infectious diseases; terms were not disclosed | 8/11/15 |
Txcell SA (Valbonne, France) | Ferring International Center SA (Saint-Prex, Switzerland) | $91.30 | Collaboration, option, development and license agreement is now assigned to Trizell Holding SA, of Lausanne, Switzerland | The 2013 Ferring deal to commercialize Ovasave valued at $91.3M in up-front and milestone playments, plus undisclosed royalties is unchanged | 1/5/15 |
Txcell SA (Valbonne, France) | Trizell Holding SA (Lausanne, Switzerland) | $1.20 | Amended their option, development and license agreement, in which Txcell will undertake a program to bring forward the preparation of Ovasave for phase III development and commercialization, notably in the areas of process and manufacturing development | To finance the program, Trizell will advance up to €1.1M (US$1.2M) in funding that was initially due after the future exercise of Trizell's option to Ovasave, and at Trizell's sole discretion, it may finance a further €4.3M | 4/24/15 |
Txcell SA (Valbonne, France) | Masthercell | ND | Agreement to produce batches of Ovasave in Txcell's ongoing phase IIb trial in refractory Crohn's disease | Txcell also said it is addressing concerns at its existing pilot Besançon manufacturing unit to ensure future GMP compliance and to recommence full manufacturing activities following a partial, temporary hold at the site | 7/30/15 |
Txcell SA (Valbonne, France) | Trizell Holding SA (Lausanne, Switzerland) | ND | Terminated collaboration, option, development and license agreement for Txcell to regain full rights to its lead product, Ovasave | The agreement gave Trizell an exclusive option to in-license development and commercialization rights to Ovasave in inflammatory bowel disease, including Crohn's disease; Trizell will be eligible to receive up to €15M (US$15.9M) from Txcell, including €2M up front; Txcell, which was paying development costs for Ovasave, said regaining the rights would have limited impact on its short-term financial outlook | 12/3/15 |
Txcell SA (Valbonne, France) | Masthercell | ND | Five-year agreement | For exclusive manufacture in Europe of all products from Txcell's Astria platform | 12/4/15 |
Ubivac LLC (Portland, Ore.) | Janssen Biotech Inc. (unit of Johnson & Johnson; New Brunswick, N.J.) | ND | Collaboration to develop preclinical and clinical versions of its Dribble immunotherapy for use in preclinical studies of oral cancer | Ubivac is set to receive an up-front payment and other undisclosed financial commitments upon achieving predetermined research, development and manufacturing milestones | 9/30/15 |
UCB SA (Anderlecht, Belgium) | Neuropore Therapies Inc. (San Diego) | $480.00 | Exclusive global license agreement to develop and commercialize Neuropore's preclinical Parkinson's disease candidate, NPT200-11 | UCB agreed to pay Neuropore $20M up front and up to $460M in potential development, regulatory and sales-based milestones; Neuropore would also earn royalties on net sales | 1/20/15 |
UCB SA (Brussels) | Dr. Reddy's Laboratories Ltd. (Hyderabad, India) | ND | Agreement to acquire a select portfolio of the established products business of UCB in the territories of India, Nepal, Sri Lanka and Maldives | The acquired business is being sold on a slump sale basis; the transaction includes approximately 350 employees engaged in operations of the India business | 4/2/15 |
Uni-Bio Science Group Ltd. (Hong Kong) | Jiangsu Hansoh Pharmaceutical Co. Ltd. | ND | Exclusive global rights to manufacture and commercialize Hansoh's mitiglinide | Hansoh will continue to provide the active pharmaceutical ingredient to Uni-Bio | 11/25/15 |
Uniqure NV (Amsterdam) | Bristol-Myers Squibb Co. (New York) | $2,000.00 | Deal to develop treatments for cardiovascular diseases, including a gene therapy for congestive heart failure that would restore the heart's ability to synthesize S100A1 | BMS will nominate nine other targets; the S100A1 program has a $254M potential value up to commercialization, and the other nine are valued at $217M; Uniqure will manufacture any products and be eligible for sales milestones and royalties; Uniqure will receive $100M near term, $50M of which is up front; BMS will pay $15M for the selection of the first three targets beyond S100A1, and is investing $32M in Uniqure stock now and a further 5% by the end of the year, with a further two options to invest; total deal is worth $2B-plus | 4/7/15 |
Uniqure NV (Amsterdam) | Bristol-Myers Squibb Co. (New York) | $150.00 | Collaboration to develop gene treatments for cardiovascular disease | BMS will make a $50M up-front payment and pay about $100M in near-term payments | 5/27/15 |
United Therapeutics Corp. (Silver Spring, Md.) | DEKA Research & Development Corp. | ND | Agreement for the development of a pre-filled semi-disposable pump system that may represent a potential technology breakthrough in the subcutanous delivery of Remodulin (treprostinil) injection to patients with pulmonary arterial hypertension | Financial terms were not disclosed | 1/2/15 |
United Therapeutics Corp. (Silver Springs, Md.) | Abbvie Inc. | $350.00 | United sold its FDA priority review voucher to a subsidiary of Abbvie | United reaped its PRV by way of the approval in March of Unituxin (dinutuximab) for the rare pediatric disease neuroblastoma | 8/20/15 |
Vaccinex Inc. (Rochester, N.Y.) | Five Prime Therapeutics Inc. (South San Francisco) | ND | Multitarget collaboration agreement to use its Activmab antibody discovery platform for the discovery of monoclonal antibodies against novel targets identified by Five Prime's platform | Five Prime will obtain exclusive, worldwide rights to develop and commercialize monoclonal antibodies discovered by Vaccinex in exchange for certain up-front fees, research support and performance payments, as well as milestone payments and low single-digit royalties | 3/20/15 |
Valeant Pharmaceuticals International Inc. (Laval, Quebec) | Astrazeneca plc (London) | $445.00 | Exclusive license agreement to develop and commercialize the interleukin-17 inhibitor in moderate to severe plaque psoriasis and psoriatic arthritis | Valeant gained global rights everywhere but certain Asian countries, including Japan; it will pay Astrazeneca $100M up front, pre-launch milestones of up to $170M and sales-related milestone payments of up to $175M following launch; the companies will share profits | 9/2/15 |
Valneva SE (Lyon, France) | Jianshun Biosciences Ltd. (Lanzhou, China) | $3.13 | Exclusive license agreement on its EB66 cell line for human and veterinary vaccines in China | Valneva received a payment of €2.5M (US$2.6M) up front and is entitled to an additional payment of €500,000 (US$530,000) in 2016, plus annual maintenance fees and half of the revenues paid to Jianshun from sublicensees; Valneva retained full ownership of the EB66 platform | 3/18/15 |
Valneva SE (Lyon, France) | Paxvax Inc. (Redwood City, Calif.) | ND | Marketing and distribution agreement for their respective travel vaccines | Valneva will distribute and promote Paxvax's typhoid vaccine Vivotif in Canada and the Nordic countries (Sweden, Norway, Denmark and Finland), while Paxvax will distribute and promote Valneva's cholera vaccine Dukoral in Italy, Spain and Portugal | 7/24/15 |
VBI Vaccines Inc. (Cambridge, Mass.) | Sanofi Pasteur Inc. (vaccines division of Sanofi SA; Paris) | ND | Research collaboration to apply its lipid particle vaccine formulation technology to further the development and improve the stability of a key Sanofi vaccine candidate | The collaboration provides Sanofi with the option to acquire certain worldwide rights to use VBI's technology in its vaccines; the vaccine candidate and the terms of the agreement were not disclosed | 4/8/15 |
Vedanta Biosciences Inc. (Boston) | Janssen Biotech Inc. (unit of Johnson & Johnson; New Brunswick, N.J.) | $241.00 | License agreement for Vedanta's lead microbiome candidate, VE202, which has shown efficacy in preclinical autoimmune models | Janssen will develop and seek to commercialize the candidate in inflammatory bowel disease; Vedanta will receive an up-front payment and is eligible to receive development and commercialization milestone payments up to a potential total of $241M, and possibly more if other indications are pursued | 1/14/15 |
Velocity Pharmaceutical Development LLC (South San Francisco) | Baxter International Inc. (Deerfield, Ill.) and the Mayo Clinic | ND | Deal to form Vitesse Biologics LLC, which will focus on developing antibody and protein-based therapeutic products for immunology, hematology and oncology | Baxter Bioscience will provide global commercialization, antibody and protein development and manufacturing; Mayo Clinic researchers will conduct the phase I trials; and Velocity will handle target identification, selection of early stage drug candidates | 6/2/15 |
Vernalis plc (Berkshire, UK) | Taisho Pharmaceutical Co. Ltd. (Tokyo) | ND | Drug discovery collaboration that will employ Vernalis' fragment- and structure-based drug discovery platform against an undisclosed target for the development of potential antibiotic agents | Financial terms were not disclosed | 4/8/15 |
Vernalis plc (Winnersh, UK) | Corvus Pharmaceuticals Inc. (Burlingame, Calif.) | $201.00 | Exclusive, worldwide rights agreement for its adenosine receptor antagonist program, including V81444, for use in all therapeutic applications to a U.S.-based biotech firm | The deal includes a $1M up-front payment from the unnamed company and offers the potential for Vernalis to earn more than $200M in development, regulatory and sales milestones; Vernalis could earn single-digit royalties if a product reaches market, with the potential for double-digit royalties in certain circumstances | 2/27/15 |
Vernalis plc (Winnersh, UK) | Pragma Pharmaceuticals LLC (Locust Valley, N.Y.) | ND | Vernalis acquired U.S. rights to Moxatag (amoxicillin extended-release tablets) | Vernalis paid an undisclosed cash amount and commited further compensation upon successful manufacture and re-launch of the finished product | 10/5/15 |
Vertex Pharmaceuticals Inc. | Parion Sciences Inc. (Durham, N.C.) | $1,170.00 | Partnership for addressing pulmonary pathology developed by Parion that could improve treatment of cystic fibrosis and other lung diseases | Vertex gains worldwide development and commercial rights to Parion's epithelial sodium channel inhibitors, including P-1037 and P-1055, in return for $80M up front plus up to $490M in milestones for CF programs; Parion will receive tiered royalties on potential sales ranging from the low double digits to midteens; deal also includes up to $370M in additional milestones tied to development in non-CF pulmonary indications, and another $230M in development and regulatory milestones could come if Vertex decides to develop an additional ENaC inhibitor from its research program | 6/8/15 |
Vical Inc. | Astellas Pharma Inc. (Tokyo) | $101.00 | In-licensing agreement for a trial-ready antifungal, ASP2397 | Vical is paying Astellas $250,000 up front and committing to pay up to $100M in milestones plus potential royalties; Astellas will also receive Vical common stock equivalent to about 1% of outstanding shares, valued at about $777,267 | 3/27/15 |
Vical Inc. (San Diego) | Anges MG (Tokyo) | ND | Collaboration to develop and commercialize an equine polyclonal antibody therapy for Ebola virus disease | Vical will develop and provide Anges with a DNA vaccine encoding the glycoprotein antigen of the 2014 Zaire strain of Ebola, formulated with Vical's Vaxfectin adjuvant; Anges will receive the right to exclusively develop and commercialize the therapy in Japan, covering all development costs; Vical gets an up-front payment and is eligible for royalties and a percentage of sublicensing payments | 1/15/15 |
Viiv Healthcare Ltd. (London) | Desano Pharmaceuticals Ltd. (Shanghai) | ND | Strategic manufacturing agreement to enable production in China of Viiv's dolutegravir 50 mg, branded Tivicay | The agreement will offer an additional source of the dolutegravir active pharmaceutical ingredient, and will allow Viiv Healthcare to offer a competitive supply of the finished product for China and a number of developing countries, subject to national approvals | 7/6/15 |
Vitae Pharmaceuticals Inc. (Fort Washington, Pa.) | Boehringer Ingelheim GmbH (Ingelheim, Germany) | ND | Vitae is regaining rights to BI1147560/VTP-36951, an orally active beta secretase inhibitors to treat and prevent Alzheimer's disease and other indications | Boeheringer decided to end its collaboration and license agreement with the company "for strategic business reasons" | 7/28/15 |
Voyager Therapeutics Inc. (Cambridge, Mass.) | Genzyme (unit of Sanofi SA; Paris) | $845.00 | Agreement to discover, develop and commercialize gene therapies for severe central nervous system disorders | Voyager takes the lead in research and development, with Genzyme having the option to license ex-U.S. rights for several programs following completion of initial proof-of-concept human trials; Voyager will retain U.S. rights to lead programs, VY-AADC01 in PD and VY-FXN01 in Friedreich's ataxia, and will split U.S. profits with Genzyme for VY-HTT01 for HD; Voyager will receive $100M up front and $745M in development and sales milestones, plus tiered royalties | 2/12/15 |
Wuxi Apptec | Astrazeneca plc (London) | $150.00 | Exclusive service and manufacturing agreement to produce a line-up of biologics for China, covering all of the big pharma's strategic therapeutic areas, respiratory, inflammation and autoimmunity, cardiovascular and metabolic disease, and oncology | Astrazeneca has also optioned to buy a Wuxi Apptec biologic facility for $100M and has committed to invest a further $50M in Astrazeneca's existing small-molecule manufacturing facility also located in Wuxi | 12/18/15 |
Wuxi Pharmatech (Cayman) Inc. (Shanghai) | Eli Lilly and Co. (Indianapolis) | ND | Collaboration to develop, manufacture and commercialize a small molecule in China | Wuxi will be responsible for regulatory, development and manufacturing activities in China, while Lilly will be responsible for commercial activities. Further financial terms of the collaboration were not disclosed, though parties will invest in its development | 11/12/15 |
X-Chem Inc. (Waltham, Mass.) | Janssen Biotech Inc. (unit of Johnson & Johnson; New Brunswick, N.J.) | ND | Multi-target collaboration focused on the discovery and development of molecules to treat inflammatory diseases | X-Chem will apply its discovery engine to identify novel compounds targeting proteins involved in the inflammatory response; Janssen gains an exclusive option to license the candidates generated; X-Chem gets an up-front payment, research funding and is eligible for research, development and commercial milestones, plus royalties | 1/12/15 |
X-Chem Inc. (Waltham, Mass.) | Navitor Pharmaceuticals Inc. (Cambridge, Mass.) | ND | Exercised option to obtain an exclusive license to a series of small molecules targeting the activation of mTORC1, a protein complex that orchestrates nutrient-mediated cellular metabolism and growth | X-Chem discovered the compounds using its screening platform against protein targets supplied by Navitor under a 2014 agreement between the companies; X-Chem received research funding from Navitor and a license fee and is eligible for additional milestone payments | 4/1/15 |
Xellia Pharmaceuticals SA (Copenhagen) | Subsidiary of Hikma Pharmaceuticals plc (London) | ND | Xellia bought manufacturing facilities in Bedford, Ohio, from the subsidiary | Terms were not disclosed | 11/30/15 |
Xencor Inc. (Monrovia, Calif.) | Amgen Inc. (Thousand Oaks, Calif.) | $1,745.00 | Licensing agreement for Xmab antibody engineering technology for inclusion in a series of preclinical bispecific antibodies targting areas of cancer immunotherapy and inflammation | The deal adds a $45M up-front payment to Xencor's till and positions it for up to $1.7B in milestone payments, plus royalties | 9/17/15 |
XL-protein GmbH (Freising, Germany) | Easton Pharmaceutical Co. Ltd. (Chengdu, China) | ND | License, development and commercialization agreement for long-acting biopharmaceutical products to address a range of unmet needs in ophthalmology and potential further indications, in which XL-protein will apply its Pasylation technology for drug half-life extension to one Easton target | XL-protein will assume responsibility for early preclinical development activities, while Easton will be entitled to further development, manufacturing and marketing of the Pasylated compound; XL-protein will get an up-front payment as well as milestones payments and tiered, mid to high single-digit royalties | 12/18/15 |
Xoma Corp. | Novartis AG (Basel, Switzerland) | $517.00 | Exclusive licensing deal that could carry up to $517M in rewards, plus royalties | The deal gives Novartis rights and full responsibility for development of Xoma's anti-transforming growth factor-beta antibody program with potential to address advanced metastatic cancer and fibrosis; Novartis paid Xoma $37M up front, and will pay up to $480M in milestones, plus tiered royalties from a mid-single-digit percentage rate to up to a low-double digit rate | 10/2/15 |
Xoma Corp. (Berkeley, Calif.) | Novo Nordisk A/S (Bagsvaerd, Denmark) | $295.00 | Out-licensing agreement for the global development and commercialization rights to its XMetA program for the portfolio of allosteric monoclonal antibodies that up-regulate the insuling receptor | Xoma retains commercialization rights for rare disease indications, although Novo has an option to add those additional rights to its license; Xoma will receive $5M up front; the agreement also includes up to $290M in additional potential development, regulatory and commercial milestones, excluding potential option payments; Xoma is eligible to receive tiered royalties on product sales | 12/2/15 |
Xrpro Sciences Inc. (Cambridge, Mass.) | Pfizer Inc. (New York) | ND | Xrpro Sciences acquired assets related to the ion channel biology platform from Pfizer, which it acquired from Icagen | Xrpro also acquired all of Pfizer's rights to the Icagen name and trademark; the firm is re-launching the Icagen brand and will provide services for ion channel and transporter drug discovery | 7/6/15 |
X-Rx Inc. (Wilmington, N.C.) | Gilead Sciences Inc. (Foster City, Calif.) | ND | Exclusive deal to develop X-Rx's small-molecule autotaxin inhibitors | Terms were not disclosed | 11/12/15 |
Yabao Pharmaceutical Co. Inc. (Beijing) | Eli Lilly and Co. (Indianapolis) | ND | Collaboration to co-develop Lilly's sodium-glucose linked transporter inhibitor molecule, which has completed a phase I study in Singapore | Yabao receives the rights to develop and commercialize the SGLT1 compound in China, while Lilly retains rights in all other markets; the parties will collaborate to determine a strategic development plan for China, and Yabao will initially be responsible to perform and fund all development; Lilly retains future buy-in options for China | 10/22/15 |
Yissum Research Development Co. Ltd. (Jerusalem) | Phytotech Medical Ltd. (West Perth, Western Australia) | ND | Exclusive licensing and collaboration agreement to develop, manufacture and market a delivery system to enhance the bioavailability of cannabidiol and/or THC, the active ingredients in cannabis, to treat a variety of medical indications | The formulations are based on oral and transbuccal delivery technologies developed by researchers at the Hebrew University of Jerusalem | 1/27/15 |
Zai Lab Ltd. (located in Zhangjiang Hi-Tech Park) | UCB SA (Brussels, Belgium) | ND | Licensing agreement for global rights to Zai Lab's first large molecule asset, set to go into phase I trials in 2016 | UCB will receive an up-front payment with milestones hinged upon future clinical development, regulatory activities and commercialization | 9/23/15 |
Zai Labs Inc. (Shanghai) | Bristol-Myers Squibb Co. (New York) | ND | Out-licensing agreement for China rights to brivanib for hepatocellular carcinoma to Zai Labs | BMS will retain all global rights outside of China, Zai Labs will be responsible for developing, commercializing and manufacturing the candidate in greater China for oncology conditions; BMS is entitled to development-based milestone payments and commercial royalties, as well as an option to co-promote the drug | 3/24/15 |
Zai Labs Ltd. (Shanghai) | Hanmi Pharmaceuticals Co. Ltd. (Seoul, South Korea) | ND | China rights deal for HM61713 | Financial terms were not disclosed | 11/25/15 |
Zogenix Inc. (San Diego) | Pernix Ireland Ltd. (subsidiary of Pernix Therapeutics Holdings Inc.; Morristown, N.J.) | $654.50 | Definitive agreement to acquire Zohydro ER franchise from Zogenix, including three extended-release hydrocodone products, Zohydro ER, Zohydro ER with Beadtek and ZX007, plus an abuse-deterrent pipeline and licenses to multiple patents to protect the franchise through 2030 | Pernix agreed to pay $100M at closing, up to $283.5M in regulatory and commercial milestones, and up to $271M in sales milestones, for a total deal value of $654.5M; the sale closed in April | 3/12/15 |
Zosano Pharma Corp. (Fremont, Calif.) | Novo Nordisk A/S (Bagsvaerd, Denmark) | ND | Discontinued collaboration agreement related to development of a transdermal version of select Novo glucagon-like peptide-1 analogues | Zosano said it was notified that the decision relates to a strategic prioritization at Novo; upon termination, all technology rights licensed to Novo Nordisk related to the field of GLP-1 products will revert to Zosano; the companies inked their deal in January 2014 | 7/7/15 |
Zymeworks Inc. (Vancouver, British Columbia) | Celgene Corp. (Summit, N.J.) | $172.00 | Early stage deal to use Zymeworks' Azymetric platform for creating bispecific antibody therapeutics; the multiproduct collaboration gives Celgene the option to advance candidates through clinical development and, if successful, on to commercialization | In exchange, Celgene agreed to make an undisclosed up-front payment plus an equity investment involving about 1.65M shares of Zymeworks for roughly C$10M (US$8.2M); Zymeworks also will be eligible for up to $164M in milestones per candidate, in addition to royalties on worldwide net sales | 1/22/15 |
Zymeworks Inc. (Vancouver, British Columbia) | Glaxosmithkline plc (London) | $440.00 | Collaboration and licensing deal to further develop Zymeworks' Effector Function Enhancement and Control Technology platform | Both companies will have the right to develop and commercialize monoclonal and bispecific antibody candidates that incorporate Zymeworks' optimized immune-modulating Fc domains; GSK will have the right to develop a minimum of four products across multiple disease areas, and Zymeworks will be eligible to receive preclinical, clinical and commercial milestones of up to $110M for each product, as well as tiered sales royalties | 12/4/15 |